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Abstract 
Voltage-gated sodium channels (VGSCs) are heterotrimeric proteins comprised of one pore-
forming, a subunit and two non-pore forming, b subunits. Variants in SCN1B, the gene which 
encodes VGSC b1 subunits, are linked to human diseases with high incidence of sudden death 
including Early Infantile-Developmental and Epileptic Encephalopathy (EI-DEE) and cardiac 
arrhythmia. Scn1b-null mice are a model of EI-DEE, including a cardiac phenotype, and 100% of 
mice die by approximately postnatal day 21. b1 subunits are classically known for their role in 
modulating the gating, kinetics, and localization of the ion channel pore. In addition, b1 is a 
member of the immunoglobulin super family of cell adhesion molecules (CAMs). b1 functions in 
both homophilic and heterophilic cell adhesion with downstream roles in neurite outgrowth and 
neuronal pathfinding and fasciculation. Although these functions explain a portion of SCN1B-
linked disease, the underlying mechanisms for differential gene expression observed in the Scn1b-
null model of EI-DEE remained poorly understood.  
Studies presented in this thesis sought to understand the contribution of b1 to transcriptional 
changes in Scn1b-null animals. We and others have shown, in addition to the aforementioned 
functions of b1, b1 is a substrate for sequential cleavage by b-site APP cleaving enzyme 1 
(BACE1) and g-secretase. We created a cell culture based assay to study the molecular mechanisms 
that regulate cleavage and its subsequent downstream signaling. Using biochemical approaches, 
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we demonstrated b1 is post-translationally palmitoylated, the addition of a 16-carbon fatty acid 
chain to a cysteine residue by a thioester bond, at p.C162. b1 palmitoylation promotes b1 
localization to the plasma membrane and consequently promotes b1 processing by BACE1 at the 
plasma membrane. Sequential cleavage generates a small, soluble peptide, the b1-intracellular 
domain (b1-ICD). b1-ICD is translocated to the nucleus where it modulates transcription. 
Expression of the b1-ICD generally downregulates gene expression of genes implicated in 
proliferation, the immune response, calcium ion binding, and voltage-gated potassium channels. 
Interestingly, these same Gene Ontology (GO) groups are upregulated in cardiac ventricle isolated 
from Scn1b-null mice, where this pathway is deleted, compared to wild-type. Subsequent increases 
in potassium current are observed in acutely isolated ventricular myocytes from Scn1b-null mice. 
In heterologous cells, expression of the b1-ICD increases Scn4a and Scn5a transcripts and 
decreases Scn3a transcripts. Expression of the b1-ICD does not lead to increases in sodium current 
density, nor does it act directly on the Nav1.5 a subunit when the peptide is profused during patch 
clamp. This work identified a novel function of a species of the b1 subunit, b1-ICD, as both a 
transcriptional modulator. Identification of this pathway provides a direct mechanism by which 
loss of b1 in the Scn1b-null model of EI-DEE, and potentially in patients with loss-of-function 
SCN1B variants, results in changes in gene expression and altered excitability.  
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Chapter 1 Introduction 
 
(Portions of this chapter have been published in Handb Exp Pharmacol. 2018;246:423-450. doi: 
10.1007/164_2017_48. Review. PMID: 28965169) 
Alexandra A. Bouza and Lori L. Isom, PhD 
 
Summary 
Voltage-gated sodium channels are protein complexes comprised of one pore forming α subunit 
and two, non-pore forming, β subunits. The voltage-gated sodium channel β subunits were 
originally identified to function as auxiliary subunits, which modulate the gating, kinetics, and 
localization of the ion channel pore. Since that time, the five β subunits have been shown to play 
crucial roles as multifunctional signaling molecules involved in cell adhesion, cell migration, 
neuronal pathfinding, fasciculation, and neurite outgrowth. Here, we provide an overview of the 
evidence implicating the β subunits in their conducting and non-conducting roles. Mutations in the 
β subunit genes (SCN1B-SCN4B) have been linked to a variety of diseases. These include cancer, 
epilepsy, cardiac arrhythmias, sudden infant death syndrome/sudden unexpected death in epilepsy, 
neuropathic pain, and multiple neurodegenerative disorders. β subunits thus provide novel 
therapeutic targets for future drug discovery. 
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The basics of the voltage-gated sodium channel β subunits 
There are five voltage-gated sodium channel (VGSC) β subunits, which are encoded by four 
genes, SCN1B-SCN4B (O'Malley and Isom 2015). SCN1B encodes the β1 subunit and the 
developmentally regulated splice variant, β1B, while the β2, β3, and β4 subunits are encoded 
by SCN2B-SCN4B, respectively (Table 1.1) (Isom, De Jongh et al. 1992); (Isom, Ragsdale et al. 
1995); (Kazen-Gillespie, Ragsdale et al. 2000);(Morgan, Stevens et al. 2000); (Patino, 
Brackenbury et al. 2011); (Qin, D'Andrea et al. 2003); (Yu, Westenbroek et al. 2003). β subunits 
each contain a large, extracellular V-set immunoglobulin (Ig) domain, making them part of the Ig 
superfamily of cell adhesion molecules (CAMs) (Brackenbury and Isom 2011);(O'Malley and 
Isom 2015). β1B differs from the other subunits in that it is the only one that is not a type I 
transmembrane protein, but rather, a soluble, secreted CAM expressed during embryonic 
development in brain and throughout development, into adulthood, in heart. The C-terminal 
domain of β1B is encoded by a retained intron, resulting in a unique polypeptide sequence that 
does not contain a transmembrane segment (Patino, Brackenbury et al. 2011). β subunit Ig domains 
are stabilized by two completely conserved cysteine residues in the extracellular portion, 
maintaining the β-sheet structure, as established by the X-ray crystal structures of β3 and β4 





  VGSC β subunits  
Gene Protein  Gene Protein 
SCN1A Nav1.1  SCN1B β1 
SCN2A Nav1.2  SCN1B β1B 
SCN3A Nav1.3  SCN2B β2 
SCN4A Nav1.4  SCN3B β3 
SCN5A Nav1.5  SCN4B β4 
SCN8A Nav1.6    
SCN9A Nav1.7    
SCN10A Nav1.8    
SCN11A Nav1.9    
 




VGSCs are comprised of one pore-forming α subunit and two different β subunits, either a β1 or 
β3 and a β2 or β4 (Fig. 1.1) (O'Malley and Isom 2015). β1 and β3 non-covalently associate with 
α, while β2 and β4 associate with α by cysteine disulfide bonds, Cys-26 and Cys-58, respectively, 
both of which are located in the extracellular Ig domain (Chen, Calhoun et al. 2012); (Gilchrist, 
Das et al. 2013); (McCormick, Isom et al. 1998); (Meadows, Malhotra et al. 2001); (Spampanato, 
Kearney et al. 2004). While there is no biochemical evidence to show that β1B associates with α 
subunits by co-immunoprecipitation, co-expression of β1B and Nav1.5 in heterologous systems 
results in plasma membrane retention of β1B and increased sodium current density, implicating 
association with α (Patino, Brackenbury et al. 2011); (Watanabe, Koopmann et al. 2008). 
Heterologous co-expression of β1B with Nav1.2 results in changes in current activation and 
inactivation, while co-expression with Nav1.3 results in subtle alternation of current properties, 
again suggesting a functional association (Kazen-Gillespie, Ragsdale et al. 2000); (Patino, 
Brackenbury et al. 2011). 
VGSC β subunits are expressed in many tissues and cell types, not all of which are excitable 
(Brackenbury and Isom 2011). The expression of each specific β subunit is also developmentally 
regulated. In rodent brain, β1B and β3 are most highly expressed during embryonic development 
and early life. This differs from heart, in which β1B and β3 expression continues into adult life 
(Kazen-Gillespie, Ragsdale et al. 2000); (Patino, Brackenbury et al. 2011); (Shah, Stevens et al. 
2001). β1 and β2 display peak expression in brain during adulthood (Isom, De Jongh et al. 
1992); (Isom, Ragsdale et al. 1995). The developmental regulation of β4 subunit expression is yet 
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to be determined. β subunits are localized to a variety of specific sub-cellular compartments. In 
the brain and peripheral nervous system, β subunits are highly enriched the axon initial segment 
and nodes of Ranvier (Buffington and Rasband 2013);(Chen, Bharucha et al. 2002); (Chen, 
Westenbroek et al. 2004); (Dhar Malhotra, Chen et al. 2001); (O'Malley, Shreiner et al. 2009). 
These sites are important in the initiation and propagation of action potentials in neurons and have 
a high density of VGSC a subunit expression (Brackenbury, Calhoun et al. 2010). In heterologous 
cells, the b1 C-terminal domain interacts with the scaffolding protein, ankyrin-G, in a tyrosine 
phosphorylation-dependent manner and a similar mechanism is proposed at the axon initial 
segment and nodes of Ranvier (Malhotra, Kazen-Gillespie et al. 2000). In cardiomyocytes, the 
phosphorylation of b1 may regulate its sub-cellular localization. Tyrosine phosphorylated b1 
subunits are localized to the intercalated disks, while non-phosphorylated b1 subunits are localized 





Figure 1.1: Cartoon diagram of the voltage-gated sodium channel (VGSC). VGSCs are comprised 
of one pore-forming, or α subunit, and one or two non-pore forming β subunits. The α subunit is 
made up four domains each of which contain six transmembrane segments. The voltage sensor is 
located in transmembrane segment four of each domain (Catterall). There are five β subunits, β1-
β4, and the developmentally regulated β1B. β1-β4 all contain an intracellular C-terminal domain, 
a single transmembrane domain, and a large extracellular immunoglobulin (Ig) domain (Isom, De 
Jongh et al. 1994). β1B also possesses an Ig domain, but does not contain an intracellular or 
transmembrane domain, resulting in a soluble, secreted protein (Patino, Brackenbury et al. 2011). 
β1 and β3 are non-covalently linked to the α subunit, while β2 and β4 are linked by disulfide bonds. 
Each β subunit is heavily glycosylated, denoted by Ψ, and β1 also contains an intracellular 
phosphorylation site at tyrosine 181 (Malhotra, Thyagarajan et al. 2004). Figure reproduced from 




In addition to phosphorylation, the β subunits are post-translationally modified by glycosylation 
and proteolytic cleavage. All 5 β subunits are highly N-linked glycosylated (Isom, De Jongh et al. 
1992). This heavy glycosylation of mature β subunits accounts for about 12 kilodaltons (kDa) of 
the ~36 kDa total molecular weight. β subunit glycosylation impacts their surface expression and 
channel modulatory properties (Johnson, Montpetit et al. 2004). Lastly, the transmembrane β 
subunits are also substrates for sequential cleavage, or regulated intramembrane proteolysis (RIP), 
by the β-site amyloid precursor protein cleaving enzyme-1 (BACE1) and γ-secretase (Wong, 
Sakurai et al. 2005). Initially, BACE1 cleaves β subunits on the extracellular side of the membrane, 
shedding the Ig domain, which may function as a soluble CAM, similar to β1B. Subsequently, γ-
secretase cleaves the β subunits in the lumen of the membrane, generating an intracellular domain 
(ICD) (Fig. 1.2) (Haapasalo and Kovacs 2011); (Wong, Sakurai et al. 2005). Evidence shows that 
the β2 subunit ICD translocates to the nucleus where it increases expression of the Nav1.1 α 
subunit (Kim, Carey et al. 2007). A similar mechanism has been proposed, but not shown, for the 
other β subunits. Sequential cleavage of β subunits may play important roles in mediating neurite 
outgrowth, migration, and cell adhesion (Brackenbury and Isom 2011); (Kim, Ingano et al. 2005). 
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Figure 1.2: Cartoon diagram of β1/β1B topology. Both intracellular and extracellular residues on 
β1 are important for interacting with the α subunit (McCormick, Isom et al. 1998, Spampanato, 
Kearney et al. 2004). Epilepsy-linked mutation sites are clustered in the Ig domain (Wallace, Wang 
et al. 1998, Meadows, Malhotra et al. 2002, Wallace, Scheffer et al. 2002, Audenaert, Claes et al. 
2003, Scheffer, Harkin et al. 2007, Patino, Claes et al. 2009). The alternative splice site for β1B, 
ankyrin interaction site (Kazen-Gillespie, Ragsdale et al. 2000, Qin, D'Andrea et al. 2003, Patino, 
Brackenbury et al. 2011), α-secretase/BACE1/γ-secretase cleavage sites (Wong, Sakurai et al. 
2005), N-glycosylation sites (Ψ) (McCormick, Isom et al. 1998), tyrosine phosphorylation site 
(Malhotra, Thyagarajan et al. 2004), and the putative palmitoylation and fyn kinase interaction 
site are designated (McEwen and Isom 2004, Brackenbury, Davis et al. 2008). Figure reproduced 




Modulation of the ion channel pore by β subunits 
 
VGSC β subunits are traditionally known for their functions in modulating the gating and kinetics 
of the VGSC pore (Calhoun and Isom 2014). In Xenopus oocytes, expression of Nav1.2 mRNA 
alone results in sodium currents that are activated and inactivated much slower than those recorded 
in neurons. Co-injection of β1 or β2 mRNA altered the sodium current parameters (Isom, De Jongh 
et al. 1992). Co-expression β1 with Nav1.2 increased peak sodium current density, shifted the 
voltage-dependence of inactivation negatively, and accelerated activation and inactivation in 
comparison to Nav1.2 alone (Isom, De Jongh et al. 1992). Co-expression of β2 with Nav1.2 also 
resulted in increased peak sodium current density and accelerated current inactivation. Expression 
of the three subunits together, β1, β2, and Nav1.2, yielded the largest peak sodium currents and 
the most rapidly inactivating channels, most closely mimicking that observed in neurons (Isom, 
Ragsdale et al. 1995). 
In addition to modulating VGSC activity, β1 can also act on Kv1.1, Kv1.2, Kv1.3, Kv1.6, Kv4.2, 
Kv4.3, and Kv7.2 in Xenopus oocytes or heterologous cells (Deschenes and Tomaselli 
2002); (Nguyen, Miyazaki et al. 2012). Interestingly, β1 and Kv4.2 co-immunoprecipitate from 
mouse brain. Kv4.2 is a major contributor to A-type potassium current. Knockdown of β1 
decreases A-type potassium current and prolongs action potential waveforms in cultured cortical 
neurons. β1 expression also increases the stability of Kv4.2 in HEK293 cells, leading to increased 
total and cell surface expression of Kv4.2 (Marionneau, Carrasquillo et al. 2012). 
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In addition to oocytes, heterologous mammalian cell lines have been utilized to study VGSC 
modulation by the β subunits. Although these models are more physiologically relevant, they 
cannot fully replicate VGSC activity in native excitable cells, such as neurons and cardiomyocytes. 
In Chinese Hamster Lung (CHL) cells, co-expression of Nav1.2 with β1 increases peak current 
density and causes a negative shift in the voltage-dependence of activation and inactivation, 
although to a lesser extent than observed in Xenopus oocytes (Isom, De Jongh et al. 1992, Isom, 
Ragsdale et al. 1995, Patino, Claes et al. 2009). Co-expression of Nav1.2 and β2 in CHL cells does 
not recapitulate the results observed in Xenopus oocytes, instead resulting in sodium currents that 
are unchanged or reduced in comparison to the expression of Nav1.2 alone (Kazarinova-Noyes, 
Malhotra et al. 2001); (McEwen, Meadows et al. 2004). In addition to altering kinetics of the ion 
channel pore, co-expression of β1 and/or β2 with Nav1.2 affects α subunit surface expression. Co-
expression of β1 with Nav1.2 increases α subunit cell surface expression (Isom, Ragsdale et al. 
1995). When β2 is added to the experiment, the cell surface expression of α subunits is even further 
increased, even though β2 cannot generate this effect in the absence of β1 (Kazarinova-Noyes, 
Malhotra et al. 2001). The modulatory and localization effects of β subunits on α subunits are 
impacted by the presence of other Ig-superfamily CAMs. In the case of the CAM, contactin, co-
expression with Nav1.2 and β1 increases α subunit cell surface expression and sodium current 
density approximately four-fold over that observed with Nav1.2 plus β1. This is also displayed 
with NF186, although to a lesser extent than the effects observed with contactin. β1B co-
expression with Nav1.2 in CHL cells also increases α subunit surface expression and peak sodium 
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current density, although, this combination only has a modest effect on channel activation and 
inactivation (Kazen-Gillespie, Ragsdale et al. 2000); (Patino, Brackenbury et al. 2011). 
The effects of the β subunits on a variety of α subunits have also been studied in Chinese Hamster 
Ovary (CHO) cells and Human Embryonic Kidney (HEK) cells. β1 or β3 co-expression with 
Nav1.3 in CHO cells results in a negative shift in the voltage dependence of inactivation, but does 
not influence the rate of inactivation. In this same system, co-expression of β2 with Nav1.3 had no 
effect on the gating or kinetics of the ion channel pore (Meadows, Malhotra et al. 2002). Co-
expression of β3 with Nav1.5 in CHO cells results in a negative shift in the voltage dependence of 
inactivation, but decreases the rate of inactivation (Ko, Lenkowski et al. 2005). Co-expression of 
β1B with Nav1.3 in CHO cells has no effect on Nav1.3 cell surface expression or sodium current 
density, different from the large effect of β1B observed in CHL cells (Kazen-Gillespie, Ragsdale 
et al. 2000); (Patino, Brackenbury et al. 2011). In HEK cells, co-expression of Nav1.5 and β4 
results in a negative shift in the voltage dependence of inactivation in comparison to expression of 
Nav1.5 alone (Medeiros-Domingo, Kaku et al. 2007). The β4 subunit, when expressed with Nav1.2 
or Nav1.4, induces a negative shift in the voltage dependence of activation (Yu, Westenbroek et 
al. 2003). This is also the case for co-expression of β4 with Nav1.1, although this results in 
increased levels of non-inactivating current (Aman, Grieco-Calub et al. 2009). Also in HEK cells, 
β1 and β3 subunits each modulate activity, cell surface expression, and glycosylation state of 
Nav1.7. β1 or β3 co-expression with Nav1.7 resulted in shifted activation and inactivation and 
increased sodium current density. Co-expression of β1 also resulted in alternative glycosylation of 
Nav1.7, while co-expression with β3 led to increased expression of fully-glycosylated Nav1.7 
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(Laedermann Cé, Syam et al. 2013). Overall, studies on β subunit modulation of VGSCs in 
heterologous systems have revealed cell type, β subunit, and α subunit specific effects. 
The most physiologically relevant method to study VGSC modulation by the β subunits is to utilize 
primary cells, e.g. neurons or cardiomyocytes. In these native cells, β subunit effects are, in 
general, more modest than observed in heterologous over-expression systems. Scn1b-null mice, 
lacking both β1 and β1B, model the epileptic encephalopathy Dravet syndrome, and exhibit 
spontaneous seizures, ataxia, and premature death around post-natal day (P) 19 (Chen, 
Westenbroek et al. 2004). Acutely isolated P10-P18 Scn1b-null pyramidal and bipolar 
hippocampal neurons show no differences in VGSC activity compared to age-matched wild-type 
animals (Chen, Westenbroek et al. 2004); (Patino, Claes et al. 2009). However, slice recordings 
from this age range revealed hyperexcitability in the Scn1b-null CA3 hippocampal region as well 
as epileptiform activity in the hippocampus and cortex, suggesting altered VGSC activity in axons 
or dendrites (Patino, Claes et al. 2009). There are altered sodium currents and decreased 
excitability in cultured Scn1b-null cerebellar granule neurons (CGNs) (Brackenbury, Calhoun et 
al. 2010). In contrast, acutely isolated Scn1b-null dorsal root ganglion (DRG) neurons are 
hyperexcitable (Brackenbury, Calhoun et al. 2010); (Lopez-Santiago, Brackenbury et al. 2011). 
These results suggest that the effects of β1 and β1B in brain are neuronal cell-type specific, 
consistent with that observed in heterologous cells. Similar to that observed in heterologous 
systems, β1/ β1B expression in vivo affects the expression of α subunits, especially Nav1.1 and 
Nav1.3. In the Scn1b-null hippocampal CA3 region, Nav1.1 expression is decreased, while Nav1.3 
expression is increased (Chen, Westenbroek et al. 2004). β2 also modulates VGSC gating and 
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kinetics in vivo. Acutely isolated Scn2b-null hippocampal neurons display a negative shift in the 
voltage dependence of inactivation in comparison to neurons from age-matched, wild-type mice 
(Chen, Bharucha et al. 2002). Acutely isolated Scn2b-null small-fast DRG neurons have decreased 
sodium current density and decreased rates of TTX-sensitive sodium current activation and 
inactivation (Lopez-Santiago, Pertin et al. 2006). Importantly, the β4 intracellular domain is 
postulated to play a role in resurgent sodium current, or the influx of sodium ions through the ion 
channel pore during repolarization. β4 knockdown in mouse CGNs showed reduced resurgent 
sodium current and repetitive firing (Bant and Raman 2010). Furthermore, expression of a β4 
intracellular domain peptide in CA3 neurons, which do not endogenously express β4 subunits, 
generates resurgent sodium current (Grieco, Malhotra et al. 2005). This activity is particularly 
important in high-frequency firing neurons. Scn4b-null mice have defects in sodium current 
modulation. Scn4b-null mice have reduced resurgent sodium current and repetitive firing in 
medium spiny neurons of the striatum, as well as increased failure rates of inhibitory postsynaptic 
currents with repetitive stimulation (Miyazaki, Oyama et al. 2014). β1 and β1B are also implicated 
in regulating resurgent sodium current in the cerebellum, as Scn1b-null CGNs have normal 
transient sodium current, but decreased resurgent sodium current, even though the overall protein 
expression of β4 is unchanged (Brackenbury, Calhoun et al. 2010). Together, these data indicate 
that modulation of sodium current by the β subunits in vivo is cell-type-, subcellular domain-, β 
subunit-, and α subunit-specific. 
VGSC β subunits are also important regulators of excitability in the heart. In ventricular 
cardiomyocytes isolated from Scn1b-null mice, transient and persistent sodium currents are 
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increased due to increased Scn5a and Nav1.5 expression, resulting in prolongation of action 
potential repolarization and the QT interval (Lin, O'Malley et al. 2014); (Lopez-Santiago, 
Meadows et al. 2007). Furthermore, Scn1b-null mice display increased susceptibility to 
polymorphic ventricular arrhythmias. Scn1b-null ventricular cardiomyocytes also have increased 
tetrodotoxin (TTX)-sensitive sodium current, increased Nav1.3 mRNA levels, increased incidence 
of delayed after-depolarizations, delayed Ca2+ transients, and frequent spontaneous Ca2+ release. 
Addition of TTX prevented the majority of changes in Ca2+ handling, indicating mutations 
in Scn1b may result in disrupted intracellular Ca2+ homeostasis in ventricular myocytes (Lin, 
O'Malley et al. 2014). Scn2b deletion in mice leads to atrial and ventricular arrhythmias and 
increased levels of atrial fibrosis. These animals exhibit region-specific effects in heart. Scn2b-
null ventricular myocytes show reduced sodium and potassium currents, with conduction slowing 
in the right ventricle compared to wild-type. Scn2b-null atria had normal levels of sodium current 
compared to wild-type (Bao, Willis et al. 2016). Scn3b-null mice also show abnormal cardiac 
excitability, with ventricular tachycardia from electrical stimulation that is not observed in wild-
type mice. Scn3b-null hearts also demonstrate atrial tachycardia during atrial burst pacing (Hakim, 
Gurung et al. 2008). 
The β subunits as cell adhesion molecules 
 
All five β subunits have an extracellular Ig domain and belong to the Ig superfamily of CAMs 
(Isom and Catterall 1996). Importantly, β subunits have also been shown experimentally to 
function as CAMs (Isom 2002). An especially large body of work in this area has been completed 
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on the β1 subunit. In Drosophila S2 cells expressing either β1 or β2, large aggregates form, 
suggesting these molecules can participate in trans homophilic cell adhesion in vitro (Malhotra, 
Kazen-Gillespie et al. 2000). Upon β1-β1 trans homophilic cell adhesion in Drosophila S2 cells, 
ankyrin is recruited to the point of cell-cell contact (Meadows, Malhotra et al. 2001). Ankyrin 
binds to the β1 subunit via the intracellular C-terminal domain in a tyrosine phosphorylation-
dependent manner. When residue Y181 of β1 is phosphorylated, ankyrin is unbound, while when 
Y181 is not phosphorylated, ankyrin binds to β1, indicating that downstream signaling events 
occur in response to cell-cell adhesion (Malhotra, Koopmann et al. 2002). In addition, β1 subunits 
can form heterophilic interactions with other CAMs, including contactin, N-cadherin, NrCAM, 
neurofascin-155, neurofascin-186, and the VGSC β2 subunit as well as the extracellular matrix 
protein, tenascin-R (Fig. 1.3) (Xiao, Ragsdale et al. 1999, McEwen and Isom 2004). β2 subunits 
can also participate in heterophilic adhesion in vitro with both tenascin-R and tenascin-C 
(Srinivasan, Schachner et al. 1998, Xiao, Ragsdale et al. 1999). Drosophila S2 cells expressing β3 
subunits do not aggregate, suggesting that β3 does not participate in trans homophilic adhesion 
(McEwen, Chen et al. 2009). In contrast, β3 subunits expressed in HEK cells participate 
in trans heterophilic adhesion with other CAMs, although this does not result in β3-ankyrin 
binding (Ratcliffe, Westenbroek et al. 2001, McEwen and Isom 2004, McEwen, Chen et al. 2009). 
The function of β4 in cell adhesion remains more poorly understood (Brackenbury and Isom 2011). 
Insights from crystallographic, mutagenic, and photo-crosslinking studies have revealed the 
structural importance of an antiparallel interface between β4 subunits in trans homophilic adhesion 
(Shimizu, Miyazaki et al. 2016). Recent evidence shows that β4 Ig domains interact in a parallel 
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manner involving a disulfide bond between cysteine 58 and hydrophobic and hydrogen bonding 
interactions between residues 30 through 35. Deletion of the β4 N-terminal domain led to 
decreased cell adhesion and increased association with the α subunit, revealing the importance of 





Figure 1.3: b1 participates in homophilic and heterophilic cell adhesion(Malhotra, Kazen-
Gillespie et al. 2000). Left: Schematic of b1-b1 homophilic cell adhesion and its downstream 
signaling. At points of cell-cell contact b1 binds to ankyrin in a phosphorylation-dependent 
manner. When b1 is not phosphorylated it is bound to ankyrin, while when tyrosine 181 is 
phosphorylated it is not bound to ankyrin (Malhotra, Kazen-Gillespie et al. 2000, Malhotra, 
Koopmann et al. 2002). In rat brain b1 interacts with receptor protein tyrosine kinase-b which 
may contribute to regulating the b1 phosphorylation state (Ratcliffe, Qu et al. 2000). Right: b1 




Consistent with the role of β1 and β2 in cell adhesion, these molecules have been identified to 
mediate neurite outgrowth in CGNs (Davis, Chen et al. 2004). In this series of experiments, CGNs 
were grown on a monolayer of CHL cells that either did, or did not, express β subunit proteins. 
When β1-β1 trans homophilic cell adhesion occurred between the CGN and the monolayer 
expressing β1, neurite length was longer than when it did not. In contrast, β2-mediated homophilic 
adhesion resulted in decreased neurite length while β4 had no effect on this biological output. 
These data suggest that β1-β1 trans homophilic cell adhesion initiates a signal transduction 
cascade to drive neurite outgrowth in vitro while β2-mediated signaling may be inhibitory. Cell 
adhesion-mediated neurite outgrowth has been shown to occur through two downstream pathways: 
either via an epidermal growth factor receptor (EGFR) or fibroblast growth factor receptor (FGFR) 
mediated signal transduction cascade, or through the fyn kinase pathway (Brackenbury, Davis et 
al. 2008). Inhibitors of FGFR and EGFR had no effect on β1-mediated neurite outgrowth in CGNs. 
In contrast, CGNs isolated from fyn-null mice grown on a CHL monolayer expressing β1 did not 
show extended neurite length, suggesting that β1-mediated neurite outgrowth signals through a 
pathway that involves fyn kinase. This hypothesis is further supported by results showing that β1 
subunit peptides associate with fyn in detergent-resistant membrane fractions solubilized from 
mouse brain (Brackenbury, Davis et al. 2008). The proteolytic processing of β1 by BACE1 and γ-
secretase is also important for β1-mediated neurite outgrowth, as inhibitors of γ-secretase block 
β1-mediated neurite outgrowth (Fig. 1.4) (Brackenbury and Isom 2011). The secreted Scn1b splice 
variant, β1B, increases neurite outgrowth to a similar extent as full-length β1 (Patino, Brackenbury 
et al. 2011)Outside of the central nervous system, the β1 subunit can induce the growth of neurite-
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like features from cultured breast cancer cells, suggesting a possible developmental role for β1 in 




Figure 1.4: β subunits are sequentially cleaved by α-secretase and/or the β-site amyloid precursor 
protein-cleaving enzyme 1 (BACE1) and subsequently by γ-secretase in the lumen of the 
membrane. Sequential cleavage generates a soluble extracellular N-terminal domain and 
intracellular C-terminal domain (Kim, Ingano et al. 2005, Wong, Sakurai et al. 2005). The soluble 
N-terminal domain participates in cell adhesion and migration, while the intracellular domain 
modulates neurite outgrowth and, in the case of β2, regulates VGSC gene transcription in vitro 
(Davis, Chen et al. 2004, Kim, Ingano et al. 2005, Kim, Carey et al. 2007, Miyazaki, Oyama et al. 




β1/β1B-mediated cell adhesive activity has been implicated in neuronal development in vivo. In 
the Scn1b-null mouse, there are fewer optic nerve nodes of Ranvier. At the ultrastructural level, 
optic nerve, spinal cord, and sciatic nerve nodes have abnormal architecture (Chen, Westenbroek 
et al. 2004). Scn1b-null mice also have defects in neuronal pathfinding and fasciculation in 
multiple brain regions. In normal cerebellum, CGN axons project from the granule layer to the 
molecular layer, where they form parallel fibers. In the Scn1b-null mouse, CGN axons are 
defasiculated, forming a disrupted molecular layer. Abnormal pathfinding and defasiculation are 
also observed in the Scn1b-null corticospinal tract and hippocampus. In a related model, dendritic 
arborization of pyramidal neurons in subiculum is reduced in Scn1b-C121W mutant animals (Reid, 
Leaw et al. 2014). The Scn2b- and Scn3b-null mouse models do not have an apparent neurological 
phenotype, although Scn2b-null mice have increased seizure susceptibility and altered pain 
sensation (Chen, Bharucha et al. 2002) (Lopez-Santiago, Pertin et al. 2006, Hakim, Gurung et al. 
2008, Hakim, Brice et al. 2010) (O'Malley and Isom 2015). CNS abnormalities in the Scn4b-null 
mouse model were recently described. Scn4b-null mice display deficits in balance and motor 
coordination and resurgent sodium current in null Purkinje neurons was reduced by approximately 
50 percent. This was further validated using in vivo short hairpin RNA knockdown of β4 in adult 
Purkinje neurons (Ransdell, Dranoff et al. 2017). Overexpression of the β4 subunit in Neuro2a 
cells results in increased neurite outgrowth, dendrite formation, and filopodia-like protrusions, 
suggesting a role for β4 in neuronal pathfinding and migration (Oyama, Miyazaki et al. 2006). 





VGSC β subunits are expressed in prostate, breast, lung, and cervical cancers. This expression is 
subunit specific and varies by cancer type (Brackenbury 2012). β1 is found in breast, prostate, and 
cervical cancers, while β2 has been detected in breast and prostate cancers, and β3 in prostate and 
lung cancers (Chioni, Brackenbury et al. 2009) (Diss, Fraser et al. 2008) (Hernandez-Plata, Ortiz 
et al. 2012) (Jansson, Lynch et al. 2012) (Roger, Rollin et al. 2007). 
β1 and β2 expression levels correspond with metastatic potential in prostate cancer cells (Chioni, 
Brackenbury et al. 2009) (Jansson, Lynch et al. 2012). Experiments performed in vitro with breast 
cancer cells have shown that β1 expression enhances cell-cell and cell-substrate adhesion and 
decreases cell migration (Chioni, Brackenbury et al. 2009). On the other hand, data suggest that 
β1 contributes to cell invasion during metastasis in breast cancer cells (Chioni, Brackenbury et al. 
2009). Overexpression of β1 increases vascular endothelial growth factor secretion and 
angiogenesis, and decreases apoptosis in endothelial cells (Andrikopoulos, Fraser et al. 2011). β1 
overexpression in an orthotopic mouse model of breast cancer increases tumor growth and 
metastasis (Nelson, Millican-Slater et al. 2014). In the well-defined prostate cancer cell line, 
LNCaP, β2 overexpression increases cell length, but reduces cell volume, which may result in 
increased cellular motility and invasion. In a wound healing assay, cells overexpressing β2 migrate 
farther than controls. To the contrary, over-expression of β2 decreases tumor formation and growth 
after tumor implantation into nude mice. Furthermore, β2 over-expression enhances invasion and 
growth on laminin (Jansson, Lynch et al. 2012). 
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Unlike β1 and β2, β3 is postulated to function as a tumor suppressor because its amino acid 
sequence contains two p53 response elements. In p53-null mouse embryo fibroblasts, Scn3b is 
increased after andriamycin treatment and β3 expression induces p53-dependent apoptosis 
(Adachi, Toyota et al. 2004). Less is known about the expression of β4 in cancer, although β4 
expression levels are lower in cervical and prostate cancer cells in comparison to noncancerous 
cells (Diss, Fraser et al. 2008) (Hernandez-Plata, Ortiz et al. 2012). β4 co-expression with Nav1.5 
has also been shown to play a role in CD4+ T cell development (Lo, Donermeyer et al. 2012). 
These data suggesting roles for VGSC β subunits in cancer indicate that these molecules are 
important to the functioning of non-excitable, in addition to excitable, cells. 
Cardiac arrhythmia 
 
The VGSC β subunits are expressed in the human heart and conduction system. Here, SCN1B is 
expressed at the highest levels in atria and endocardium, while SCN2B and SCN3B are expressed 
throughout the human heart (Gaborit, Le Bouter et al. 2007). In mouse ventricular cardiomyocytes, 
β2, β4, and tyrosine-phosphorylated β1 subunits are expressed at the intercalated disc along with 
Nav1.5, the predominant heart α subunit, (Maier, Westenbroek et al. 2004) (Malhotra, Thyagarajan 
et al. 2004). At t-tubules of ventricular cardiomyocytes, β2, β3, and non-phosphorylated β1 are co-
expressed with Nav1.1, Nav1.3, and Nav1.6 α subunits (Dhar Malhotra, Chen et al. 2001) (Maier, 
Westenbroek et al. 2004) (Malhotra, Thyagarajan et al. 2004). Cardiac VGSC β subunits are 
critical for action potential upstroke, conduction velocity, and excitation-contraction coupling, 
 23 
suggesting that abnormal expression of β subunits may contribute to cardiac disease states (Remme 
and Bezzina 2010). 
Mutations in genes encoding VGSC β subunits are linked to multiple types of cardiac disease (Bao 
and Isom), including long QT syndrome (LQTS) (Medeiros-Domingo, Kaku et al. 2007) (Riuro, 
Campuzano et al. 2014), a ventricular arrhythmia in which there is delayed action potential 
repolarization, resulting in prolongation of the QT interval on the electrocardiogram. LQTS causes 
an increased risk of ventricular fibrillation (VF) and sudden cardiac death (Alders and Christiaans 
1993). There is now an extensive list of LQTS mutations, including mutations in ion channel genes 
(Nakano and Shimizu 2016) (Tester and Ackerman 2014). Two mutations, resulting in gain-of-
function activity, have been identified in SCN1B and SCN4B, respectively (Medeiros-Domingo, 
Kaku et al. 2007) (Nakano and Shimizu 2016) (Riuro, Campuzano et al. 2014), including β1B 
p.P213T, which results in increased late sodium current and action potential duration, shifted 
window current, and decreased rate of slow inactivation, and β4 p.L179F, which results in a 
positive shift in sodium current inactivation causing abnormal action potential repolarization 
(Riuro, Campuzano et al. 2014) (Medeiros-Domingo, Kaku et al. 2007). 
Multiple mutations in SCN1B have also been linked to Brugada syndrome (BrS) (Holst, Saber et 
al. 2012) (Hu, Barajas-Martinez et al. 2012) (Watanabe, Koopmann et al. 2008) (Yuan, 
Koivumaki et al. 2014). BrS patients have an increased risk of sudden cardiac death due to VF 
(Watanabe, Koopmann et al. 2008). SCN1B mutations are associated with reductions in Nav1.5-
generated sodium current density, hyperpolarized voltage-dependence of sodium current 
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inactivation, and/or alterations in the rate of recovery from inactivation (Watanabe, Koopmann et 
al. 2008). A missense mutation in SCN2B, p.D211G, has been linked to BrS and results in reduced 
sodium current density by decreasing Nav1.5 cell surface expression (Riuro, Beltran-Alvarez et 
al. 2013). Mutations in all four of the VGSC β subunit genes are linked to atrial fibrillation (AF) 
(Li, Wang et al. 2013) (Olesen, Jespersen et al. 2011) (Wang, Yang et al. 2010) (Watanabe, Darbar 
et al. 2009). 
Mouse models lacking individual β subunits show the important roles of these subunits in cardiac 
function. Cardiac function in Scn1b-null mice is altered, even after blocking autonomic input. 
These animals exhibit action potential depolarization and prolonged QT intervals, suggesting a 
LQTS phenotype. Scn1b-null ventricular myocytes have increased transient and persistent sodium 
current in comparison to wild-type animals, and an increase in Nav1.5 transcript and protein levels 
(Lopez-Santiago, Meadows et al. 2007)l. Scn1b-null mice also show increased TTX-sensitive 
sodium current in the ventricular myocyte midsection, concurrent with increased Scn3a mRNA 
levels. Cardiac-specific Scn1b-null mice also display increased Scn3a mRNA, lengthened action 
potential repolarization, delayed after repolarizations and Ca2+ transients, and frequent 
spontaneous release of Ca2+. Alterations in Ca2+ levels were blocked by TTX (Lin, O'Malley et al. 
2014). Scn2b-null mice exhibit a mixed, Brugada-atrial fibrillation like phenotype. Scn2b-null 
ventricular myocytes have alterations in sodium and potassium current densities, particularly in 
the right ventricular outflow tract. Similar to Scn2b-null brain, total levels of Nav1.5 protein were 
found to be similar to those from wild-type animals, supporting the hypothesis that a main function 
of β2 in the ventricle is to chaperone VGSC α subunits to the cell surface without changing overall 
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channel expression. In contract, Scn2b-null atria had normal levels of sodium and potassium 
currents but increased levels of fibrosis. Lastly, Scn2b-null hearts display increased susceptibility 
to atrial fibrillation and repolarization dispersion compared to wild-type animals (Bao, Willis et 
al. 2016). Scn3b-null mice also show cardiac dysfunction. In both atria and ventricles, Scn3b-null 
mice display an increased susceptibility to arrhythmia, reduced peak sodium current, conduction 
abnormalities that are similar to Brugada syndrome models, bradycardia, AV block, and deficits 
in sinoatrial node recovery (Hakim, Gurung et al. 2008). The role of β4 in cardiac function has yet 
to be reported using the null mouse model. 
Epilepsy 
 
Many mutations in VGSC genes have been linked to epilepsies, including SCN1B (Kaplan, Isom 
et al. 2016). There has as yet been no explicit neurological phenotype associated with SCN3B and 
no epilepsy phenotype linked to SCN4B. The mutation SCN1B p.C121W, identified in a patient 
with Generalized Epilepsy with Febrile Seizures plus (GEFS+), was one of the first epilepsy 
mutations ever identified (Wallace, Wang et al. 1998). GEFS+ patients initially experience febrile 
seizures, which then progress to persistent afebrile seizures (Wallace, Wang et al. 1998). The 
heterozygous p.C121W knock-in mouse has been shown to model the GEFS+ phenotype 
(Wimmer, Reid et al. 2010). The p.C121W mutation disrupts a key disulfide bond in the Ig loop 
(McCormick, Isom et al. 1998) (Wallace, Wang et al. 1998). Although p.C121W traffics 
appropriately to the plasma membrane and its co-expression increases VGSC α subunit cell surface 
levels in culture, it is unable to participate in trans-homophilic cell adhesion or modulate sodium 
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current in vitro (Meadows, Malhotra et al. 2002). Studies of p.C121W subcellular localization in 
cultured neurons showed that, unlike wildtype β1, mutant subunits do not traffic to specialized 
axonal subdomains including the AIS and nodes of Ranvier. Phenotypically, p.C121W 
homozygous mice model Dravet syndrome, displaying brain-region specific hyperexcitability, 
reduced dendritic arborization of pyramidal neurons in the subiculum, and an increased 
susceptibility to febrile and spontaneous seizures (Wimmer, Reid et al. 2010). Animals that are 
heterozygous for this mutation are more susceptible to hyperthermia-induced seizures 
than Scn1b+/- or Scn1b+/+ animals. Even though β1-C121W is localized to the cell surface of 
neurons in vivo, they are incompletely glycosylated and do not interact with α subunits (Kruger 
and Isom 2016). Additional GEFS+ mutations in SCN1B, p.R85C and p.R85H, have also been 
studied in heterologous cells in vitro (Xu, Thomas et al. 2007). Both mutants have decreased 
expression compared to wild-type and are unable to modulate α subunits. Although of the two, 
only p.R85H has been shown to reach the plasma membrane (Patino, Claes et al. 2009) (Xu, 
Thomas et al. 2007). 
The Scn1b-null mouse line is a model of Dravet Syndrome (DS), and mutations in Scn1b are linked 
to DS (Chen, Westenbroek et al. 2004) (Patino, Claes et al. 2009), a severe and intractable pediatric 
epileptic encephalopathy that typically presents within the first year of life with myoclonic seizures 
that can change etiology over time. DS patients also suffer from a variety of comorbidities 
including ataxia, behavioral and developmental delay, and a high risk of sudden unexpected death 
in epilepsy, or SUDEP (Gataullina and Dulac 2017). DS mutations in SCN1B are homozygous 
recessive. The first DS mutation identified in SCN1B was p.R125C. This mutation has abnormal 
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trafficking and does not reach the cell surface in vitro, resulting in a functional null phenotype 
(Patino, Claes et al. 2009). An additional SCN1B DS mutations, p.I106F, was later identified, 
although the mechanism underlying this mutation remains unknown (Ogiwara, Nakayama et al. 
2012). Scn1b-null mice further validate the role of β1 in DS. These animals have frequent 
spontaneous seizures and abnormal neuronal excitability and development, consistent with that 
observed in DS patients (Chen, Westenbroek et al. 2004). In addition, Scn1b-null mice die at ~P 
21, and are thus a SUDEP model. 
Heterozygous mutations in SCN1B have been linked to a variety of other epilepsies. These include 
p.R85C, p.R85H, p.R125L, and an in-frame deletion mutation (Fendri-Kriaa, Kammoun et al. 
2011) (Scheffer, Harkin et al. 2007) (Wallace, Wang et al. 1998). One mutation that is specific to 
the developmentally regulated splice variant, β1B, has also been identified, p.G257R, and is linked 
to idiopathic epilepsy in multiple pedigrees. In vitro, this mutation also has defects in membrane 
trafficking (Patino, Brackenbury et al. 2011). Except for this mutation specific to β1B, all epilepsy-
linked mutations in SCN1B code for amino acids in the Ig loop domain, suggesting the clinical 
relevance of cell adhesion in the pathogenesis of epilepsy. 
Scn2b-null mice express approximately half of normal levels of cell surface TTX-sensitive VGSCs 
in brain. These animals are also more prone to pharmacologically induced seizures compared to 
wild-type animals (Chen, Bharucha et al. 2002). Additionally, a polymorphism 
in SCN2B (rs2298771) has been associated with idiopathic epilepsy (Baum, Haerian et al. 2014). 




β subunits have been implicated in neurodegenerative disorders including amyotrophic lateral 
sclerosis (ALS), Alzheimer’s Disease (AD), Huntington’s disease (HD), Multiple Sclerosis (MS), 
and Parkinson’s disease (PD) (Calhoun and Isom 2014) (O'Malley and Isom 2015). ALS is 
characterized by the degeneration of motor neurons in the spinal cord, motor cortex, and brainstem 
(Al-Chalabi, van den Berg et al. 2017). Differential gene expression of Scn1b and Scn3b have been 
observed in the Sod1 mouse model of ALS. Scn1b mRNA and protein are decreased, while there 
is increased Scn3b mRNA and protein in ventral dorsal horn. Neuronal hyperexcitability is found 
in ALS, thus, alterations in the expression of Scn1b and Scn3b, as well as the changes reported in 
the expression of Nav1.6, may explain hyperexcitability in ALS patients (Nutini, Spalloni et al. 
2011). 
Like that of the Amyloid Precursor Protein (APP), most famously known for its potential 
implications in AD, β subunits are substrates for sequential cleavage by β-site APP cleaving 
enzyme-1 (BACE1) and γ-secretase, potentially linking the β subunits to AD (Wong, Sakurai et 
al. 2005). In AD pathology, APP is initially cleaved on the extracellular portion of the membrane 
by BACE1 and then subsequently cleaved in the lumen of the membrane by γ-secretase, generating 
the amyloid β (Aβ) peptide. Aβ then accumulates and forms amyloid plaques. BACE1 is 
ubiquitously expressed throughout the body, but is expressed at highest levels in the pancreas and 
brain (Cole and Vassar 2007). The expression of BACE1 increases with age in the cortex of AD 
patients (Evin, Barakat et al. 2010). Interestingly, AD patients are at increased risk of seizures, 
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further supporting a potential role of VGSCs in AD (Pandis and Scarmeas 2012). BACE1 cleavage 
of β2 reverses normal β2 modulation of VGSC β subunits. In BACE1-null mice, decreased 
cleavage of β2 (or possibly other BACE1 substrates, including other VGSC β subunits) may 
contribute to the increased neuronal excitability observed in AD patients (Kim, Gersbacher et al. 
2011). In addition, SCN3B mRNA is lower in AD brains with neurofibrillary tangles (NFTs), 
another pathological issue displayed in some AD cases, suggesting β subunits may be implicated 
in the formation of NFTs and hyperexcitability in AD (Dunckley, Beach et al. 2006). 
β2 and β4 have been linked to HD, a genetic, neurodegenerative disease that affects motor 
coordination and mental ability. Ultimately, many of these patients lose their ability to walk and/or 
talk. In HD patient postmortem brain samples, SCN4B is downregulated in the striatum. This is 
mimicked in mouse models, where it has been shown to occur prior to loss of motor 
coordination. In vitro, β4 overexpression is implicated in neuronal development, suggesting that 
in HD, β4 dysregulation may contribute to neural degeneration. A decrease in β2 expression is also 
observed in the same mouse model of HD, but later in the pathogenesis of disease than observed 
for Scn4b (Oyama, Miyazaki et al. 2006). 
Although Scn2b-null mice have normal myelination, at least in the optic nerve, deletion of Scn2b is 
neuroprotective in the Experimental Allergic Encephalomyelitis (EAE) model of MS. 
Interestingly, Scn2b deletion in the EAE mouse model leads to decreased axonal degeneration, 
fewer demyelinated and dysmyelinated axons, reduced phenotypic severity, and increased survival 
(O'Malley, Shreiner et al. 2009). β2 may also be implicated in MS through sequential cleavage by 
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BACE1 and γ-secretase. In cerebrospinal fluid from MS patients, there is decreased BACE1 
activity and this biomarker in MS is linked to a more severe and prolonged disease state. 
Throughout MS progression, BACE1 expression continues to decline (Mattsson, Axelsson et al. 
2009). 
VGSC β1 subunits are also implicated in maintaining normal myelination. Scn1b-null mice 
phenotypically display abnormal optic nerve myelination, spinal cord dysmyelination, increased 
axonal degeneration, fewer optic nerve nodes of Ranvier, and defects in nodal ultrastructure in 
both the central and peripheral nervous systems. Loss of β1 expression, and thus adhesion, at nodes 
of Ranvier leads to abnormalities in the formation of paranodal junctions, suggesting β1 
contributes to myelination (Chen, Westenbroek et al. 2004). 
Increased expression and glycosylation of the VGSC β4 subunit compared to wild-type animals 
has been identified in a mouse model of PD. Studies of neurite outgrowth in response to expression 
of WT vs. mutant β4 that could not be glycosylated showed that neurite outgrowth was accelerated, 
with an increased level of filopdia-like protrusions. Thus, the glycosylation state of β4 may be 
critical for neuronal morphology and may be involved in PD pathogenesis (Zhou, Zhang et al. 
2012). Overall, β subunits contribute to myelination and neurodegenerative disease states through 
a variety of mechanisms. 
Neuropathic pain 
 
A variety of factors can cause neuropathic pain, including genetic mutations and nerve injury. This 
leads to defects in nociception, the neuronal pathways implicated in sensing noxious stimuli. The 
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VGSC β subunits are expressed in dorsal root ganglion (DRG) neurons and peripheral nerves, 
suggesting potential roles for these proteins in neuropathic pain (Lopez-Santiago, Pertin et al. 
2006). Behavioral pain phenotypes are difficult, if not impossible, to study in Scn1b-null mice due 
to their severe seizures and early post-natal death (Chen, Westenbroek et al. 2004). In spite of 
this, Scn1b-null DRG neurons are hyperexcitable, suggesting that these mice may have some form 
of allodynia (Lopez-Santiago, Brackenbury et al. 2011). On the other hand, Scn1b mRNA levels 
are increased in a model of chronic constrictive nerve injury, complicating the interpretation of the 
role of β1 in neuropathic pain (Blackburn-Munro and Fleetwood-Walker 1999). 
Studies examining the role of β2 in neuropathic pain have also led to conflicting results. 
While Scn2b-null mice are less sensitive than wild-type littermates in models of inflammatory and 
neuropathic pain, β2 protein levels are increased in injured and non-injured wild-type neurons in 
spared nerve injury and spinal nerve ligation models in rat (Lopez-Santiago, Pertin et al. 
2006) (Pertin, Ji et al. 2005). The latter occurs without a corresponding increase in mRNA levels 
(Pertin, Ji et al. 2005). Lastly, Scn2b mRNA levels are downregulated in cervical sensory ganglia 
after avulsion injury, but increased in a model of chronic constrictive nerve injury (Blackburn-
Munro and Fleetwood-Walker 1999) (Coward, Jowett et al. 2001). 
Scn3b mRNA expression is increased in multiple pain models, including in small C-fibers, in a 
chronic constrictive injury model in rats, in Aδ fibers in the streptozotocin model of diabetic 
neuropathy in rat, in the small and medium fibers in the sciatic nerve transection model, and finally, 
in the spared nerve injury model of neuropathic pain suggesting Scn3b may play a role in 
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modulating pain (Shah, Stevens et al. 2000, Shah, Stevens et al. 2001) (Takahashi, Kikuchi et al. 
2003).  
Although there are little data to directly implicate β4 in pain, the C-terminal portion of β4 plays a 
role in generating resurgent sodium current in DRG neurons (Grieco, Malhotra et al. 2005). 
Paroxysmal Extreme Pain Disorder (PEPD) is an inherited neuropathic pain syndrome linked to 
gain-of-function mutations in SCN9A, encoding Nav1.7. When PEPD-linked Nav1.7 mutants are 
co-expressed with the C-terminal β4 peptide, differential enhancement of resurgent current is 
observed, suggesting a potential role for β4 in pain (Theile, Jarecki et al. 2011). In all, the β 
subunits contribute to pain phenotypes in a cell-type and subunit-specific manner. 
Sudden Infant Death Syndrome (SIDS) and Sudden unexpected death in epilepsy (SUDEP) 
 
Sudden Infant Death Syndrome, or SIDS, is the unexpected death of a child up to one year of age 
where a clear cause of death cannot be identified via autopsy (Krous, Beckwith et al. 2004). The 
mechanism of SIDS remains to be elucidated, but one out of ten cases is associated with cardiac 
ion channel gene mutations, including in genes encoding the β subunits (Van Norstrand and 
Ackerman 2009). p.V36M and p.V54G mutations in SCN3B and p.S206L in SCN4B have been 
linked to SIDS (Tan, Pundi et al. 2010). Importantly, p.V36M in SCN3B has also been linked to 
idiopathic ventricular fibrillation, a potential fatal cardiac arrhythmia, and p.S206L in SCN4B also 
leads to abnormal excitability in rat ventricular myocytes (Tan, Pundi et al. 2010) (Valdivia, 
Medeiros-Domingo et al. 2010). There has been one instance of SIDS in a child with a p.R214Q 
in β1B, which has also been associated with Brugada Syndrome (Hu, Barajas-Martinez et al. 
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2012). β1B modulates Nav1.5 function, potentially providing an underlying mechanism 
for SCN1B linked cardiac dysfunction (Patino, Brackenbury et al. 2011). To date, no mutations 
in SCN2B have been linked to SIDS. 
Some ion channel genes that have been linked to SIDS have also been linked to Sudden 
Unexpected Death in EPilepsy (SUDEP). SUDEP is defined as the sudden and unexpected death 
of a person with epilepsy without any identifiable cause of death during autopsy (Nashef, So et al. 
2012). SUDEP occurs in up to 17% of epileptic patients and those diagnosed with Dravet syndrome 
(DS) are at an especially high risk for SUDEP (Ficker, So et al. 1998). Seizures that are difficult 
to treat by pharmacological intervention are also associated with increased SUDEP risk 
(Hesdorffer, Tomson et al. 2012). Currently, there are no reliable biomarkers for SUDEP, but it is 
likely that death is initiated by dysfunction in multiple organ systems, including autonomic 
dysfunction, cardiac arrhythmia, central or obstructive apnea, hypoventilation, and pulmonary 
edema (Surges and Sander 2012). Several types of cardiac events are known to occur during or 
after seizure activity in epilepsy patients. These include asystole, atrial fibrillation, bradycardia, 
tachycardia, and T-wave alterations (Jansen and Lagae 2010). Epileptic activity may affect the 
autonomic nervous system, which is known to be a critical regulator of cardiac function. 
Dysregulation of the autonomic nervous system and spreading depression to the brain stem centers 
during an epileptic event can result in fatal cardiac abnormalities (Jansen and Lagae 
2010) (Massey, Sowers et al. 2014) (Surges and Sander 2012). 
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Multiple DS and epilepsy animal models also serve as models for SUDEP, including the previously 
discussed Scn1b-null mouse line (Chen, Westenbroek et al. 2004). Additional models 
include Scn1a+/− mice, which model the haploinsufficiency observed in most DS patients, and 
the Kcna1-null mouse line, which deletes the voltage-gated potassium channel Kv1.1 (Glasscock, 
Yoo et al. 2010) (Oakley, Kalume et al. 2011). Intriguingly, each of these SUDEP models presents 
with different cardiac alterations that may mechanistically contribute to SUDEP. Scn1b-null mice 
display increased cardiac sodium current and prolonged QT and RR intervals. Scn1b-null mice 
treated with atropine or propranolol do not show differences in QT interval compared to vehicle 
treated animals, indicating the cardiac phenotype may not be a result of an abnormal autonomic 
activity (Lopez-Santiago, Meadows et al. 2007). Scn1a+/− mice also display increased cardiac 
sodium current, but additionally have bradycardia, focal discharges, a variable RR interval, and 
bundle branch block (Auerbach, Jones et al. 2013) (Kalume, Westenbroek et al. 2013). Kcna1-null 
mice display a cardiac phenotype as well, including atrioventricular (AV) block, bradycardia, 
premature ventricular contractions and altered heart rate variability (Glasscock, Yoo et al. 2010). 
Contrary to Scn1b-null mice, treatment of Scn1a+/− and Kcna1-null animals with atropine reverses 
AV block, suggesting parasympathetic hyperexcitability in these models (Glasscock, Yoo et al. 
2010) (Kalume, Westenbroek et al. 2013). In summary, studies with animal models and patient 
mutations provide evidence that β subunits are likely key regulators in the pathogenesis of SIDS 
and SUDEP, although additional work must be completed to further understand and ultimately 









Regulated Intramembrane Proteolysis (RIP) 
 
Transmembrane spanning b subunits are substrates for sequential cleavage by BACE1 and g-
secretase, a process also referred to as Regulated Intramembrane Proteolysis (RIP) (Fig. 1.6). RIP 
of transmembrane-spanning proteins has been identified over the last 20 years as an essential 
cellular process which is conserved from mammalian cells down to unicellular organisms (Lal and 
Caplan 2011). Like more classic examples of transmembrane signaling, such as receptor-
dependent signaling, RIP permits transmission of information across cellular compartments (Lal 
and Caplan 2011). The family of proteases that catalyze RIP are integral membrane proteins called 
intramembrane Cleaving Proteases (iCLiPs) (Wolfe, De Los Angeles et al. 1999). iCLiP catalytic 
residues are located within the hydrophobic environment of the membrane. This group of proteins 
can be divided into three conserved families: aspartyl proteases, zinc metalloproteinase site-2 
proteases, and serine proteases (Lemberg and Freeman 2007, Spasic and Annaert 2008). For many 
iCLiPs, initial cleavage of the substrate by an ectodomain sheddase, or secretase, is required. 
Ectodomain shedding occurs at a peptide bond near the transmembrane surface. Ectodomain 
shedding is carried out by either proteases of the integrin and metalloprotease (ADAM) family, 
matrix metalloproteases, or the aspartyl proteases, b-site APP cleaving enzymes (BACE) (Lal and 
Caplan 2011). Initial cleavage by an ectodomain sheddase is required to prime the substrate for 
subsequent cleavage by an iCLiP. Sequential cleavage by first, an ectodomain sheddase, and 
subsequently by an iCLiP, results in the generation of a liberated protein domain (LPD) capable 
of intercellular signaling (Haapasalo and Kovacs 2011, Lal and Caplan 2011). Susbstrate LPDs 
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generated by these sequential cleavage events may signal within the nucleus, cytosol, or 
extracellular space depending on the particular characteristics and orientation in the membrane of 
each individual substrate LPD (Haapasalo and Kovacs 2011, Lal and Caplan 2011). Here, we will 
focus on ectodomain sheddase, BACE1, and iCLiP, g-secretase, as these enzymes were identified 









Ectodomain shedding cleaves membrane protein substrates near or within the transmembrane 
domain, releasing a soluble extracellular domain (ectodomain) from a fragment that remains in the 
membrane (Lichtenthaler, Lemberg et al. 2018). The freed ectodomain often signals to other 
nearby cells. For many substrates of sheddase, or secretase, activity, the remaining fragment is 
further proteolytically processed by an iCLiP (Lichtenthaler, Haass et al. 2011, Lichtenthaler, 
Lemberg et al. 2018). BACE1 is a type-I transmembrane aspartyl-protease that assembles as a 
homodimer and functions as an ectodomain sheddase, or secretase (Vassar, Bennett et al. 1999, 
Hemming, Elias et al. 2009). Originally identified as the enzyme responsible for processing APP 
to generate Ab, proteomic studies have now identified greater than 40 substrates of BACE1, many 
of which are involved in contact-dependent intracellular communication or serve as receptors 
(Vassar, Bennett et al. 1999, Hemming, Elias et al. 2009). Thus far, all known BACE1 substrates 
are transmembrane proteins, the vast majority of which are of type-I topology. BACE1 has loose 
substrate specificity that does not obey strict cleavage recognition motifs. Many of the identified 
substrates are yet to be examined under physiological conditions and the functional consequence 
of their cleavage by BACE1 remains undetermined. Of the sheddase substrates that have been 
studied, shedding can have multiple biological outputs. These include providing a mechanism to 
terminate the function of a full-length membrane protein, to release a biologically active substrate 
ectodomain to activate a membrane protein, or to induce further processing by an iCLiP 
(Hemming, Elias et al. 2009, Lichtenthaler, Lemberg et al. 2018).  
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BACE1 enzymatic activity plays important roles in numerous physiological functions (Yan 2017). 
These include astrogenesis (Hu, He et al. 2013), neurogenesis (Morrison, Perez et al. 2000, 
Breunig, Silbereis et al. 2007, Hu, He et al. 2013), myelination and remyelination (Hu, Hicks et 
al. 2006, Willem, Garratt et al. 2006, Hu, Fan et al. 2016), neuronal excitability (Wong, Sakurai et 
al. 2005, Kim, Carey et al. 2007, Sachse, Kim et al. 2013, Agsten, Hessler et al. 2015), muscle 
spindle activity (Cheret, Willem et al. 2013), axonal growth and neuronal migration (Rajapaksha, 
Eimer et al. 2011, Cao, Rickenbacher et al. 2012, Hitt, Riordan et al. 2012, Barao, Gartner et al. 
2015), and synaptic function (Wang, Song et al. 2008, Mei and Nave 2014, Wang, Megill et al. 
2014, Yan, Fan et al. 2016). Unsurprisingly, dysregulation or loss of BACE1 leads to aberrant 
progression of the aforementioned physiological processes, which may contribute to BACE1-
linked disease onset and/or progression, such as Alzheimer’s disease (AD). In addition to AD, 
BACE1 activity is linked to epilepsy and retinopathy. BACE1-null mice display spontaneous 
convulsive seizure activity. Epileptic activity begins early in life in BACE1-null mice and becomes 
more frequent with age (Kobayashi, Zeller et al. 2008, Hitt, Jaramillo et al. 2010, Hu, Zhou et al. 
2010). Although the mechanism of how BACE1 deletion leads to seizure activity is unknown, 
cleavage of ion-channel subunits by BACE1 may contribute (Wong, Sakurai et al. 2005, Kim, 
Carey et al. 2007, Kim, Gersbacher et al. 2011, Sachse, Kim et al. 2013, Agsten, Hessler et al. 
2015). Additional work has linked BACE1 activity to retinopathy, although conflicting results 
have been reported. BACE1 deletion in mice, as well as the administration of multiple BACE1 
inhibitors, cause retinal thinning (Cai, Qi et al. 2012, Fielden, Werner et al. 2015). Some studies 
have linked BACE1 to retinal thinning via a mechanism mediated by vascular endothelial growth 
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factor receptor (VEGFR1) cleavage (Fielden, Werner et al. 2015). More recent work has shown 
that retinopathy from BACE1 inhibition is due to off-target inhibition of cathepsin D (Zuhl, Nolan 
et al. 2016). Furthermore, BACE1-null rats and some lines of BACE1-null mice do not show a 
retinopathy phenotype (Fielden, Werner et al. 2015). Additional work must be completed to 
determine whether BACE1 is directly implicated in these physiological processes and disease 
states or if aberrant processing of specific BACE1 substrates is the causative mechanism.  
g-secretase 
 
g-secretase comprises a protein complex of presenilin-1 (PS1) or presenilin-2 (PS2), nicastrin, 
anterior pharynx defective-1 (Aph-1), and presenilin enhancer-2 (Pen-2). These four proteins (in 
1:1:1:1 stoichiometry) are necessary and sufficient to form functional g-secretase (Edbauer, 
Winkler et al. 2003, Selkoe and Wolfe 2007, Spasic and Annaert 2008). PS contains the aspartyl-
protease catalytic site of g-secretase. The precise contributions of the remaining three components 
of the g-secretase complex to function are still under debate, but aid in forming the mature enzyme 
(Haapasalo and Kovacs 2011). Substrates of g-secretase, although diverse in structure, localization, 
and function, share some uniting characteristics. Most g-secretase substrates are type-I 
transmembrane proteins with a large ectodomain that often contains CAM-like domains 
(Haapasalo and Kovacs 2011). Furthermore, the substrates typically contain a single-pass 
transmembrane domain and a cytoplasmic C-terminus that can mediate intracellular signaling 
(Haapasalo and Kovacs 2011). g-secretase substrate proteins tend to function in cell signaling 
related to cell fate determination, adhesion, migration, neurite outgrowth, axon guidance, or the 
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formation and/or maintenance of synapses (Spasic and Annaert 2008). g-secretase preferentially 
cleaves membrane-bound protein stubs generated after ectodomain shedding of the full-length 
substrate by an a- and/or b-secretase. Initial ectodomain shedding may occur constitutively or 
when induced by a stimulus (Haapasalo and Kovacs 2011). Although g-secretase cleavage is not 
dependent on a specific amino acid sequence, cleavage occurs at or near the boundary of the 
transmembrane and cytoplasmic domains, typically flanking a stretch of hydrophobic amino acid 
sequence rich in positively charged residues (Spasic and Annaert 2008). Rather than sequence-
specificity, it appears that substrate recognition is dependent on the conformational state of the 
transmembrane domain. Ultimately, cleavage by g-secretase releases the intracellular domain 
(ICD) of the substrate protein. Of the studied substrate ICDs, several translocate to the nucleus 
where they are thought to play a role in modulating transcription. Generation of the ICD can be 
prevented by inhibition of g-secretase by pharmacological inhibitors or lack of functional g-
secretase, resulting in an accumulation of the substrate C-terminal fragment left in the membrane 
after ectodomain shedding (Haapasalo and Kovacs 2011). Substrate ICDs are highly labile and 
often accumulate in the presence of protease inhibitors, suggesting the proteasome, at least in part, 
contributes to ICD degradation (Kopan and Ilagan 2004, Lal and Caplan 2011).  
g-secretase activity is implicated in a number of physiological processes, including maintenance 
and proliferation of neural stem cells, regulation of cell fate, regulation of cell death, axon 
guidance, neurite outgrowth, cell adhesion, spine maturation, synaptogenesis, angiogenesis, and 
tumorigenesis (Paris, Quadros et al. 2005, Haapasalo and Kovacs 2011). Many of these are 
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mediated through g-secretase cleavage of its numerous substrates (Haapasalo and Kovacs 2011). 
Due to its important and wide-spanning roles in biological processes, variants in g-secretase itself 
or its substrates are associated with pathophysiological conditions. Most widely known, variants 
in PSEN, which encodes the catalytic subunit of g-secretase, are linked to Familial Alzhiemer’s 
Disease (FAD) (Wolfe 2019). FAD-linked PSEN variants increase the ratio of Ab towards the 
amyloidogenic form, Ab42, or increase the total amount of total Ab produced (Chavez-Gutierrez, 
Bammens et al. 2012). Work examining the genetic basis of Hidradenitis Suppurativa (HS), a 
debilitating and chronic inflammatory skin condition, identified heterozygous variants in g-
secretase genes, PSEN1, PSENEN, and NCSTN, in a small set of HS patients. The resulting variant 
mRNAs, although not examined experimentally, are predicted to undergo nonsense-mediated 
decay (Pink, Simpson et al. 2013). Variants in Notch, a well characterized g-secretase substrate, 
have been linked to T-cell lymphoblast and leukemia (TLL) (Aster, Blacklow et al. 2011). These 
variants can alter Notch processing by g-secretase or lead to nuclear accumulation of the Notch-
ICD (NICD) generated by RIP (Chadwick, Zeef et al. 2009, Aster, Blacklow et al. 2011, Bray and 
Gomez-Lamarca 2018). Other substrate variants have not been examined, but, like BACE1, 
dysregulation of substrate cleavage by g-secretase may lead to abnormal function and 






In conclusion, VGSC β subunits play critical roles in modulating the gating, localization, and 
kinetics of the VGSC pore as well as modulate the activities of some potassium channels (O'Malley 
and Isom 2015). In addition, these non-pore-forming proteins function as CAMs and signaling 
molecules in both excitable and non-excitable cell types (O'Malley and Isom 2015). Their 
importance as CAMs is implicated in neurite outgrowth, axonal pathfinding and fasciculation, and 
migration in cancerous cells (Malhotra, Kazen-Gillespie et al. 2000, Brackenbury, Calhoun et al. 
2010, Brackenbury and Isom 2011, Brackenbury 2012). β subunits are also substrates for 
sequential cleavage by BACE and γ-secretase (Wong, Sakurai et al. 2005). Variants in the genes 
encoding β subunits are linked to a variety of devastating diseases, including epilepsy, SIDS and 
SUDEP, cancer, neuropathic pain, and some of the major neurodegenerative disorders (Fig. 1.5) 
(Calhoun and Isom 2014). Additional research needs to be completed in order to further understand 
the biology of these critical proteins and their potential as novel therapeutic targets for a wide 
variety of disease states. The overall goal of the work described in this thesis is to further 




Chapter 2 VGSC b1 Subunit Processing by BACE1 and g-secretase Regulates Excitability by 
Ion Channel Gene Transcription 
 
 
Alexandra A. Bouza, Nnamdi Edokobi, Alexa M. Pinsky, James Offord, PhD, Lin Piao, MD, PhD, 
Anatoli N. Lopatin, PhD, Luis F. Lopez-Santiago, PhD, and Lori L. Isom, PhD 
Summary 
Loss-of-function variants in SCN1B, encoding voltage-gated sodium channel (VGSC) β1 subunits, 
are linked to human diseases that carry a high risk of sudden death, including epileptic 
encephalopathy and cardiac arrhythmia.  β1 subunits modulate the cell-surface localization, gating, 
and kinetics of VGSC pore-forming a subunits. They also participate in cell-cell and cell-matrix 
adhesion, resulting in intracellular signal transduction, promotion of cell migration, calcium 
handling,  and regulation of cell morphology. Here, we show that, in addition to their known 
functions in channel modulation and cell adhesion at the plasma membrane, β1 subunits are 
substrates for sequential regulated intramembrane proteolysis (RIP) by BACE1 and γ-secretase, 
resulting in the generation of a soluble intracellular domain (ICD) that is translocated to the 
nucleus. Using an unbiased, RNA-seq approach, we identified a subset of genes that are 
downregulated by β1-ICD overexpression in heterologous cells but upregulated in Scn1b null 
cardiac tissue which, by definition, lacks β1-ICD signaling, suggesting that the β1-ICD may 
normally function as a molecular break on gene transcription in vivo. We propose that human 
disease variants resulting in SCN1B loss-of-function cause transcriptional dysregulation that 
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contributes to altered excitability. These results provide important new insights into the mechanism 
of SCN1B-linked channelopathies, adding RIP-excitation coupling to the multi-functionality of 




Loss-of-function (LOF) variants in SCN1B, encoding voltage-gated sodium channel (VGSC) β1 
subunits, are linked to human diseases that carry a high risk of sudden death, including early 
infantile epileptic encephalopathy type 52 (EIEE52, OMIM 617350), Brugada Syndrome 5 
(OMIM 612838), and Atrial Fibrillation Familial 13 (OMIM 615377). β1 subunits are type one 
transmembrane proteins containing a single, extracellular V-type immunoglobulin (Ig) domain, 
making them part of the Ig-superfamily of cell adhesion molecules (CAMs) (O'Malley and Isom 
2015, Bouza and Isom 2018). β1 subunits are multifunctional proteins. In addition to their 
canonical roles in modulating the cell-surface localization, gating, and kinetics of VGSC pore-
forming, α subunits (Isom, De Jongh et al. 1992, Isom, Scheuer et al. 1995), β1 subunits modulate 
voltage-gated potassium currents and participate in cell-cell and cell-matrix adhesion as CAMs 
(Isom and Catterall 1996, Malhotra, Kazen-Gillespie et al. 2000, Deschenes and Tomaselli 2002, 
Nguyen, Miyazaki et al. 2012). Scn1b null mice, which model EIEE52 and have cardiac 
arrhythmia, have cell type specific alterations in sodium current (Lopez-Santiago, Meadows et al. 
2007, Brackenbury, Calhoun et al. 2010, Lopez-Santiago, Brackenbury et al. 2011, Lin, O'Malley 
et al. 2015), multiple deficits in neuronal migration and pathfinding in the cerebellum 
(Brackenbury, Yuan et al. 2013), fewer nodes of Ranvier in the optic nerve (Chen, Westenbroek 
et al. 2004), aberrant neuronal pathfinding and fasciculation in the corticospinal tract 
(Brackenbury, Davis et al. 2008), delayed maturation of GABAergic signaling in brain (Yuan, 
O'Malley et al. 2019), abnormal formation of cardiac intercalated discs (Veeraraghavan, Hoeker 
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et al. 2018), and altered calcium signaling in cardiac ventricular myocytes (Lin, O'Malley et al. 
2015). Finally, VGSC β1 subunits are essential for life: Scn1b null mice have severe seizures, 
ataxia, and cardiac arrhythmia, with 100% mortality by postnatal day (P) 21 (Chen, Westenbroek 
et al. 2004, Lopez-Santiago, Meadows et al. 2007).  
Previous work by others showed that β1 subunits undergo regulated intramembrane proteolysis 
(RIP) through sequential cleavage by the β-site Amyloid Precursor Protein (APP) cleaving 
enzyme-1 (BACE1) and γ-secretase (Wong, Sakurai et al. 2005). Initial cleavage by BACE1 sheds 
the β1 Ig domain, which our laboratory previously showed functions as a ligand for cell adhesion, 
and leaves the β1-C-termnial fragment (β1-CTF) in the membrane (Davis, Chen et al. 2004, Patino, 
Brackenbury et al. 2011). Initial cleavage by BACE1 was reported to be the rate-limiting step in 
β1 RIP. γ-secretase subsequently cleaves the remaining β1-CTF in the lumen of the membrane, 
generating a soluble intracellular domain (β1-ICD) (Fig. 2.1B) (Wong, Sakurai et al. 2005).  
Although typically studied as neuronal enzymes, BACE1 and γ-secretase are expressed 
ubiquitously throughout the body and have been shown to play important roles in other tissues. 
For example, in cardiac myocytes, KCNE1, which assembles with KCNQ1 channels to generate 
delayed-rectifier potassium current, is a BACE1 substrate (Sachse, Kim et al. 2013, Agsten, 
Hessler et al. 2015). Atrial cardiomyocytes isolated from BACE1 null mice show a decrease in 
total steady-state potassium current (Agsten, Hessler et al. 2015). Lastly, presenilins, the catalytic 
component of the γ-secretase complex, have been implicated in degradation of the ryanodine 
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receptor in cardiomyocytes (Pedrozo, Torrealba et al. 2013). BACE1 and γ-secretase also play 
roles in cancer. For example, inhibitors of γ-secretase inhibit growth of human glioblastoma as 
well as human lung adenocarcinoma tumors xenografted into nude mice (Paris, Quadros et al. 
2005, Li, Chen et al. 2011, Pedrozo, Torrealba et al. 2013, Sachse, Kim et al. 2013, Chen, Liu et 
al. 2016).  
Evidence from other BACE1 and γ-secretase substrates suggests that ICDs generated by RIP are 
translocated to the cell nucleus where they modulate transcription (Kim, Carey et al. 2007, 
Haapasalo and Kovacs 2011). Based on this evidence, we proposed that the β1-ICD may 
participate in transcriptional regulation in vivo and that the absence of β1 intramembrane cleavage 
and downstream signaling may contribute to disease mechanisms in patients with LOF SCN1B 
variants. Thus, the goal of this study was to test the hypothesis that the β1-ICD couples membrane 
excitability as a VGSC subunit to transcriptional regulation (RIP-excitation coupling). Using an 
unbiased RNA-seq approach, we identified multiple gene pathways that are downregulated by β1-
ICD overexpression in heterologous cells. Due to our previous work showing the important role 
of Scn1b in cardiac physiology, we also performed RNA-seq to examine gene expression profiling 
in mouse cardiac ventricle isolated from P10 Scn1b wild-type (WT) vs. Scn1b null animals, in 
which the β1-ICD signaling pathway is deleted. In general, we found that the gene groups that 
were downregulated by β1-ICD overexpression in heterologous cells were upregulated in Scn1b 
null cardiac ventricle, suggesting that the β1-ICD may normally act as molecular break on gene 
expression in heart. We showed that the observed transcriptional upregulation of potassium 
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channel gene expression translates to increased potassium currents in Scn1b null cardiac myocytes. 
Finally, we showed that calcium current is decreased in Scn1b null ventricular myocytes, 
consistent with alterations in calcium ion binding proteins and calcium channel modulatory 
proteins identified by RNA-seq experiments. Taken together, our work identifies a novel VGSC 
β1-mediated signal transduction cascade in heart with physiological implications for the regulation 
of normal development as well as pathology. The absence of β1 intramembrane cleavage and 
downstream signaling, as modeled by Scn1b null mice, may contribute to cardiac disease 




β1 is sequentially cleaved by BACE1 and γ-secretase in vitro.  
We used stably transfected Chinese Hamster Lung (CHL) fibroblasts to confirm previous results 
identifying β1 as a substrate for RIP by BACE1 and γ-secretase, as well as to establish a model 
system to study downstream signaling from b1 cleavage (Fig. 2.1 A and B) (Wong, Sakurai et al. 
2005). CHL cells are optimal for this work because they do not express endogenous VGSC β1 
subunit mRNA (Isom, Scheuer et al. 1995), but do express low levels of both BACE1 and γ-
secretase (Fig. 2.1C). We generated a bicistronic, full-length WT VGSC β1 subunit cDNA 
expression vector containing a C-terminal V5 epitope tag, a cleaving 2A sequence, and enhanced 
Green Fluorescent Protein (eGFP) to establish a stable β1-V5-2AeGFP-CHL cell line. Western 
blot analysis of cell lysates revealed an immunoreactive band at ~37 kDa, the expected molecular 
weight (MW) of full-length β1. An additional band was present at ~20 kDa, consistent with the 
previously identified apparent MW of the β1-CTF that remains in the membrane following initial 
cleavage by BACE1 (Fig. 2.1D) (Wong, Sakurai et al. 2005). To determine if the ~20 kDa 
fragment was the β1-CTF, β1-V5-2AeGFP-CHL cells were treated with vehicle (0.1% DMSO) or 
increasing concentrations (50 nM to 1000 nM) of the γ-secretase inhibitor, DAPT (Wong, Sakurai 
et al. 2005, Kim, Carey et al. 2007). If the ~20 kDa fragment were indeed the β1-CTF, DAPT 
would block the second cleavage event by g-secretase leading to an accumulation of the 
intermediary cleavage product produced by BACE1, β1-CTF, in the membrane. DAPT treatment 
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resulted in a concentration-dependent accumulation of the 20 kDa fragment, suggesting that this 
band represented β1-CTF, which would have been subsequently processed by g-secretase in the 
absence of drug (Fig. 2.1 E and F).  
 
To determine if initial β1 cleavage was the result of BACE1 activity, rather than activity of another 
protease, e.g. an α-secretase, β1-V5-2AeGFP-CHL cells were treated with vehicle (0.1% DMSO), 
1000 nM DAPT, or 200 nM of β-secretase inhibitor IV (BSI) (Kim, Carey et al. 2007), varying 
the order of addition. Treatment of cells with 200 nM BSI alone did not alter the level of β1-CTF, 
as assessed by western blot. Instead, treatment with DAPT was required to detect differences in 
the amount of β1-CTF generated. Co-administration of BSI plus DAPT resulted in a significant 
decrease in the level of β1-CTF generated in comparison to DAPT treatment alone. Treatment with 
DAPT seven hours prior to BSI treatment did not change the amount of β1-CTF generated. Taken 
together, these results suggest that RIP of β1 occurs sequentially, with  initial cleavage by BACE1 
(Fig. 2.1 G and H). The data presented in Fig. 2.1 strengthen previous evidence showing that β1 is 
a substrate for sequential cleavage by BACE1, which generates the β1-CTF, followed by γ-




Figure 2.1 β1 subunits are substrates for BACE1 and γ-secretase intramembrane cleavage. A. 
Cartoon diagram of the proposed β1-mediated signal transduction cascade. B. Schematic of β1 
with BACE1 and γ-secretase cleavage sites. C. Chinese Hamster Lung (CHL) cells stably 
expressing WT β1-V5 also endogenously express BACE1 and presenilin-1, the catalytic subunit of 
γ-secretase. D. WT β1-V5 is cleaved by BACE1 and the β1-C-terminal fragment (β1-CTF) is found 
in the membrane fraction. E. Treatment with γ-secretase inhibitor, DAPT, leads to a concentration-
dependent accumulation of β1-CTF. F. Quantification of E. Protein levels were normalized to the 
loading control and reported as fold change respective to the vehicle treated group. Significance 
(p-value <0.05) was determined using a one-way ANOVA between each treatment and the negative 
control (vehicle treatment). G. Scheduled treatments with DAPT and β-secretase inhibitor IV 
inhibit formation of respective cleavage products in a manner consistent with sequential cleavage. 
H. Quantification of G. Protein levels were normalized to the loading control and reported as fold 
change respective to the vehicle treated group.  Significance (p-value <0.05) was determined using 
a one-way ANOVA between each treatment and the positive control (DAPT treatment alone). Data 
are represented as the mean ± SEM. 
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The β1 ICD localizes to the nucleus.  
To determine if the β1-ICD localizes to the nucleus, similar to other substrates of intramembrane 
sequential BACE1 and γ-secretase cleavage, we cloned and transiently expressed WT β1-V5 or 
β1-ICD-V5 in CHL cells (Haapasalo and Kovacs 2011). Immunofluorescence staining with anti-
V5 showed that, unlike full-length β1-V5, for which there was little nuclear staining, 
approximately 50% of the expressed β1-ICD-V5 localized to the nucleus of CHL cells, as 





Figure 2.2: β1-ICD-V5 localizes to the nucleus. A. Full-length WT β1-V5 shows little to no nuclear 
localization, as determined by staining for the V5-epitope tag and DAPI. Strong colocalization is 
observed between staining for the V5-epitope tag of the β1-ICD and the nucleus (DAPI, yellow). 
B. Staining for the V5-epitope tag for β1-p.Y181A-V5, β1-p.Y181F-V5, and β1-p.Y181E-V5 
colocalizes with the nucleus. C. Quantification of intensity of V5 and DAPI staining across the 
transfected cell. Average data from 11-17 cells per condition is shown. Data are represented as 




β1-ICD overexpression in CHL cells leads to differential expression of VGSC genes. 
After identifying the β1-ICD in the nucleus, a key question was to determine whether the β1-ICD 
can modulate transcription. To investigate this problem, we generated CHL cell lines which stably 
overexpressed either eGFP or β1-ICD-V52A-eGFP (Fig. 2.3 A and B). Paired-end RNA-Seq was 
performed on each cell line as fee-for-service at the University of Michigan Sequencing Core.  
Data were normalized and differential expression analysis was performed with DESeq2 as fee-for-
service by the University of Michigan Bioinformatics Core. Samples grouped according to 
genotype by principal component analysis (PCA) (Supplemental Fig. 2.2A). 1,396 genes were 
found to be differentially expressed in the β1-ICD line compared to the eGFP-only control line. 
Interestingly, of the genes identified using this unbiased approach, three VGSC genes were 
identified as differentially expressed: Scn3a was downregulated in the β1-ICD overexpressing line 
compared to the control line, while both Scn4a and Scn5a were upregulated compared to the 
control line (Fig. 2.3C). RT-qPCR experiments confirmed these alterations in VGSC gene 
expression in the presence of the β1-ICD (Fig. 2.3D).  
 
To ask whether the observed changes in VGSC transcription resulted in detectable changes in 
sodium current (INa), we overexpressed b1-ICD-V5-2A-eGFP or eGFP in Human Embryonic 
Kidney (HEK) cells using transient transfection and tested for INa using whole cell voltage clamp 
~24 hours later (Fig. 2.4 β A). Four independent experiments were performed per condition. No 
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significant differences in INa density were observed in cells expressing the β1-ICD compared to 
control.  We next transiently transfected cells that already expressed INa,  HEK-Nav1.5 cells, with 
eGFP (negative control), WT b1-V5-2A-eGFP (positive control), or b1-ICD-V5-2A-eGFP to ask 
whether β1-ICD expression could change INa density.  eGFP positive cells were analyzed by whole 
cell patch clamp 24 hours post-transfection. Four independent experiments were performed per 
condition. Co-expression of the b1-ICD with Nav1.5 did not significantly change INa density or the 
voltage-dependence of INa activation or inactivation compared to eGFP alone. Taken together, 
these results suggest that the combined b1-ICD-driven up- and down-regulation of VGSC a 
subunit gene expression may not be sufficient to change whole cells INa density in heterologous 
cells (Supplemental Fig. 2.1 B-E).  Nevertheless, our previous in vivo work showing that Scn1b 
deletion results in upregulation of Scn3a and Scn5a/Nav1.5 expression and increased INa in cardiac 
myocytes is consistent with the idea that the β1-ICD regulates these genes (Lopez-Santiago, 
Meadows et al. 2007, Lin, O'Malley et al. 2015). However, the extent and direction of this 
regulation (up or down) may be cell type specific and/or developmentally regulated. 
 
In addition to their nuclear functions, some ICDs play local roles at their site of cleavage (Lee and 
Ch'ng 2020). To test whether acute application of the β1-ICD could modulate INa directly,  we 
applied a synthetic β1-ICD peptide (β1183-218) through the patch pipet during whole cell voltage 
clamp recording of HEK-Nav1.5 cells. No significant differences in INa density or in the voltage-
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Figure 2.3: Expression of the β1-ICD alters VGSC gene expression. A. Immunocytochemistry for 
V5 for eGFP stable line and wild-type β1-ICDV52AeGFP stable line. DAPI in blue, eGFP in 
green, and V5 in red. B. Immunoblot (anti-GFP) of CHL cells stably overexpressing eGFP only 
or wild-type β1-ICD with a V5 epitope tag and a 2A-eGFP sequence on the 3’ end. C. VGSC genes 
are differentially expressed in presence of β1-ICD compared to control. D. qPCR confirms some 
VGSC genes are differentially expressed in the presence of β1-ICD compared to control. Data 




Supplemental Fig. 2.1: b1-ICD has no effect on sodium current in heterologous cells. A. 
Expression of b1-ICD-V5-2Ae-GFP does not increase INa density in parental HEK cells 
compared to control, eGFP-only. N=3, n=12-17 per condition. B. INa density is increased when 
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WT b1-V5-2A-eGFP is co-expressed with Nav1.5 compared to eGFP-only control. Co-expression 
with b1-ICD-V5-2A-eGFP does not increase INa density compared to eGFP-only control. C. 
Maximal current is increased when WT β1-V5-2A-eGFP, but not β1-ICD-V5-2A-eGFP, is co-
expressed with Nav1.5 compared to eGFP control. D. Co-expression of WT β1-V5-2A-eGFP or 
β1-ICD-V5-2A-eGFP has no effect on the voltage-dependence of INa activation compared to 
eGFP control. E. Co-expression of WT β1-V5-2A-eGFP or β1-ICD-V5-2A-eGFP has no effect on 





 Transient INa density (pA/pF) Persistent INa density (pA/pF) 
hNav1.5 alone -156.8±30.2 -0.9±0.2 
hNav1.5+ICB peptide -177.6±29.5 -0.6±0.2 
 
Table 2.1: b1-ICD peptide has no effect on Nav1.5 transient or persistent sodium current density. 
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Yin-Yang of gene expression changes 
 
Gene Ontology (GO) analysis revealed groups of genes that were changed by overexpression of 
the β1-ICD via RNA seq (Fig. 2.4A and Supplemental Figure 2.3). The primary sets of genes 
differentially expressed included, but were not limited to, those involved in cell adhesion, the 
immune response, cellular proliferation, and calcium ion binding. (Fig. 2.4B, left). To determine 
whether the expression of any of these sets of genes was also modulated in an excitable tissue that 
is known to normally express Scn1b, and for which Scn1b LOF is critical to disease mechanisms, 
we performed a second RNA-Seq experiment from P10 Scn1b WT and null mouse cardiac 
ventricle (Fig. 2.4A). We chose P10 because this developmental time point is prior to disease onset 
in Scn1b null mice, and thus uncomplicated by possible secondary effects of epilepsy (Yuan, 
O'Malley et al. 2019). Paired-end RNA-Seq, normalization of data, and differential expression 
analysis with DESeq2 were performed as above. Samples grouped according to genotype by PCA 
(Supplemental Fig. 2.2B). 696 genes were found to be differentially expressed between Scn1b WT 
and null tissues. Although some of these changes in gene expression may be compensatory to 
deletion of the full-length b1 protein, rather than solely to the absence of the b1-ICD, we 
hypothesized that those which changed in a manner consistent with genes altered by 
overexpression of the b1-ICD may result from the loss of this novel signaling pathway. GO 
analysis revealed many similar groups of differentially expressed genes as in the CHL cell 
experiment, including genes in the immune response, proliferation, and calcium ion binding 
pathways (Fig. 2.4B, right). Importantly, in heterologous cells where the β1-ICD was 
overexpressed, the majority of these gene groups were downregulated. In contrast, where the β1-
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ICD was deleted (Scn1b null cardiac tissue), these same gene groups were generally upregulated 
(Fig. 2.4C-G). Taken together, these data suggest that the β1-ICD may normally participate in gene 
suppression in vivo. In contrast to our previous work showing increased Scn3a and Scn5a 
expression at P14-17 in Scn1b-null hearts (Lopez-Santiago, Meadows et al. 2007, Lin, O'Malley 
et al. 2015), the present RNA-seq results showed no changes in VGSC gene expression at P10. 
Thus, Scn1b deletion may lead to developmentally regulated changes in VGSC a subunit 





Figure 2.4: The β1-ICD modulates gene transcription in vitro and in vivo. A. Experimental design. 
B. Gene ontology (GO) groups overrepresented in analysis from CHL cells overexpressing the β1-
ICD (left) and Scn1b null cardiac ventricle (right). C/D/E. Heat maps depicting genes altered in 
each RNA-seq related to calcium ion binding (C), the immune response (D), and proliferation (E). 
F. Percent of genes downregulated in each data set for calcium ion binding, immune response, 
and proliferation GO groups. G. Percent of genes upregulated in each data set for calcium ion 




Supplemental Fig. 2.2:  Principal Component Analysis (PCA) for RNA-Seq experiments. A. CHL 
cells stably overexpressing eGFP only (▲) or β1-ICD-V5-2A-eGFP (⬤) samples bin according 





Supplemental Fig. 2.3: ClueGO network analysis of RNA-seq data sets. A. ClueGO network 
analysis for Scn1b+/+ vs. Scn1b-/- cardiac ventricle RNA-seq for GO groups with an adjusted p-
value ≤ 0.05. B. ClueGO network analysis for CHL cells stably overexpressing eGFP or the β1-
ICD and eGFP for GO groups with an adjusted p-value ≤ 0.0001. 
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Potassium currents are increased in Scn1b-null ventricular cardiac myocytes.  
Over-expression of the β1-ICD in CHL cells resulted in changes in the expression of potassium 
channel genes compared to controls: downregulation of Kcns3, and Kcnk2, and upregulation of 
Kcnk3. In contrast, a set of potassium channel genes, Kcnma1, Kcnmb4, Kcnk12, Kcnn1, Kcnd3, 
Kcnu1, were upregulated in Scn1b null cardiac ventricular tissue, in which the β1-ICD signaling 
pathway is deleted (Fig. 2.5A and B). To investigate functional changes in potassium channel gene 
expression in Scn1b null cardiac ventricle, we recorded potassium currents in acutely dissociated 
ventricular cardiac myocytes from the left ventricular wall of P17 Scn1b WT and null mice.  
A pre-pulse to -120 mV was required for this study since the voltage-dependence of steady state 
inactivation of the peak potassium current, and of most of the individual potassium current 
components, were significantly shifted to hyperpolarized potentials in myocytes isolated from P17 
mice of both genotypes, compared to those previously reported in myocytes from adult mice 
(Zhou, Jeron et al. 1998, Xu, Guo et al. 1999). This may result from differences in myocyte 
preparation between laboratories or in the developmental stage of the cells and will be an 
interesting topic for future studies. 
Whole-cell potassium currents were qualitatively similar in myocytes from Scn1b null and WT 
mice (Fig. 2.5C and D). Current amplitudes in myocytes from Scn1b null mice were smaller 
compared to those from WT animals, however, as observed previously during examination of INa 
(Lopez-Santiago, Meadows et al. 2007), Scn1b null myocytes had a significantly smaller 
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membrane capacitance (Cm) (WT, Cm = 92.45 ± 5.13 pF, n = 17, and Scn1b-/-, Cm = 62.32 ± 1.15 
pF, n =17 p < 0.001), resulting in increased potassium current densities of ~27% and ~53% for 
Ipeak (Fig. 2.6A and Supplemental Table 2.3) and for Iend (Fig. 2.6B and Supplemental Table 2.3), 
respectively (Lopez-Santiago, Meadows et al. 2007). Scn1b deletion did not affect either the 
voltage-dependence or slope of inactivation of the peak current (Fig. 2.6C and Supplemental Table 
2.3). For the voltage-dependence of inactivation of Iend, which is best described by the sum of two 
Boltzmann functions, Scn1b deletion resulted in a ~70% increase in the amplitude of the major 
component (A1), while the minor component (A2) was reduced by ~40% (Fig. 2.6D and 
Supplemental Table 2.4). V1, 1/2 was unaffected, however V2, 1/2 was shifted ~ +14 mV for Scn1b 
null myocytes compared to WT (Fig. 2.6D and Supplemental Table 2.4).  
Detailed analysis of the decay phase of the potassium current revealed the presence of Ito f, Ito s, IK 
slow, and Iss. With the exception of Ito f, the current densities (at +60 mV, from -120 mV pre-pulse 
potential) of all other components were significantly increased in Scn1b null myocytes compared 
to WT (Fig. 2.7A). At strongly hyperpolarized membrane potentials (-120 to -90 mV) the 
availabilities of Ito s (Fig. 2.7D), IK slow (Fig. 2.7E), and Iss (Fig. 2.7F) were increased in Scn1b null 
myocytes, although for Ito s this increase was not significant. In contrast, at hyperpolarized 
potentials Ito f channels (Fig. 2.7C) exhibited similar availability, and at mildly depolarized 
potentials (-70 to -60 mV) availability was higher in myocytes from Scn1b null animals. While Iend 
also showed increased availability at hyperpolarized potentials (Fig. 2.7D), at -70 to -40 mV Iend 
availability in Scn1b null myocytes was less than that in WT animals (p = 0.05 to 0.1 at individual 
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membrane potentials). This difference was even more significant when Iend availability was 
averaged within this voltage range (WT Iend= 10.3 ± 0.8 pA/pF, Scn1b-/- Iend= 6.6 ± 2.0 pA/pF, p < 
10-6), with a ~36% loss in average availability following loss of Scn1b expression. Scn1b deletion 
resulted in a similar reduction of Iss between -70 and -40 mV (Fig. 2.6F) (average Iss at -70 to -50 
mV reduced ~21%, p < 0.05). For the voltage-dependence of inactivation, both Ito f (~+ 8 mV) and 
Iss (~+10 mV) exhibited a significant depolarizing shift in response to Scn1b deletion. The slope 
(λ) for Ito f increased approximately 2-fold while that of IK slow showed an approximate 50% increase 
(Supplemental Table 2.5). Additionally, decay of IK slow (at +60 mV) is slowed in Scn1b null 






Figure 2.5: b1-ICD regulates potassium channel genes and potassium currents in cardiac 
ventricular myocytes. A. Experimental design of RNA-Seq experiments from CHL cells stably 
overexpressing the β1-ICD and from P10 Scn1b WT or Scn1b null mouse cardiac ventricle. B. 
RNA-seq showed that β1-ICD expression downregulates potassium channel genes, while Scn1b 
null mice show upregulated potassium channel gene expression in cardiac ventricle. C. 
Representative potassium currents recorded from ventricular myocytes obtained from WT and 
Scn1b null mice. To assess the I-V relationship 5 sec pulses were applied in +10 mV increments 
from -70 mV to +70 mV, following a 5 sec prepulse to -120 mV. D. Typical traces observed during 
investigation of voltage-dependence of steady-state inactivation. 5 sec conditioning pulses were 
applied in +10 mV increments from -120 to -10 mV followed by a 5 sec depolarization to +60 mV. 





 A (pA/pF) V½ (mV) λ C (pA/pF) 
WT 87.6±6.0  -74.1±2.8  -0.06±0.00  3.4±0.6 
Scn1b-/- 111.3±5.1** -75.9±3.6  -0.06±0.00  5.2±1.0 
 
Table 2.3: Voltage-dependence of inactivation of peak potassium currents recorded from 
dissociated ventricular cardiomyocytes. C denotes the average pedestal current, while A 
describes the amplitude, and V½ and λ the average half-voltage and slope values, respectively, of 
the voltage-dependence of inactivation of the peak (Ipeak) potassium currents (see Fig. 7C) as 
described in Materials and Methods. Scn1b deletion results in a ~27% increase in A (Ipeak 
amplitude) and ~53% increase in the pedestal current (C) amplitude but does not affect V½ or λ. 
15 myocytes were examined from each group. Myocytes were isolated from 3 WT and 2 Scn1b-/- 






Figure 2.6: Comparison of current density and voltage-dependence of inactivation of peak and 
end potassium currents. A-B. Scn1b deletion results in increased peak (Ipeak) (A) and end (Iend) 
(B) potassium current densities at depolarized potentials. C-D. Availability of both Ipeak (C) and 
Iend (D) current is increased at hyperpolarized potentials following Scn1b deletion, while Iend 
availability is decreased at more depolarized potentials (double-ended arrow). Voltage-
dependence of inactivation for Ipeak and Iend are described in Tables 1 and 2, respectively. *P ≤ 











 A1 (pA/pF) V1, ½ (mV) λ1 A2 (pA/pF) V2, ½ (mV) λ2 C (pA/pF) 
WT 16.2±1.1 -95.8±1.6 
-
0.13±0.01 













Table 2.4: Voltage-dependence of inactivation of end potassium currents. As described in 
Materials and Methods, the voltage-dependence of Iend is best described by the sum of two 
Boltzmann functions. A1, V1, ½, and λ1 represent amplitude, half-voltage, and slope of the major 
component, respectively, while A2, V2, ½, and λ2 represent the parameters of the minor 
component. C describes the average pedestal current (see Fig. 7D). Scn1b deletion increases the 
amplitude of the major component (A1) by approximately 70% compared to current in myocytes 
from WT animals, while the amplitude of the minor component (A2) shows a loss of ~40%. V2, ½ 





Figure 2.7: Comparison of current density, rate of decay, and availability of individual 
components of the potassium current. A-B. Mean current density (A) and time-constant of current 
decay (B) measured at +60 mV for Ito f, Ito s, IK slow, and Iss currents in myocytes from WT (open 
columns) and Scn1b-/- (filled columns) mice. At +60 mV current density of Ito f is unchanged (A) 
while that of Ito s, IK slow, and Iss is increased with Scn1b deletion. At +60 mV Scn1b deletion results 
in slower decay of IK slow (B) (inset, Ito f data shown at higher magnification). C-F. Voltage-
dependence of inactivation of Ito f (C), Ito s (D), IK slow (E), and Iss (F) current in myocytes from WT 
(open circles) and Scn1b-/- (filled circles) mice. With Scn1b deletion, Ito s, IK slow, and Iss availability 
increases at hyperpolarized potentials, Ito f availability increases at moderately depolarized 
potentials, while at depolarized potentials Iss availability is decreased (double-ended arrow). 





  A (pA/pF) V½ (mV) λ C (pA/pF) n 
Itof 
WT 46.1±5.2 -67.1±2.4 -0.15±0.01 1.9±1.1 14 
Scn1b-/- 47.9±4.7 -58.9±1.2** -0.26±0.02** 2.1±0.4 14 
Itos 
WT 13.0±6.2 -63.3±5.9 -0.20±0.12 0.5±2.2 3 
Scn1b-/- 16.0±3.1 -74.4±7.3 -0.14±0.05 2.0±1.4 4 
IK 
slow 
WT 19.0±2.4 -86.6±3.4 -0.08±0.01 10.3±3.3 5 
Scn1b-/- 26.7±1.7* -92.1±1.8 -0.12±0.01* 10.6±0.6 7 
Iss 




-91.1±3.2 * -0.20±0.03 6.4±0.8* 5 
 
Table 2.5: Voltage-dependence of inactivation of Ito f, Ito s, IK slow, and Iss. A, V½, λ, and C 
represent amplitude, half-voltage, slope and pedestal current, respectively, for Ito f (see Fig. 8C), 
Ito s (Fig. 8D), IK slow (Fig. 8E) and Iss (Fig. 8F) as indicated in Materials and Methods. Both Ito f 
and Iss exhibited a shift in V½ of ~+ 8 mV and ~+10 mV, respectively, on Scn1b deletion. Ito f 
underwent an approximately 2-fold increase in slope while that of IK slow showed ~50% increase. 
**P < 0.01, *P < 0.05, n refers to the number of cells examined. 
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Calcium currents are decreased in Scn1b null ventricular cardiac myocytes.  
 
RNA-seq analysis of b1-ICD overexpression in CHL cells as well as of Scn1b null ventricular 
tissue showed alterations in the expression of genes encoding proteins known to modulate voltage-
gated calcium channel (VGCC) activity. b1-ICD overexpression resulted in downregulated 
expression of the VGCC b4 subunit gene, Cacnb4. In contrast, P10 Scn1b null cardiac ventricle 
showed upregulation of the VGCC b1 subunit gene, Cacna1b (Supplemental Fig. 2.4). In general, 
b1-ICD overexpression led to decreased expression of calcium ion binding protein (CBP) genes, 
while Scn1b deletion led to increased expression of CBP genes (Fig. 2.4C). CBPs are complex 
regulators of VGCCs that can increase or decrease calcium current, depending on the particular 
CBP(s) at play (Nejatbakhsh and Feng 2011). To determine whether calcium handling was altered 
by Scn1b expression in vivo, we performed whole-cell voltage-clamp recording of L-type calcium 
current  (ICa,L) and simultaneously added the calcium indicator, fluo-4, through the micropipette to 
record ICa,L-triggered calcium transients (Fig. 2.8A). Single ventricular cardiac myocytes were 
voltage-clamped and depolarized from a holding potential of -50 mV to +60 mV in 10 mV 
increments. At the same time, intracellular calcium dynamics were imaged by confocal 
microscopy, using the line-scan mode, at each depolarization voltage. During the imaging, 20 mM 
caffeine was rapidly perfused to determine sarcoplasmic reticulum calcium content at the peak of 
the caffeine-elicited calcium transient. Supplemental Fig. 2.5 shows that sarcoplasmic reticulum 
calcium content of cardiac myocytes was not different between genotypes. For calcium transients, 
the amplitude, time-to-peak, maximum rise rate, and full-duration at half-maximum were 
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analyzed. Fig. 2.8B shows that that ICa,L is decreased in Scn1b null mouse ventricular myocytes 
compared to WT. In contrast, we found no differences in the calcium transient amplitude between 
genotypes (Fig. 2.8C). Finally, we calculated the excitation-contraction coupling gain (the 
amplification factor between calcium release from the sarcoplasmic reticulum via the ryanodine 
receptor  and ICa), which is an indicator of intracellular Ca releasability, and found it to be increased 






Figure 2.8: Excitation-contraction (E-C) coupling in ventricular myocytes from P16-19 Scn1b 
null and WT mice. A. Representative example of E-C coupling recording. Top: ICa triggered by 
voltage-clamp depolarization; middle: whole cell Ca2+ transient; bottom: Ca2+ transient time 
profile. B. I-V curve shows decreased ICa in CMs from Scn1b null mice compared to WT. C. No 
change in Ca2+ transient amplitude between genotypes. D. E-C coupling gain (ratio between the 




Supplemental Fig. 2.4: RNA-seq identifies changes in VGCC b subunit genes. Blue bar is from 





















Supplemental Fig. 2.5:  Sarcoplasmic reticulum calcium content of cardiac myocytes is not 
different between genotypes. A. Representative example of recorded sarcoplasmic reticulum 






VGSC β1 subunits, encoded by SCN1B, play important roles in cardiac physiology. SCN1B 
variants are linked to human cardiac disease, including Brugada syndrome and atrial fibrillation, 
although recent work suggests that SCN1B may not be a monogenic cause of Brugada syndrome 
(Gray, Hasdemir et al. 2018). Our previous work showed that Scn1b null mouse ventricular cardiac 
myocytes have increased transient and persistent INa, action potential (AP) prolongation, prolonged 
calcium transients, and increased incidence of delayed afterdepolarizations (Lopez-Santiago, 
Meadows et al. 2007, Lin, O'Malley et al. 2015). Scn5a/Nav1.5 and Scn3a expression, as well as 
3H-saxitoxin binding, which measures levels of TTX-sensitive (TTX-S) VGSC expression, are 
increased in Scn1b null heart (Lopez-Santiago, Meadows et al. 2007, Lin, O'Malley et al. 2015). 
AP prolongation and aberrant calcium release in Scn1b null mice are TTX-S, implicating increased 
persistent INa via a TTX-S VGSC a subunit, perhaps Nav1.3, leading to activation of reverse Na/Ca 
exchange in the mechanism of arrhythmogenesis (Lin, O'Malley et al. 2015). Scn1b null mouse 
ventricles have abnormally formed intercalated discs that show perinexal de-adhesion, 
with significantly greater perinexal inter-membrane distances compared to WT littermates, due to 
the loss of β1-β1 homophilic cell adhesion (Veeraraghavan, Hoeker et al. 2018). Finally, Scn1b 
null mouse ECGs show prolonged QT intervals (Lopez-Santiago, Meadows et al. 2007).  
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RIP substrate are involved in a wide variety of biological processes. These include, but are not 
limited to, neurite outgrowth, cell adhesion, lipid metabolism, receptor protein tyrosine kinase 
signaling, axon guidance, calcium signaling, the immune response, and cellular proliferation 
(Haapasalo and Kovacs 2011). Some of these implications may be a result of transcriptional 
changes downstream of RIP from substrate-ICDs. Our work suggests that the β1-ICD regulates 
similar gene groups. Immune response, proliferation, potassium channel, and calcium ion binding 
genes are upregulated in Scn1b null mouse cardiac ventricle, while they are generally 
downregulated when the β1-ICD is overexpressed in CHL cells, suggesting that the β1-ICD may 
normally act as a transcriptional repressor in heart in vivo.  
 
BACE1 null mice have brain region specific, developmentally regulated alterations in the 
expression levels of Scn1a, Scn2a, and Scn8a, as well as altered INa and neuronal activity (Hu, 
Zhou et al. 2010, Kim, Gersbacher et al. 2011). BACE1 null atrial cardiomyocytes have decreased 
steady-state potassium current (Agsten, Hessler et al. 2015). Cardiomyocytes isolated from 
transgenic mice with inducible Notch-ICD (NICD) overexpression, which is generated by RIP, 
have prolonged AP duration, reduced upstroke amplitude, reduced rapidly activating voltage-gated 
potassium current, and reduced transient INa (Borghetti, Eisenberg et al. 2018). Treatment of 
cultured neonatal mouse myocytes with a γ-secretase inhibitor to decrease NICD production 
resulted in increased transcript levels of Kcnip2, encoding the potassium channel-interacting 
protein 2, KChIP2, and enhanced potassium current density (Borghetti, Eisenberg et al. 2018). In 
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other work, Kcnip2 silencing in neonatal rat cardiac myocytes resulted in reduced levels of Scn1b 
and Scn5a mRNA (Deschenes, Armoundas et al. 2008). Taken together, these studies suggest that 
RIP substrates regulate sodium, potassium, and possibly other ion channel gene transcription. In 
support of this hypothesis, the present data show that VGSC β1 subunits undergo RIP through 
sequential intramembrane cleavage by BACE1 and γ-secretase, resulting in the generation of a 
soluble ICD that is translocated to the nucleus where it participates in transcriptional regulation of 
multiple gene families, including sodium and potassium channels (Summarized in Fig. 2.9). Using 
an unbiased, RNA-seq approach, we identified a subset of gene groups that are primarily 
downregulated when the β1-ICD is overexpressed in heterologous cells, but upregulated in Scn1b 
null cardiac tissue, suggesting that the β1-ICD may normally act as a molecular break on gene 
expression in heart in vivo. Consistent with the present RNA-seq results, our previous work 
showed increased INa in Scn1b null ventricular myocytes compared to WT (Lopez-Santiago, 
Meadows et al. 2007, Lin, O'Malley et al. 2015) and new data presented here show increased 
potassium currents and decreased calcium currents in Scn1b null myocytes compared to WT. 
While b1 subunits have been shown to facilitate sodium and potassium channel a subunit targeting 
to the plasma membrane (Marionneau, Carrasquillo et al. 2012, Calhoun and Isom 2014), this 
mechanism cannot explain the increased currents recorded in Scn1b null myocytes. To our 
knowledge, there is no evidence to date that VGSC b1 subunits affect VGCC a subunit targeting 
to the plasma membrane. Instead, our new data suggest the b1-ICD regulates the expression of a 
complex group of genes encoding proteins important in modulating VGCCs, including VGCC b 
subunits and CBPs. CBPs have been shown to both inactivate and facilitate ion conduction through 
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the channel pore (Nejatbakhsh and Feng 2011). The mechanism of decreased ICa,L observed in 
Scn1b null ventricular myocytes is likely the result of complex gene regulation and will be the 
focus of future work. Taken together, this present study solidifies the critical, multi-functional 
roles of VGSC β1 subunits in cardiac physiology and adds RIP-excitation coupling to the complex 
list of β1 functionality. 
 
Despite the identification of a growing list of RIP substrates, the factors that initiate RIP in specific 
cell types and subcellular domains are poorly understood. Neuronal activity and ligand binding 
have been shown to activate RIP at the synapse (Lee and Ch'ng 2020), but little is known about 
the initiation of RIP in heart. Our previous work showed that pretreatment with  -secretase 
inhibitors blocked β1- β1 trans homophilic cell adhesion mediated neurite outgrowth 
(Brackenbury and Isom 2011), consistent with the idea that β1 binding to other β1 subunits on 
adjacent cells may initiate RIP. In ventricular myocytes, β1- β1 trans homophilic adhesion at the 
intercalated disk may provide a similar environment for RIP activation (Veeraraghavan, Hoeker 
et al. 2018). Substrate post-translational modification, such as ubiquitination and palmitoylation, 
and specific subcellular localization/co-compartmentalization have been shown to be critical 
factors in regulating BACE and g-secretase cleavage  (McCarthy, Coleman-Vaughan et al. 2017, 
Lee and Ch'ng 2020). While our previous work has shown that β1 subunits are post-translationally 
modified by glycosylation and tyrosine phosphorylation (Malhotra, Koopmann et al. 2002, Kruger, 
O'Malley et al. 2016), we have not yet investigated ubiquitination or palmitoylation. 
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Other ion channel proteins have been shown to participate in transcriptional regulation (Gomez-
Ospina, Tsuruta et al. 2006, Kim, Carey et al. 2007, Schroder, Byse et al. 2009, Gomez-Ospina, 
Panagiotakos et al. 2013, Lu, Sirish et al. 2015). For example, the voltage-gated calcium channel 
Cav1.2 C-terminus contains a transcription factor, although the mechanism by which it is generated 
remains under debate. Some groups have shown that Cav1.2 encodes a transcription factor, CCAT, 
in its C-terminal region that is driven via a cryptic promoter located within exon 46. In contrast, 
others have shown the Cav1.2 C-terminus is a fragment generated by proteolysis. Regardless of its 
origin, evidence shows that the Cav1.2 C-terminus can localize to the nucleus and modulate 
transcription (Gomez-Ospina, Tsuruta et al. 2006, Schroder, Byse et al. 2009, Gomez-Ospina, 
Panagiotakos et al. 2013). Similar work on Cav1.3 demonstrated transcriptional activity of the 
protein’s C-terminus (Lu, Sirish et al. 2015). Similar to β1, VGSC β2 subunits are also substrates 
of BACE1 and γ-secretase. In neuroblastoma cells, RIP generates a β2-ICD that can translocate to 
the nucleus and increase expression of SCN1A, which encodes the VGSC α subunit, Nav1.1 (Kim, 
Carey et al. 2007). 
 
Most BACE1 and γ-secretase substrate proteins are type-I transmembrane proteins with 
extracellular domains that often contain CAM-like loops. The released C-terminal domains have 
been shown to translocate to the nucleus where they participate in regulating genes that are 
involved in cell fate determination, adhesion, migration, neurite outgrowth, axon guidance, and/or 
synapse formation and maintenance (Haapasalo and Kovacs 2011, Pardossi-Piquard and Checler 
 91 
2012). Because β1 is structurally and functionally similar to other BACE1 and γ-secretase 
substrates, we hypothesized that the β1-ICD generated by RIP may function in a similar manner 
(Isom, De Jongh et al. 1992, Isom and Catterall 1996, McCormick, Isom et al. 1998, Malhotra, 
Kazen-Gillespie et al. 2000, Davis, Chen et al. 2004, Brackenbury, Davis et al. 2008, Brackenbury, 
Calhoun et al. 2010). A large body of work has examined the transcriptional regulatory roles of 
the many substrate ICDs generated by BACE1 and γ-secretase (Haapasalo and Kovacs 2011). 
Notch-1, although initially cleaved by an α-secretase, is subsequently processed by γ-secretase, 
generating a NICD, which translocates to the nucleus to regulate transcription (Kopan, Nye et al. 
1994, van Tetering and Vooijs 2011, Bray and Gomez-Lamarca 2018). The NICD associates with 
the DNA binding protein, CSL, and the transcriptional coactivator, Mastermind (MAM). The 
primary role of this assembled ternary complex is to activate transcription of Notch target genes 
(Bray and Gomez-Lamarca 2018). While the Notch activator complex is well conserved, the 
repressor complex is more diverse and the switch between activation and repression depends on 
the precise cellular context during the regulatory process (Contreras-Cornejo, Saucedo-Correa et 
al. 2016). This can be further complicated by cell-type specific effects on NICD-mediated 
transcriptional changes(Bray and Gomez-Lamarca 2018). The ICD generated by sequential 
cleavage of APP (AICD) by BACE1 and γ-secretase, AICD, forms a complex with the nuclear 
adaptor protein, Fe65, and the histone acetyltransferase, Tip60, to regulate transcription (Cao and 
Sudhof 2001). Subsequent studies have demonstrated that the AICD can function as a 
transcriptional activator or as a repressor, depending on the target gene (Kim, Kim et al. 2003, Cao 
and Sudhof 2004, von Rotz, Kohli et al. 2004, Ozaki, Li et al. 2006, Zhang, Wang et al. 2007). 
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VGSC β2 subunits are also substrates for intramembrane processing by BACE1 and γ-secretase 
(Kim, Mackenzie Ingano et al. 2005). Over-expression of the β2-ICD in SH-SY5Y cells increases 
expression of SCN1A (Kim, Carey et al. 2007). Complex formation of the β2-ICD with other DNA 
binding proteins has not been investigated. Because neither the β1-ICD nor the β2-ICD contain a 
DNA binding domain, they may require binding partner(s) to mediate their effects on gene 
expression, similar to NICD and AICD.  
 
Variants in BACE1 and/or γ-secretase substrates, as well as variants in PSEN1, encoding the 
catalytic domain of γ-secretase, are linked to many pathophysiological conditions, including 
Alzheimer’s disease, epileptic encephalopathy, cardiac disease, and cancer (Scheffer, Harkin et al. 
2007, Watanabe, Koopmann et al. 2008, Patino, Claes et al. 2009, Aster, Blacklow et al. 2011, Li, 
Chen et al. 2011, Li, Wang et al. 2013, Kruger, O'Malley et al. 2016, Kelleher and Shen 2017). 
SCN1B variants, which are linked to epileptic encephalopathy and cardiac arrhythmia, may also 
be involved in cancer, especially through dysregulation of cell-cell or cell-matrix adhesion and 
transcriptional regulation. β1 overexpression in vitro induces the growth of neurite-like projections 
from cultured breast cancer cells (Brackenbury, Davis et al. 2008, Nelson, Millican-Slater et al. 
2014). β1 subunits are expressed in breast, cervical, non-small cell lung, and prostate cancers 
(Brackenbury 2012) and their expression is upregulated in patient breast and prostate cancer 
samples (Diss, Fraser et al. 2008, Nelson, Millican-Slater et al. 2014). In prostate cancer, β1 
expression correlates with metastatic strength (Diss, Fraser et al. 2008). Mouse xenografts of β1-
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overexpressing MDA-MB-231 breast cancer cells promote primary tumor growth and metastasis 
compared to untransfected cells. Conversely, β1-overexpressing MDA-MB-231 cells display 
decreased motility and proliferation compared to the parental cell line in in vitro cultures (Nelson, 
Millican-Slater et al. 2014). Interestingly, knockdown of endogenous β1 subunits in MCF-7 breast 
cancer cells increases cell migration, while β1 expression inhibits cell motility in cervical cancer, 
suggesting that β1 expression may encourage tumor growth and metastasis (Chioni, Brackenbury 
et al. 2009, Sanchez-Sandoval and Gomora 2019). The present work suggests that transcriptional 
regulation via the cleaved β1-ICD may play a role in these cellular changes and that the presence 
of SCN1B variants may affect cancer outcomes. NICD dysregulation is similarly linked to disease. 
Variants in Notch receptor genes are linked to adult T cell acute lymphoblastic leukemia and 
lymphoma (T-LL). The most common type of Notch1 variants in human T-LL lead to ligand-
independent metalloproteinase (α-secretase) cleavage (Aster, Blacklow et al. 2011). Activating 
Notch receptor variants can lead to nuclear accumulation of the NICD in T-LL. Here, nominated 
genes identified by overexpression of the β1-ICD in CHL cells and by Scn1b deletion suggest that 
β1-ICD-mediated gene transcription may regulate proliferation, calcium ion binding, and immune 
response genes in vivo. Each of these gene groups has direct relationships to SCN1B-linked disease 
states, including epileptic encephalopathy, cardiac arrhythmia, and cancer (Bouza and Isom 2018). 
Thus, we propose that dysregulation of the β1-ICD signaling pathway may contribute to β1-linked 
pathophysiology. In conclusion, our work adds to the multi-functionality of VGSC β1 subunits 
and provides novel insights into disease mechanisms linked to variants in SCN1B.  Out work also 
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adds to the growing body of evidence suggesting that substrate ICDs generated by RIP are 








Materials and Methods 
Animals 
Scn1b+/+ and Scn1b-/- mice were generated from mating of Scn1b+/- mice congenic on the 
C57BL/6J background for over 20 N generations, as described(Yuan, O'Malley et al. 2019). 
Animals were housed in the Unit for Laboratory Animal Medicine at the University of Michigan. 
All procedures were performed in accordance with the NIH and the University of Michigan 
Institutional Animal Care and Use Committee (IACUC).   
Antibodies 
Primary antibodies used were: anti-β1intra (1:1000 dilution), anti-V5 (1:1000 dilution, Invitrogen), 
anti-α-tubulin (1:1000 dilution, Cedar Lane) anti-presenilin-1 (1:200, APS18 Invitrogen), anti-
BACE1 (1:1000, Invitrogen), or anti-HSP90 (1:1000 dilution, EnzoScientific). The specificity of 
anti-β1intra has been shown previously by western blot. HRP-conjugated secondary antibodies were 
used in this study. Goat anti-rabbit or goat anti-mouse HRP-conjugated antibodies were diluted 
1:1000 (anti-β1intra, anti-α-tubulin, anti-presenilin-1, anti-BACE1) or 1:10,000 (anti-V5 or anti-
HSP90). Alexa Fluor 568 anti-mouse was used as a secondary (1:500 dilution) as a secondary 
antibody for anti-V5 in immunocytochemistry experiments. 
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Expression Vectors 
A synthesis-optimized human WT β1-V5 cDNA was generated by gBLOCK from Integrated DNA 
technologies. The bicistronic cDNA construct included an in-frame  1 C-terminal V5 epitope tag 
followed by a self-cleaving 2A peptide and enhanced Green Fluorescent Protein (eGFP) to 
facilitate immune-detection of β1 as well as transfected cells by eGFP. β1-p.Y181A-V5, β1-
p.Y181E-V5, and β1-p.Y181F-V5 were generated by site-directed mutagenesis using the WT β1-
V5 cDNA construct in pENTR-SD/D TOPO as the template. The eGFP alone control and β1-V5-
ICD-2A-eGFP constructs were generated by PCR from their respective full-length template 
cDNAs containing WT β1-V5, β1-p.Y181A-V5, β1-p.Y181E-V5, or β1-p.Y181F-V5. Using the 
Gateway cloning system, all constructs were moved from pENTR-SD/D-TOPO to pcDNAdest40 
via LR Clonase reaction according to the manufacturers’ protocol. 
Cell lines 
All CHL cells and HEK Nav1.5 cells were maintained at 37°C with 5% CO2 in Dulbecco’s 
Modified Eagle Medium supplemented with 5% heat inactivated fetal bovine serum and 
penicillin/streptomycin. Stably transfected cell line media also included 600 µg/mL G418. To 
generate stable cell lines 1 µg of cDNAs were transfected with 5 µL of Lipofectamine 2000. 48 
hours post transfection, cells were passed into fresh media containing 600 µg/mL G418. The cells 
were incubated for approximately one week or until eGFP positive cell colonies were visible. 
Individual colonies were isolated and grown until confluent and subsequently passaged for 
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biochemical characterization. Electrophysiological experiments used transient transfection. 1 µg 
of each cDNA was transfected with 5 µL of Lipofectamine 2000. Approximately 12 hours post-
transfection cells were passaged onto glass cover slips for electrophysiological analysis. 
Electrophysiological recordings were taken approximately 24 hours post-final plating. 
Measurement of sodium currents by whole-cell voltage clamp 
Voltage-clamp recordings were performed at room temperature in the whole-cell configuration 
using a Multiclamp 700B amplifier and pClamp (versions 11, Molecular Devices, San Jose, CA) 
with 1.5–2.5 MΩ patch pipettes. Sodium currents were recorded in the presence of a bath solution 
containing (in mM): 120 NaCl, 1 BaCl2, 2 MgCl2, 0.2 CdCl2, 1 CaCl2, 10 HEPES, 20 TEA-Cl and 
10 glucose (pH 7.35 with CsOH, Osmolarity: 300 – 305 mOsm). Fire-polished patch pipettes were 
filled with an internal solution containing (in mM): 1 NaCl, 150 N-methyl-D-glucamine, 10 
EGTA, 2 MgCl2, 40 HEPES, and 25 phosphocreatine-tris, 2 MgATP, 0.02 Na2GTP, 0.1 Leupectin 
(pH 7.2 with H2SO4).  Sodium current was recorded in response to a series of voltage steps between 
-100 and +30 mV in 5 mV increments, from a holding potential of -90 mV for 200 msec. A step 
back to -20 mV for 200 msec was used to determine the voltage-dependence of inactivation. Series 
resistance was compensated 40–65% and leak subtraction performed by application of a standard 
P/4 protocol. Normalized conductance and inactivation curves were generated as described 
previously.(Patino, Claes et al. 2009) Current densities were determined by dividing current 
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amplitude by the cell capacitance (Cm), as determined by application of +10 mV depolarizing test 
pulses. 
Measurement of potassium currents by whole-cell voltage clamp 
The bath solution contained in mM: 137 NaCl, 5.4 KCl, 1.5 CaCl2, 0.5 MgCl2, 10 HEPES, 0.16 
NaH2PO4, 3 NaHCO3, 0.002 nicardipine, 0.02 ouabain, pH 7.35 with NaOH. Nicardipine and 
ouabain were used to block L-type Ca2+ channels and Na/K pumps, respectively. Stock solutions 
for nicardipine (10 mM) and ouabain (20 mM) were prepared in DMSO and H2O, respectively and 
diluted to the appropriate concentration in bath solution before use. Patch pipettes (2 - 3 MΩ) were 
filled with (in mM): 130 KCl, 2 K2-ATP, 1 EGTA, 10 HEPES, pH 7.3 with KOH. Series resistance 
was routinely compensated to ~80% before the recordings. Holding potential was set to -70 mV 
and current traces filtered at 1 kHz. To assess voltage-dependence of activation, whole-cell 
outward potassium currents were recorded in response to 5 sec depolarizing voltage steps to 
potentials between -70 and +70 mV from a 5 sec -120 mV pre-pulse potential. To examine steady 
state inactivation, potassium currents were evoked during a 5 sec depolarization to +60 mV, after 
5 sec pre-pulses to potentials between -120 to -10 mV in 10 mV increments at 15 sec inter-sweep 
intervals. The values of the Ipeak and Iend (“end-current”) were obtained at ~ 20 msec (variable) and 
4.88 sec after the beginning of the depolarization, respectively.  
The decay phases of the outward potassium currents were fit by the sum of three exponentials 
using the following expression: I(t)= Ito f x e-t/τf + Ito s x e-t/τs + IK slow x e-t/τK slow + ISS, where t is 
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time, τf, τs, and τK slow are the time constants of decay of Ito fast (Ito f), Ito slow (Ito s), and IK slow. Iss 
denotes the steady state current. Steady state inactivation curves for Ipeak, Iend, Ito f, Ito s, IK slow, and 
Iss were fit using the following Boltzmann functions:   
I= A/[1+exp(-λ(Vm-V½))], (single) 
I= {A1/[1+exp(-λ1(Vm-V1½))]} +{A2/[1+exp(-λ2(Vm-V2½))]}+C, (double) 
where A, A1 and A2 denote amplitudes; Vm is the pre-pulse voltage; V½, V1½, and V2½ are the 
voltages of half-maximal inactivation; λ, λ1, and λ2 are the slope factors, and C is the “pedestal” 
current. 
Measurements of calcium currents, calcium transients, and sarcoplasmic reticulum calcium 
content in cardiac myocytes 
P16-19 mouse ventricular cardiac myocytes were isolated as previously described (Zhao, Valdivia 
et al. 2015). ICa and ICa-triggered whole cell calcium transients were recorded simultaneously as 
previously described (Zhao, Valdivia et al. 2015). Briefly, single ventricular myocytes were 
depolarized from a holding potential of -50mV to +60mV in 10mV increments for 300 ms. At the 
same time, intracellular calcium dynamics were imaged by confocal microscopy using the line-
scan mode of a Nikon A1R microscope at each depolarization voltage. Sarcoplasmic reticulum 
calcium content was measured as previously described (Zhao, Guo et al. 2017). Briefly, single 
ventricular myocytes were loaded with fluo-4-AM (ThermoFisher Scientific) and imaged by 
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confocal microscopy in line-scan mode. 20 mM caffeine was rapidly perfused onto the cell. 
Sarcoplasmic reticulum calcium content was determined by the peak of the caffeine-elicited 
calcium transient. 
Western blot analysis of cell lysates 
Cell lysates were prepared either as described below for cleavage assays or surface biotinylation 
assays, as appropriate. Samples were mixed with loading buffer containing SDS, 5mM β-
mercaptoethanol, and 1% dithiothreitol and heated for 10 min at 85°C. Proteins were separated by 
SDS-PAGE on 10, 12, or 15% polyacrylamide gels as indicated in the figure legends, transferred 
to nitrocellulose membrane overnight (16 h, 55 mA, 4°C), and probed with appropriate antibodies, 
as indicated in the figure legends. Incubations with anti-V5 or anti-β1intra and their respective 
secondary antibodies were performed using a SnapID with 10-20 min incubations. Anti-α-tubulin 
and anti-HSP90 antibodies were incubated overnight at 4°C. Secondary antibodies for anti-α-
tubulin and anti-HSP90 were incubated for 1 h at room temperature (RT). Immunoreactive bands 
were detected using West Femto chemiluminescent substrate (GE Health Sciences) and imaged 
using an iBrightFL1000 (Invitrogen). Immunoreactive signals from cleavage assays were 




Stably transfected cells were grown until approximately 70% confluent in 100 mm tissue culture 
plates. Cells were treated with either vehicle (0.1% DMSO), varying concentrations of DAPT 
(Cayman Chemical) ranging from 50 nM to 1 µM, or 200 nM β-secretase inhibitor IV (Millipore), 
as indicated in the figure legends. 24 h post-treatment, cells were harvested, and membranes were 
prepared. Briefly, harvested cell pellets were resuspended in 50 mM Tris, pH 8.0 with Complete 
protease inhibitors, EDTA-Free (Roche). On ice, cells were broken with a dounce homogenizer 
and sonicated. Lysates were spun at 2,537xg for 10 min to remove nuclei and other large insoluble 
cell fragments. The supernatant was then removed spun at 80,000 x g for 15 min at 4°C. The 
supernatant was removed, and the membrane-containing pellets were resuspended in 133 µL of 50 
mM Tris, pH 8.0 with Complete protease inhibitors, EDTA-Free (Roche) and sonicated on ice. 
Samples separated using 12% SDS-PAGE gels and western blots were performed as described 
above. 
Immunocytochemistry and confocal microscopy 
CHL cells were transiently transfected with cDNA constructs, as indicated in the figure legends, 
with Lipofectamine 2000. 24 h post transfection, cells were fixed with ice cold 100% methanol for 
15 min then washed quickly 3x times with Dulbecco’s Phosphate Buffered Saline (DPBS). Cells 
were blocked for approximately 1 h at RT in 90% DPBS, 10% goat serum, and 0.3% triton. Anti-
V5 antibody was diluted 1:1000 in block (90% DPBS, 10% goat serum, and 0.3% triton) and 
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incubated with cells overnight at RT in a humidified chamber. Cells were washed three times for 
10 min with DPBS. Cells were then incubated with secondary antibody for 2 h at RT in a 
humidified chamber. The secondary antibody, Alexa Fluor 568, was diluted 1:500 in block (90% 
DPBS, 10% goat serum, 0.3% triton x100). Cells were washed three times for 10 min with DPBS 
and allowed to dry. Cover slips were mounted with ProLong Gold (Invitrogen) with DAPI. 
Transfected cells were imaged while blinded at 63x on a Zeiss 880 confocal microscope in the 
University of Michigan Department of Pharmacology. Images were analyzed while blinded in 
ImageJ using plot profile. 
RNA-Seq 
RNA was isolated from CHL-eGFP, CHL-β1-ICD, or cardiac ventricle of P10 Scn1b+/+ or Scn1b-
/- mice using the Qiagen RNeasy Plus kit according to the manufacturer’s instructions. Cells were 
lysed through a sterile, 18 gage hypodermic needle. As a fee for service, the University of 
Michigan Sequencing Core converted RNA to cDNA libraries using TrueSeq Kit (Illumina) and 
sequenced using Illumnia HiSeq4000 with 50 cycles of paired end sequencing. Chinese Hamster 
reference genome, CriGri_1.0, and mouse reference genome, UCSC mm10.fa, were used as the 
refence genome sequences. For the ICD RNA-Seq, eGFP and β1-ICD-V5-2A-eGFP transgenes 
were added to the reference. Quality of reads for each sample were assessed using FastQC (version 
v0.11.3). The University of Michigan Bioinformatics Core Facility completed DeSEQ2 analysis 
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as a fee for service. Genes and transcripts were considered differentially expressed if they met the 
following three criteria: test status = “OK”, false discovery rate ≤0.05, and a fold change ≥1.5.  
RT-qPCR 
RNA was isolated from cardiac ventricles of P10 Scn1b+/+ or Scn1b-/- mice or from CHL cells, as 
indicated in the figure legends, using the Qiagen RNeasy Plus kit according to the manufacturer’s 
instructions. Cell or tissues were lysed through a sterile, 18 gage hypodermic needle or vortexed 
for 30 sec (heterologous cells). RNA was stored at -80°C until use. cDNA was generated from 1-
2 µg of RNA using Reverse Transcriptase SuperScript III (RT SS III) and random primers 
(Invitrogen). Primers, dNTPs, and RNA were incubated at 65°C for 5 min. Salt buffers, RT SS III, 
and RNaseOUT were added and incubated at 25°C for 5 min, 50°C for 60 min, and then 75°C for 
15 min. cDNA was diluted 1:3- to 1:5-fold in water. Comparative qPCR using SYBR Green 
(Applied Biosystems) and gene-specific primers (Integrated DNA Technologies) was completed. 
ΔΔCt values were calculated by comparing genes of interest with GAPDH and normalizing to the 
control condition (WT or lipofectamine only treatment) to determine comparative gene expression. 
Data are presented as gene expression ±SEM. Statistical significance (p-value <0.05) of 
comparisons between Scn1b+/+ and Scn1b-/- mice were determined using Student’s t-test. Statistical 
significance (p-value <0.05) of comparisons between lipofectamine treated, eGFP, and WT β1-
ICD-V5 transfected cells were determined using one-way ANOVA for each examined gene. 
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Statistics  
Statistical analysis for cleavage assay experiments were completed with n=3-4 for each 
experiment. The DAPT concentration response and  -secretase inhibitor experiments were one-
way ANOVA with multiple comparisons. Data are represented as the mean ± SEM. β1 mutant 
cleavage experiments were completed as unpaired t-tests between vehicle and DAPT treated 
groups. For the fyn kinase assay, three independent experiments were performed. Statistical 
significance was determined with Student’s t-test. Data are represented as the mean ± SEM. 
Electrophysiology experiments had an n of 10-15 cells per condition for each experiment from a 
minimum of three independent transfections. The voltage-dependence of activation and 
inactivation were compared using nonlinear fit, maximum current was analyzed using one-way 
ANOVA with multiple comparisons, and current density was compared to the control, eGFP, with 
an unpaired t-test at each voltage-step. Analysis of co-localization between the β1-ICD constructs 
and nuclei, DAPI, were completed blinded using the ImageJ coloc2 package. Pearson’s correlation 
coefficient for each cell (n=11-17 for each condition, from three independent transfections) was 
recorded. One-way ANOVA with multiple comparisons was completed. Data are represented as 
the mean ± SD. Differences were considered significant if the p-value was less than 0.05. 
University of Michigan Bioinformatics Core Facility completed DeSEQ2 analysis as a fee for 
service. The For each experiment, n=4 was used for each condition. Genes and transcripts were 
considered differentially expressed if they met the following three criteria: test status = “OK”, false 
discovery rate ≤0.05, and a fold change ≥1.5. 
 106 
Data availability 
RNA-Seq data have been submitted to the repository at NCBI GEO. Accession numbers: 
GSE136927 and GSE136535 
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Chapter 3 VGSC b1 Palmitoylation Promotes its Plasma Membrane Localization  
 
 
Alexandra A. Bouza*, Julie M. Philippe*, Nnamdi Edokobi, Alexa M. Pinsky, James Offord, PhD, 
Jeffrey D. Calhoun, PhD, Mariana Lopez-Floran, Luis F. Lopez-Santiago, PhD, Paul M. Jenkins, 
PhD, and Lori L. Isom, PhD 
*These authors contributed equally to this work. 
Summary 
Voltage-gated sodium channel (VGSC) β1 subunits are multifunctional proteins that modulate 
VGSC α subunit biophysical properties and cell surface localization, as well as participate in cell-
cell and cell-matrix adhesion, all with important implications for intracellular signal transduction, 
cell migration, and differentiation. Human loss-of-function variants in SCN1B, encoding the 
VGSC b1 subunits, are linked to severe diseases with high risk of sudden death, including epileptic 
encephalopathy and cardiac arrhythmia. We showed previously that β1 subunits are post-
translationally modified by tyrosine phosphorylation. We also showed that β1 subunits undergo 
regulated intramembrane proteolysis (RIP) via the activity of BACE1 and γ-secretase, resulting in 
the generation of a soluble intracellular domain, b1-ICD, which modulates transcription. Here, we 
show that b1 subunits are phosphorylated by fyn kinase. In addition, we show that β1 subunits are 
S-palmitoylated. Mutation of a single residue in b1, cysteine (C) 162 to alanine (A), prevents 
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palmitoylation, reduces the level of b1 polypeptides at the plasma membrane, and results in a 
reduction in the extent of β1 RIP, suggesting that the plasma membrane is the site of β1 proteolytic 
processing. Treatment with the clathrin-mediated endocytosis inhibitor, Dyngo-4a, restores plasma 
membrane association of b1-p.C162A to WT levels. In spite of these observations, palmitoylation-
null b1-p.C162A modulates sodium current and sorts to detergent-resistant membrane fractions 
normally. This is the first demonstration of S-palmitoylation of a VGSC b subunit, establishing 




Voltage gated sodium channels (VGSCs) are heterotrimeric protein complexes composed of one 
pore-forming α subunit and two non-pore forming b subunits (O'Malley and Isom 2015). VGSC 
b1 through b4 subunits contain a single, extracellular V-type immunoglobulin (Ig) domain and are 
thus members of the Ig superfamily of cell adhesion molecules (Ig-CAMs) (O'Malley and Isom 
2015, Bouza and Isom 2018). b1 subunits are expressed in multiple tissues, including brain and 
heart, where they modulate the gating, kinetics, and plasma membrane localization of VGSC α 
subunits through non-covalent association (Isom, De Jongh et al. 1992, Isom, Ragsdale et al. 1995, 
Bouza and Isom 2018, Hull and Isom 2018). b1 subunits are multi-functional and play both 
conducting and non-conducting roles. In addition to modulating VGSCs, they contribute to 
voltage-gated potassium channel function, cell-cell and cell-matrix adhesion and cell migration, 
intracellular calcium signaling, neuronal pathfinding and fasciculation, neurite outgrowth, and 
cardiac intercalated disk formation (Malhotra, Kazen-Gillespie et al. 2000, Malhotra, Koopmann 
et al. 2002, Malhotra, Thyagarajan et al. 2004, Brackenbury, Davis et al. 2008, Brackenbury, 
Calhoun et al. 2010, Marionneau, Carrasquillo et al. 2012, Brackenbury, Yuan et al. 2013, Bouza 
and Isom 2018, Veeraraghavan, Hoeker et al. 2018). Concordant with their CAM function, β1-β1 
trans homophilic cell adhesion in vitro results in outside-in signaling that includes ankyrin 
recruitment to points of cell-cell contact, which is terminated by β1 tyrosine phosphorylation 
(Malhotra, Kazen-Gillespie et al. 2000, Malhotra, Koopmann et al. 2002). In cultured cerebellar 
granule neurons, β1-β1 trans homophilic cell adhesion drives neurite extension through a 
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mechanism that includes fyn kinase (Brackenbury, Davis et al. 2008). β1 subunits form 
heterophilic partnerships with other CAMs, including contactin, N-cadherin, NrCAM, 
neurofascin, and VGSC β2 subunits, and associate with the extracellular matrix protein, tenascin-
R, to modulate cell migration (Xiao, Ragsdale et al. 1999, McEwen and Isom 2004, McEwen, 
Meadows et al. 2004). Thus, β1 CAM activity is critical for neuronal development.  
Human variants in VGSC genes are linked to the developmental and epileptic encephalopathies 
(DEEs) and to cardiac arrhythmia. Loss-of-function (LOF) variants in SCN1B, encoding b1, result 
in early infantile developmental and epileptic encephalopathy (EI-DEE) and Generalized Epilepsy 
with Febrile Seizures plus (Bouza and Isom 2018, Aeby, Sculier et al. 2019). Scn1b-null mice 
model EI-DEE, with severe spontaneous seizures of multiple etiologies, ataxia, and sudden death 
in the third week of life (Chen, Westenbroek et al. 2004). Consistent with loss of β1-mediated cell-
cell and cell-matrix adhesion, Scn1b-null mice have neuronal pathfinding and fasciculation defects 
in brain (Brackenbury, Davis et al. 2008, Brackenbury, Yuan et al. 2013). SCN1B is expressed in 
heart in addition to brain. Scn1b-null mice have prolonged QT and RR intervals. Scn1b-null 
ventricular cardiomyocytes have increased sodium current, altered calcium handling, altered 
intercalated disc structure, and prolonged action potential duration (Lopez-Santiago, Meadows et 
al. 2007, Lin, O'Malley et al. 2015, Veeraraghavan, Hoeker et al. 2018). SCN1B variants are 
associated with human cardiac disease, including Brugada syndrome and atrial fibrillation 
(Watanabe, Koopmann et al. 2008, Watanabe, Darbar et al. 2009, Olesen, Holst et al. 2012, Ricci, 
Menegon et al. 2014, Gray, Hasdemir et al. 2018). Thus, SCN1B is essential for life.   
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β1 subunits undergo regulated intramembrane proteolysis (RIP) through the sequential activity of 
β-site Amyloid Precursor Protein (APP) cleaving enzyme-1 (BACE1) and γ-secretase (Wong, 
Sakurai et al. 2005, Bouza 2020). BACE1 cleavage, the rate-limiting step in this process, releases 
the extracellular β1 Ig domain, which functions as a CAM ligand to stimulate neurite outgrowth 
(Davis, Chen et al. 2004, Patino, Brackenbury et al. 2011). The remaining membrane-bound β1-
C-terminal fragment (β1-CTF) is cleaved by γ-secretase in the lumen of the membrane, generating 
a soluble, intracellular domain, b1-ICD, that translocates to the nucleus to regulate transcription 
(Wong, Sakurai et al. 2005, Haapasalo and Kovacs 2011). Thus, b1 RIP plays important roles in 
neurite outgrowth, cell migration, cell adhesion, and transcription (Kim, Ingano et al. 2005, 
Brackenbury and Isom 2011).  
BACE1- and γ-secretase-mediated processing of the well-studied RIP substrate, amyloid-β 
precursor protein (APP), is regulated by S-palmitoylation, the covalent addition of a 16-carbon 
fatty acid to cysteine residues via thioester bond formation (Bhattacharyya, Barren et al. 2013). 
Palmitoylation targets APP to its proper membrane domains, bringing it in close proximity to 
proteolytic enzymes for subsequent cleavage (Bhattacharyya, Barren et al. 2013). Here, we asked 
whether post-translational modification of β1 subunits by tyrosine phosphorylation or S-
palmitoylation could regulate its plasma membrane localization and subsequent RIP. In contrast 
to β1-ankyrin association, for which β1 tyrosine phosphorylation is critical (Malhotra, Koopmann 
et al. 2002), we found that the tyrosine phosphorylation state of b1 has no effect on its membrane 
localization, intramembrane cleavage, or ability to modulate sodium current (INa). We report for 
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the first time that b1 subunits are S-palmitoylated in mouse brain. Using heterologous cells, we 
found that substitution of cysteine (C) residue 162 with alanine (A) abolishes b1 palmitoylation, 
decreases the fraction of b1 in the plasma membrane as assessed by surface biotinylation and 
immunocytochemistry, and thus reduces the level of b1 that is available for RIP. Treatment of 
cells with the clathrin-mediated endocytosis inhibitor, Dyngo-4a, restores b1-p.C162A to wild-
type (WT) levels at the plasma membrane. Finally, we show that b1-mediated modulation of 
sodium current (INa) and β1 sorting to detergent-resistant membrane fractions do not depend on b1 
palmitoylation. Taken together, our work suggests that multiple post-translational modification 
events regulate β1 function. Tyrosine phosphorylation regulates the association of β1 subunits with 
ankyrin but does not affect its plasma membrane localization. In contrast, S-palmitoylation 
regulates the cell-surface localization of b1 and consequently its extent of RIP, indicating that β1 
cleavage occurs at the plasma membrane. This work provides novel insights into β1 subunit 





β1 RIP occurs independently of β1 tyrosine phosphorylation. 
b1 tyrosine residue (Y) 181, located in the intracellular domain, is important for β1-mediated 
downstream signaling (Malhotra, Koopmann et al. 2002) (Fig. 3.1A). In previous work, we used 
phosphorylation-null and phosphomimetic mutant constructs to show that phosphorylation of 
residue Y181 is a key regulatory mechanism for ankyrin binding (Malhotra, Koopmann et al. 
2002). Our work in cerebellar granule neurons demonstrated that β1-β1 trans homophilic 
adhesion-mediated neurite outgrowth is inhibited by the administration of γ-secretase inhibitors 
and in neurons isolated from fyn null mice (Brackenbury, Davis et al. 2008, Brackenbury and Isom 
2011). Taken together, these data suggested that β1-mediated neurite outgrowth requires 
association of the β1 intracellular domain with ankyrin, via residue Y181, which then triggers β1 
RIP. Here, we tested the hypothesis that b1 tyrosine phosphorylation regulates cleavage using a 
multi-disciplinary approach. 
 
We used a cell-free fyn kinase assay (Promega), in which ADP was measured via luciferase 
activity and positively correlated to kinase activity, to determine whether fyn directly 
phosphorylates a β1 peptide, QENASEYLAITC, at position Y181. Poly E4Y1 peptide was used as 
a positive control for fyn kinase activity (Fig. 3.1B).  Inclusion of WT β1 peptide in the assay 
increased luciferase activity by approximately 3-fold over the no-substrate control. In contrast, 
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luciferase activity levels in the presence of Y181E β1 peptide (pYβ1) were not different from the 
no-substrate control. These data indicate that fyn kinase can directly phosphorylate b1 at the Y181 
position (Fig. 3.1B). 
 
To understand whether β1 phosphorylation at Y181 affects β1 RIP, we generated two 
phosphorylation-null, β1-p.Y181A-V5-2AeGFP and β1-p.Y181F-V5-2AeGFP, and one 
phosphomimetic, β1-p.Y181E-V5-2AeGFP mutant constructs. Chinese Hamster Lung (CHL) cell 
lines stably overexpressing each construct were generated, and plasma membrane localization of 
each mutant polypeptide was investigated using cell-surface biotinylation assays (29, 30). Similar 
to WT β1, all three β1 mutants were detected in the plasma membrane fraction (Fig. 3.1C). To 
determine if β1 phosphorylation at residue Y181 regulates BACE1- and γ-secretase-mediated 
cleavage of β1, each cell line was treated with vehicle (0.1% DMSO) or 1 µM DAPT, the γ-
secretase inhibitor, and analyzed by western blot. Treatment with DAPT leads to an accumulation 
of the intermediary cleavage product, b1-CTF, generated by BACE1 cleavage (Bouza 2020). We 
found that levels of b1-CTF were generated similarly to WT in all three mutant lines and 
accumulated similarly to WT following treatment with DAPT, suggesting that neither BACE1 nor 
γ-secretase cleavage of b1 depends on its phosphorylation state (Fig. 3.1 D and E). These results 
also suggest that our previous work, demonstrating that γ-secretase inhibitors block b1-mediated 






Figure 3.1: β1 phosphorylation at residue Y181 does not affect its RIP. A. Schematic of β1 
identifying the location of the phosphorylation site, Y181, as well as BACE1 and g-secretase 
cleavage sites. B. A β1 peptide (QENASEYLAITC) is directly phosphorylated at Y181 by fyn kinase 
in a cell-free assay. N=3. C. Cell surface biotinylation indicates that similar to WT β1-V5, β1-
p.Y181A-V5, β1-p.Y181F-V5, and β1-p.Y181E-V5 are localized to the plasma membrane. N=3. D. 
WT β1-V5, β1-p.Y181A-V5, β1-p.Y181F-V5, and β1-p.Y181E-V5 are cleaved by BACE1 and γ-
secretase. N=4. E. Quantification of D. Protein levels were normalized to the loading control and 
reported as fold change respective to the vehicle treated group. Significance (p-value <0.05) was 
determined using a one-way ANOVA. 
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β1 modulation of INa occurs independently of β1 tyrosine phosphorylation. 
We next asked whether the phosphorylation state of residue Y181 affects the ability of β1 to 
modulate INa. Human Embryonic Kidney (HEK) cells stably expressing Nav1.5 were transiently 
transfected with soluble enhanced Green Fluorescent Protein (eGFP), WT β1-V5-2AeGFP, β1-
p.Y181A-V5-2AeGFP, β1-p.Y181F-V5-2AeGFP, or β1-p.Y181E-V5-2AeGFP. Inclusion of 
eGFP facilitated the identification of transfected cells for whole cell voltage patch clamp 
recordings. Co-expression of WT β1-V5-2AeGFP, β1-p.Y181A-V5-2AeGFP, or β1-p.Y181E-V5-
2AeGFP with Nav1.5 increased INa density compared to a alone (transfection of soluble eGFP), 
suggesting that the phosphorylation state of residue Y181 does not affect the ability of β1 to 
modulate INa density (Fig. 3.2 A and B). We observed no effects of any of the β1 constructs on the 
voltage-dependence of INa activation or inactivation compared to the eGFP control (Fig. 3.2 C and 
D). Interestingly, β1-p.Y181F-V5-2AeGFP, which was detected in the plasma membrane fraction 
biochemically, similar to WT β1, predicting its expression at the cell surface, had no effect on INa 
density. These results, showing that β1-p.Y181F localizes to the plasma membrane, functions as a 
homophilic CAM (Malhotra, Koopmann et al. 2002), and is post-translationally processed by 
BACE1 and γ-secretase, but does not modulate INa density (Fig. 3.2 A and B), is the first 




Figure 3.2: β1-mediated modulation of INa is not dependent on phosphorylation of residue Y181. 
A. INa density is increased when WT β1-V5, β1-p.Y181A-V5, or β1-p.Y181E-V5 is co-expressed 
with Nav1.5. β1-p.Y181A-V5 and β1-p.Y181E-V5 increase INa density over a alone (eGFP). B. 
Maximal current is increased when WT β1-V5, β1-p.Y181A-V5, or β1-p.Y181F-V5 is co-expressed 
with Nav1.5 compared to eGFP control. β1-p.Y181A-V5 and β1-p.Y181F-V5 increase maximal 
current to levels similar to WT β1-V5. β1-p.Y181F-V5 has no effect on maximal current compared 
to the eGFP control. C. Co-expression of WT or mutant β1-V5 subunits has no effect on the 
voltage-dependence of INa activation compared to eGFP control. D. Co-expression of WT or 
mutant β1-V5 subunits has no effect on the voltage-dependence of INa inactivation compared to 




β1 is S-palmitoylated in vitro and in vivo.  
APP is a type I transmembrane topology BACE1 substrate that results in the generation of Aβ 
peptides to form protein aggregates that can contribute to Alzheimer’s disease pathogenesis (Cole 
and Vassar 2007). BACE1-mediated cleavage of APP is highly dependent on the proper 
localization of APP in lipid raft microdomains (Bhattacharyya, Barren et al. 2013). The post-
translational lipid modification, S-palmitoylation, is required for proper targeting of APP to lipid 
rafts (Bhattacharyya, Barren et al. 2013). In lipid rafts, palmitoylated APP interacts with BACE1 
for subsequent cleavage (Bhattacharyya, Barren et al. 2013). Given its similarity to APP, we asked 
whether b1 is also S-palmitoylated and, if so, whether S-palmitoylation regulates b1 subcellular 
localization and RIP. To assess steady-state palmitoylation of β1, we used the Acyl Resin Assisted 
Capture (Acyl RAC) assay, in which free cysteines are first blocked with the alkylating reagent 
methyl methanethiosulfonate (MMTS). Then, thioester bonds between the cysteine residue of the 
protein and the palmitate are cleaved using the reducing agent hydroxylamine (HA/NH2OH), to 
liberate the previously palmitoylated cysteine residues. The liberated cysteines are selectively 
captured on activated thiol Sepharose beads and eluted, allowing for specific immunoblotting of 
palmitoylated proteins of interest (Forrester, Hess et al. 2011). We used endogenous flotillin-1, a 
known constitutively palmitoylated protein (Giri, Dixit et al. 2007), as a positive control for the 
Acyl RAC assay. In cells stably expressing WT β1-V5-2AeGFP, we observed that β1 is S-
palmitoylated, as evidenced by hydroxylamine-dependent binding of β1-V5 to Sepharose beads 
(Fig. 3.3A).  
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We next asked whether β1 palmitoylation occurs in vivo. Using whole mouse brain lysates 
subjected to Acyl RAC, we observed β1 palmitoylation, as evidenced by hydroxylamine-
dependent binding of endogenous β1 to Sepharose beads (Fig. 3.3B). These data demonstrate that 
β1 is S-palmitoylated in vitro as well as in mouse brain, providing feasibility for investigating the 





Figure 3.3: β1 is S-palmitoylated in CHL cells and in mouse brain. A. CHL cells stably expressing 
β1-V5-2AeGFP were processed for the Acyl-RAC assay to detect S-palmitoylation. S-
palmitoylation of β1-V5 is detected in CHL cells using an antibody against V5, as shown by the 
anti-V5 signal in the +HA lane, compared to the expected absence of signal in the -HA lane. 
Flotillin-1 is used as a positive control for the Acyl-RAC assay. N=3. B. Whole mouse brain lysates 
were subjected to the Acyl-RAC assay to detect S-palmitoylation. S-palmitoylation of endogenous 
β1 is detected in whole mouse brains, using an antibody against the C-terminus of β1, as shown 





β1 is S-palmitoylated at cysteine residue 162.  
To identify the palmitoylated cysteine residue(s) in β1, we first determined the number of 
palmitoylated sites on β1 using a mass-tag labeling technique, Acyl PolyEthylene Glycol  
exchange (Acyl PEG). In this assay, free cysteine residues are blocked with the alkylating reagent, 
N-ethyl maleimide. Palmitate groups linked to cysteine residues are subsequently cleaved with 
hydroxylamine and replaced with a 10 kDa PEG-maleimide group, resulting in a 10 kDa shift in 
the apparent molecular weight of the polypeptide for each palmitoylated cysteine residue, as 
detected by western blot (Percher, Ramakrishnan et al. 2016). CHL cells stably expressing WT 
β1-V5-2AeGFP were subjected to Acyl PEG. We observed a single 10 kDa shift in the apparent 
molecular weight of β1-V5, which occurred in a hydroxylamine specific manner, suggesting that 
β1 is singly palmitoylated (Fig. 4A).  Based on homology models with the CAM myelin P0, which 
is S-palmitoylated at cysteine 153, we predicted that β1 would be palmitoylated at the homologous 
residue, cysteine 162 (Bharadwaj and Bizzozero 1995). Using site-directed mutagenesis, we 
engineered a cDNA construct in which b1 cysteine (C) residue 162 was converted to an alanine 
(A) and generated a stable β1-p.C162A-V5-2AeGFP CHL cell line. To test the effects of the 
C162A mutation on b1 palmitoylation, we subjected β1-p.C162A-V5-2AeGFP CHL cell lysates 
to both Acyl PEG and Acyl RAC. Using Acyl PEG, showed a hydroxylamine-dependent 
PEGylation-induced mass shift in WT β1-V5 but not in β1-p.C162A-V5, suggesting that β1-
p.C162A-V5 cannot be palmitoylated (Fig. 3.4A). We confirmed these results by subjecting β1-
p.C162A-V5-2AeGFP CHL cell lysates to Acyl RAC, where we observed virtually no 
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hydroxylamine-dependent signal for β1-p.C162A-V5, compared to WT β1-V5 (Fig. 3.4B). These 
results demonstrate that β1 is singly palmitoylated at cysteine 162 and that mutating this site to 








Figure 3.4: β1 is S-palmitoylated at cysteine 162. A. CHL cells stably expressing β1-V5-2AeGFP 
or β1-p.C162A-V5-2AeGFP were processed for the Acyl PEG assay to determine the number of 
palmitoylated cysteines on β1. A single 10 kDa shift in the apparent molecular weight of β1 was 
observed in a hydroxylamine-specific manner, using an antibody against V5. Compared to WT β1-
V5, β1-p.C162A-V5 showed no hydroxylamine-dependent PEGylation-induced mass shift, 
suggesting loss of the palmitoylation site upon mutation of cysteine to alanine at β1 residue 162 
of β1. N=3. B. CHL cells stably expressing β1-p.C162A-V5-2AeGFP were subjected to the Acyl-
RAC assay to detect the effect of the mutation of β1 S-palmitoylation. S-palmitoylation of β1-
p.C162A-V5 is not detected in CHL cells using an antibody against V5, as shown by the absence 
of anti-V5 signal in the +HA lane, compared to WT β1-V5. N=3. C. Cartoon diagram of β1 and 





β1 S-palmitoylation regulates its plasma membrane localization. 
  
We asked whether palmitoylation regulates β1 association with the plasma membrane by 
comparing β1-p.C162A-V5 to WT β1-V5 in cell surface biotinylation assays. We found the level 
of β1-p.C162A-V5 polypeptide associated with the plasma membrane to be 63% less than WT 
(6%±4.05 for mutant versus 16%±2.249 for WT), as indicated by the reduced β1-p.C162A-V5 
signal in the neutravidin-selected lane, compared to WT β1-V5 (Fig. 3.5 A and B). To further 
examine membrane localization of WT vs. palmitoylation-deficient β1, we performed 
immunocytochemistry followed by confocal microscopy. CHL cells stably transfected with WT 
b1-V5-2A-eGFP or β1-p.C162A-V5-2A-eGFP were stained with the plasma membrane marker, 
Wheat Germ Agglutinin (WGA) and an antibody directed against the V5-epitope tag to detect WT 
or mutant β1 (Fig. 3.5C). Colocalization maps were generated using ImageJ. Green signal indicates 
WGA signal only, red indicates V5 signal only, and white indicates colocalization between V5 
signal and WGA. WT β1-V5 and WGA showed strong colocalization at the plasma membrane, as 
represented by the white arrows. In contrast, there was a marked reduction in the level of 
colocalization of the β1 palmitoylation-deficient mutant, β1-p.C162A-V5, and WGA (Fig. 3.5C, 
right-most column). These results suggest that S-palmitoylation promotes plasma membrane 
association of β1. However, in this overexpression system, only a small portion (~16%) of WT 
b1-V5 is localized to the plasma membrane. Using immunocytochemistry with antibodies directed 
against the endoplasmic reticulum marker, calnexin, and the V5-epitope tag, we determined that 
the majority of both WT b1-V5 and b1-p.C162A-V5 is localized to ER (Supplemental Fig. 3.1).  
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Figure 3.5: S-palmitoylation regulates plasma membrane localization of β1.CHL cells stably 
expressing β1-V5-2AeGFP or β1-p.C162A-V5-2AeGFP were processed for cell surface 
biotinylation assay. The level of β1-p.C162A-V5 protein in the biotinylated plasma membrane 
fraction was reduced compared to WT β1-V5, as evidenced by the lower anti-V5 signal in the 
neutravidin-selected lane. Soluble HSP90 was used as a negative control. N=4. B. Quantification 
of A. C. CHL cells stably expressing β1-V5-2AeGFP or β1-p.C162A-V5-2AeGFP were stained for 
the plasma membrane marker, Wheat Germ Agglutinin (WGA; red), and β1 (V5-epitope tag; 
white). Colocalization map shows WGA signal only in green, V5 signal only in red, and 
colocalization in white. WT β1 shows strong colocalization with WGA, while palmitoylation-






Supplemental Fig. 3.1: The majority of WT b1-V5 or b1-p.C162A-V5 subunits are localized to the 
ER in heterologous cells.  CHL cells stably expressing β1-V5-2AeGFP or β1-p.C162A-V5-





S-palmitoylation regulates b1 endocytosis, but not sorting into detergent-resistant membranes  
 
Palmitoylation has been shown to regulate the partitioning of certain proteins to cholesterol-rich 
lipid raft microdomains (Levental, Lingwood et al. 2010). We asked whether palmitoylation 
governed the localization of β1 to lipid rafts, similarly to what has been shown previously for APP 
(Bhattacharyya, Barren et al. 2013). β1 is known to localize to detergent-resistant membrane 
(DRM) fractions of mouse brain and primary neuronal cultures (Wong, Sakurai et al. 2005, 
Brackenbury, Davis et al. 2008). To verify the presence of β1 in DRM fractions in CHL cells stably 
expressing WT β1-V5, we prepared DRMs using density gradient centrifugation and analyzed 
them by western blot using anti-V5 antibody. We found that WT β1-V5 was present in both 
detergent-insoluble fractions, marked with flotillin-1, and in detergent-soluble fractions, marked 
with transferrin receptor, similar to previous results (Davis, Chen et al. 2004) (Fig. 3.6A). We 
observed no differences in this distribution for the palmitoylation-null mutant, β1-p.C162A-V5, 
as evidenced by the presence of anti-V5 signal in both flotillin-1-marked DRMs and transferrin 
receptor-marked non-lipid raft domains (Fig. 3.6A). These data suggest that, while palmitoylation 
of β1 is necessary for its proper association with the plasma membrane, it does not regulate the 
partitioning of β1 into lipid-raft domains.  
 
Due to the observed reduction of β1-p.C162A at the plasma membrane, we compared the extent 
of WT β1 vs β1-p.C162A internalization through endocytosis. We treated CHL cells stably 
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expressing β1-V5-2A-eGFP or β1-p.C162A-V5-2A-eGFp with vehicle (0.1% DMSO) or 1 µM of 
the dynamin inhibitor, Dyngo-4a, and assessed the amount of β1-V5 vs. β1-p.C162A-V5 
accumulation at the cell surface by biotinylation. Anti-HSP90 antibody was used as a negative 
control for the plasma membrane fraction and anti-transferrin receptor (TfR) antibody was used as 
a positive control for endocytosis inhibition with Dyngo-4a. We found that Dyngo-4a 
administration normalized the level of β1-p.C162A-V5 in the plasma membrane fraction to that of 
WT β1, implicating clathrin-dependent endocytosis in this process (Fig. 3.6B). This work adds 
new information to the VGSC field, showing that WT β1 subunits undergo endocytosis via a 








Figure 3.6: S-palmitoylation regulates b1 endocytosis, but not sorting into detergent-resistant 
membranes. A. CHL cells stably expressing β1-V5-2A-eGFP or β1-p.C162A-V5-2A-eGFP were 
processed for discontinuous flotation density gradients to investigate the role of palmitoylation in 
detergent-resistant membrane partitioning of β1. β1-p.C162A-V5 did not partition differently than 
WT β1-V5. Flotillin-1 was used as a marker for lipid rafts, whereas Transferrin Receptor (TfR) 
was used as a marker for non-raft domains. N=3. B. CHL cells stably expressing β1-V5-2A-eGFP 
or β1-p.C162A-V5-2A-eGFP were treated with vehicle (0.1% DMSO) or 1 µM Dyngo-4a and 
assessed by cell surface biotinylation. Dyngo-4a treatment restores the plasma membrane level of 
β1-p.C162A-V5 to that of WT β1. N=3.   
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The level of β1-p.C162A RIP is reduced compared to WT. 
We hypothesized that reduction in plasma membrane localization of β1-p.C162A-V5 would 
reduce its level of RIP. To test this hypothesis, we treated stable β1-V5-2AeGFP or β1-p.C162A-
V5-2AeGFP CHL cells with vehicle (0.1% DMSO) or 1 µM DAPT, and assessed formation of the 
~20 kDa β1 intramembrane CTF by western blot analysis. As shown previously, inhibition of γ-
secretase by DAPT results in β1-CTF accumulation in the presence of normally occurring BACE1 
cleavage (Bouza 2020). If BACE1-mediated β1 cleavage is altered or reduced, DAPT 
administration results in reduced levels of β1-CTF accumulation, due to a reduction in available 
substrate for γ-secretase-mediated RIP. As expected, DAPT treatment of CHL cells stably 
expressing WT β1-V5 resulted in β1-CTF accumulation (Fig. 3.7A and B). In contrast, using the 
β1-p.C162A-V5 mutant construct as substrate resulted in an 80% loss in the level of cleavage 
product compared to WT (Fig. 3.7A and B). This result suggests that BACE1 cleaves the small 
fraction of β1-p.C162A-V5 that is localized to the plasma membrane, generating a reduced level 
of β1-CTF in response to DAPT treatment, compared to WT β1. These data demonstrate that β1 




Figure 3.7: The absence of β1 S-palmitoylation at cysteine 162 reduces its intramembrane 
cleavage. A. CHL cells stably expressing β1-V5-2AeGFP or β1-p.C162A-V5-2AeGFP were 
treated with vehicle (0.1% DMSO) or 1 µM DAPT. Lysates were subjected to western blotting 
analysis to investigate the level of β1 cleavage. Compared to WT β1-V5, β1-p.C162A-V5, shows 
little to no cleavage product. N=3. B. Quantification of A. Protein levels were normalized to the 
loading control and reported as fold change respective to the vehicle treated group. Significance 
(p-value <0.05) was determined using a Student’s t-test between vehicle and DAPT treated groups 





β1 mediated modulation of INa is not affected by palmitoyalation   
We next asked whether palmitoylation-deficient β1-p.C162A-V5 could modulate INa. WT β1-V5-
2AeGFP, β1-p.C162A-V5-2AeGFP, or eGFP were transiently expressed in HEK cells stably 
overexpressing Nav1.5. We found that WT β1-V5 and β1-p.C162A-V5 increased INa density to a 
similar extent, compared to the soluble eGFP control (Fig. 3.8A and B). We observed no effect of 
either β1 construct on the voltage-dependence of INa activation or inactivation (Fig. 3.8C and D). 
These data suggest that the small fraction of β1-p.C162A-V5 that remains properly localized to 





Figure 3.8: β1-mediated modulation of INa density is not dependent on S-palmitoylation of β1 at 
residue C162. A. INa density is increased when WT β1-V5 or β1-p.C162A-V5 is co-expressed with 
Nav1.5 in HEK cells. B. Co-expression of WT β1-V5 or β1-p.C162A-V5 with Nav1.5 increases 
maximal INa compared to eGFP control. C. Neither WT β1-V5 nor β1-p.C162A-V5 affects the 
voltage-dependence of INa activation compared to eGFP control. D.  Neither WT β1-V5 nor β1-
p.C162A-V5 affects the voltage-dependence of INa inactivation compared to eGFP control. N=3, 





VGSC b1 subunits are multi-functional. In addition modulation of the gating, kinetics, and 
localization properties of VGSC α subunits, β1 subunits function in cell adhesion, cell migration, 
calcium handling, modulation of potassium currents, neuronal pathfinding, fasciculation, and 
neurite outgrowth (Bouza and Isom 2018). Human SCN1B LOF variants are linked to EI-DEE and 
cardiac arrhythmia, often resulting in sudden death (Bouza and Isom 2018).  
 
It’s important to understand how β1 subunits are post-translationally processed. We showed 
previously that β1 is tyrosine phosphorylated. Here, we extend those findings to show that fyn 
kinase directly phosphorylates a β1 peptide. β1 subunits undergo RIP through the activity of 
BACE1 and γ-secretase (Wong, Sakurai et al. 2005, Bouza 2020). Initial cleavage of β1 by BACE1 
sheds the β1 Ig ectodomain and leaves behind the β1 C-terminal fragment in the membrane, which 
undergoes subsequent cleavage by γ-secretase to generate a soluble intracellular domain (b1-ICD) 
(Wong, Sakurai et al. 2005). Recent work by our laboratory demonstrated that b1-ICD translocates 
to the nucleus, where it acts as a transcriptional regulator and modulates sodium, potassium, and 
calcium currents in mouse ventricular myocytes (Bouza 2020). Overexpression of b1-ICD resulted 
in the downregulation of genes related to proliferation, immune response, and sodium and 
potassium channels. In contrast, loss of b1-ICD in Scn1b-null mouse cardiac ventricular tissue 
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resulted in the upregulation of these gene groups, suggesting that the b1-ICD may act as a 
transcriptional repressor under normal physiological conditions.  
Here, we demonstrate that b1 is lipid-modified by S-palmitoylation in the brain, that S-
palmitoylation, but not tyrosine phosphorylation, regulates b1 RIP by facilitating b1 localization 
to the plasma membrane, and that b1 subunits undergo clathrin-mediated endocytosis. This work 
suggests that b1 must be associated with the plasma membrane for RIP to occur and that S-
palmitoylation modulates b1 plasma membrane association and b1 endocytosis. Residue C162, at 
which b1 is palmitoylated, is conserved in VGSC b2 and b3 subunits, and thus may implicate 
palmitoylation as a similar regulatory mechanism in these proteins. Previous work has shown that 
palmitoylation of APP also promotes its RIP through its proper subcellular localization 
(Bhattacharyya, Barren et al. 2013). Although other RIP substrates, e.g. LRP1 and N-cadherin, 
have been shown to be palmitoylated, whether palmitoylation regulates their RIP in not known 
(Haapasalo and Kovacs 2011, Blanc, David et al. 2015).   
 
S-palmitoylation is a reversible posttranslational modification, making it a highly dynamic and 
tunable process (El-Husseini Ael, Schnell et al. 2002, Noritake, Fukata et al. 2009, Brigidi, Sun et 
al. 2014, Brigidi, Santyr et al. 2015).  Multiple palmitoyl acyltransferase enzymes, which mediate 
substrate palmitoylation, as well as protein thioesterases, which depalmitoylate substrates, are 
implicated in this process. The molecular identities of the enzymes that palmitoylate and 
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depalmitoylate b1 subunits are not known, but may be identified in the future to discover novel 
targets for SCN1B-linked pathophysiology. In addition, we do not know whether the level of β1 
palmitoylation can be dynamically regulated by extracellular stimuli or by altered excitability, but 
this information will be important to elucidate as attempts to implicate this posttranslational 
processing in disease mechanisms move forward. It is possible that β1-mediated transcriptional 
regulation vai RIP can be manipulated via altering the level of b1 palmitoylation.  Finally, the 
effects of SCN1B disease-linked variants on β1 subunit palmitoylation, RIP, and transcriptional 
regulation should be considered.  
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Materials and Methods 
Cell culture 
 
CHL stably expressing cell lines and HEK Nav1.5 cells were sustained  in Dulbecco’s Modified 
Eagle Medium with 5% heat inactivated fetal bovine serum, penicillin/streptomycin, and 600 
µg/mL at 37°C, 5% CO2. Stable cell lines were created by transfecting parental CHL cells with 1 
µg of cDNA with 5 µL of Lipofectamine 2000. 48 hours following transfection, cells were split 
into media containing 600 µg/mL G418 (Gibco). The cells were grown for approximately one 
week or until eGFP positive colonies were large enough to isolate. Individual colonies were 
selected and grown until confluent and characterized by western blot analysis. Patch clamp 
experiments used transient transfection of SCN1B cDNAs into HEK cells stably expressing 
Nav1.5. 1 µg of cDNA was transfected with 5 µL of Lipofectamine 2000 (Invitrogen). 
Approximately 12 hours post-transfection cells were plated for electrophysiological recordings. 
Patch clamp was completed approximately 12 hours post final plating.  
Antibodies 
Primary antibodies used were: anti-β1intra (1:1000 dilution), anti-V5 (1:1000 dilution, Invitrogen), 
anti-α-tubulin (1:1000 dilution, Cedar Lane), anti-BACE1 (1:1000, Invitrogen), anti-HSP90 
(1:1000 dilution, EnzoScientific), anti-TfR (1:1000 dilution, Thermo), and anti-Flotillin-1 (1:1000, 
Cell Signaling Technologies). The specificity of anti-β1intra has been shown previously by western 
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blot. HRP-conjugated secondary antibodies were used in this study. Goat anti-rabbit or goat anti-
mouse HRP-conjugated antibodies were diluted 1:1000 (anti-β1intra, anti-α-tubulin, anti-presenilin-
1, anti-BACE1, anti-TfR) or 1:10,000 (anti-V5, anti-Flotillin-1 or anti-HSP90). Alexa Fluor 568 
anti-mouse was used as a secondary (1:500 dilution) as a secondary antibody for anti-V5 in 
immunocytochemistry experiments. 
Expression Vectors 
A synthesis-optimized human WT β1-V5-2A-eGFP cDNA was generated by gBLOCK from 
Integrated DNA technologies. The bicistronic cDNA construct included an in-frame β1 C-terminal 
V5 epitope tag followed by a self-cleaving 2A peptide and enhanced Green Fluorescent Protein 
(eGFP) to facilitate immune-detection of β1 as well as transfected cells by eGFP. β1-p.C162A-
V5-2A-eGFP, β1-p.Y181A-V5-2A-eGFP, β1-p.Y181E-V5-2A-eGFP, and β1-p.Y181F-V5-2A-
eGFP were generated by site-directed mutagenesis using the WT β1-V5-2A-eGFP cDNA 
construct in pENTR-SD/D TOPO as the template. The eGFP alone control was generated by PCR 
from their respective full-length template cDNAs containing WT β1-V5-2A-eGFP. Using the 
Gateway cloning system, all constructs were moved from pENTR-SD/D-TOPO to pcDNAdest40 
via LR Clonase reaction according to the manufacturers’ protocol. 
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Measurement of sodium currents by whole-cell voltage clamp 
Voltage-clamp recordings were performed at room temperature in the whole-cell configuration 
using an Axopatch 700B amplifier and pClamp (versions 11, Axon Instruments, Foster City, CA) 
with 1.5–2.5 MΩ patch pipettes. Sodium currents were recorded in the presence of a bath solution 
containing (in mM): 120 NaCl, 1 BaCl2, 2 MgCl2, 0.2 CdCl2, 1 CaCl2, 10 HEPES, 20 TEA-Cl 
and 10 glucose (pH 7.35 with CsOH, Osmolarity: 300 – 305 mOsm). Fire-polished patch pipettes 
were filled with an internal solution containing (in mM): 1 NaCl, 150 N-methyl-D-glucamine, 10 
EGTA, 2 MgCl2, 40 HEPES, and 25 phosphocreatine-tris, 2 MgATP, 0.02 Na2GTP, 0.1 Leupectin 
(pH 7.2 with H2SO4).  Sodium current was recorded in response to a series of voltage steps 
between -100 and +30 mV in 5 mV increments, from a holding potential of -90 mV for 200 msec. 
A step back to -20 mV for 200 msec was used to determine the voltage-dependence of inactivation. 
Series resistance was compensated 40–65% and leak subtraction performed by application of a 
standard P/4 protocol. Normalized conductance and inactivation curves were generated as 
described previously . Current densities were determined by dividing current amplitude by the cell 
capacitance (Cm), as determined by application of +10 mV depolarizing test pulses. 
Western blot analysis of cell lysates 
Cell lysates were prepared either as described below for cleavage assays, surface biotinylation 
assays or DRMs, as appropriate. Loading buffer containing SDS, 5mM β-mercaptoethanol, and 
1% dithiothreitol was added to samples and heated for 10 min at 85°C. Protein lysates were 
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separated by SDS-PAGE on 10 or 12% Tris-Glycine polyacrylamide gels as indicated in the figure 
legends, transferred to nitrocellulose membrane overnight (16 h, 55 mA, 4°C), and probed with 
the needed antibodies, as indicated in the figure legends. Incubations with anti-V5 or anti-β1intra 
and their respective secondary antibodies were performed using a SnapID with 10-20 min 
incubations. Anti-α-tubulin, anti-TfR, anti-Flotillin-1, and anti-HSP90 antibodies were incubated 
overnight at 4°C. Secondary antibodies for anti-α-tubulin, anti-TfR, anti-Flotillin-1, and anti-
HSP90 were incubated for 1 h at room temperature (RT). Immunoreactive bands were detected 
using West Femto chemiluminescent substrate (GE Health Sciences) and imaged using an 
iBrightFL1000 (Invitrogen). Immunoreactive signals from cleavage assays were quantified using 
ImageJ and normalized to the level of α-tubulin and subsequently to vehicle treated samples. 
Cleavage assays 
Stably transfected CHL cells were grown until approximately 70% confluent in 100 mm tissue 
culture plates. Cells were treated with either vehicle (0.1% DMSO) or 1 µM DAPT (Cayman 
Chemical), as indicated in the figure legends. After a 24 hour treatment, cells were harvested, and 
membranes were prepared. Briefly, cells pellets were harvested and resuspended in 50 mM Tris, 
pH 8.0 with Complete protease inhibitors, EDTA-Free (Roche). On ice, cells were homogenized 
10 times with a dounce followed by sonication. To remove nuclei and insoluble material, lysates 
were spun at 2,537xg for 10 at 4°C. The supernatant was removed and spun at 80,000 x g for 15 
min at 4°C. The supernatant was removed, and the membrane-containing pellets were resuspended 
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in 133 µL of 50 mM Tris, pH 8.0 with Complete protease inhibitors, EDTA-Free (Roche) and 
sonicated on ice to resuspend the membrane-containing pellets. Samples were heated at 85°C for 
10 minutes and separated using 12% SDS-PAGE gels and western blots were performed as 
described above. 
Surface biotinylation assays 
Stably transfected cells were grown to 90%-100% confluence in 100 mm tissue culture plates. Cell 
surface proteins were biotinylated using the Cell Surface Protein Isolation Kit (Pierce) following 
the manufacturer’s instructions and as previously described (Patino, Claes et al. 2009). All samples 
were heated at 85°C for 10 minutes and separated on 10% SDS-PAGE gels. Western blots were 
performed as described above. For endocytosis experiments, prior to cell surface biotinylation, 
cells were treated with vehicle (0.1% DMSO) or 1 µM Dyngo-4a for two hours in a 37°C incubator 
with 5% CO2. 
Detergent Resistant Membrane (DRM) preparations 
10, 100mm dishes of CHL cells stably transfected with WT b1-V5-2AeGFP or p.C162A b1-V5-
2AeGFP were grown to 90-100% confluent. As described previously (Reverter, Rentero et al. 
2011), cells were washed and resuspended in 2.5 mL of HES buffer (20mM HEPES, 1mM EDTA, 
250mM sucrose, pH7.4) supplemented with 1mM Na3VO4 and Complete Protease Inhibitors 
(Roche). Cells were homogenized by 10 passages through a 22 gauge needle and centrifuged at 
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245,000g for 90 minutes at 4°C. Membranes were resuspended with 10 passages through a 22 
gauge needle in 2.5 mL of MBS buffer (25mM MES, 150mM NaCl, pH6.5) with 1% Triton X-
100 and Complete Protease Inhibitors (Roche) and incubated for 20 minutes at 4°C. Homogenate 
was mixed with 2.5 mL of 90% sucrose. 5 mL of 35% sucrose and 2.5 mL of 5% sucrose were 
overlaid and samples were centrifuged at 200,000g in a swinging bucket rotor for 17 hours. 1 mL 
fractions were collected from top to bottom, heated at 85°C for 10 minutes with sample buffer, 
and subsequently analyzed by western blot.  
Immunocytochemistry and confocal microscopy 
Approximately 100,000 CHL cells stably expressing WT β1-V5-2AeGFP, p.C162A-V5-2AeGFP, 
or eGFP were plated on 10mm MatTek glass bottom dishes. 24 hours post plating, cells were 
incubated on ice for 15 minutes at 4°C before staining with wheat germ agglutinin (WGA) for 10 
minutes at 4°C. Cells were washed 2x with PBS for 5 minutes at 4°C. For ER staining with the ER 
marker calnexin, cells were fixed with 100% methanol for 5 minutes, permeabilized with 0.1% 
triton in PBS for 5 minutes, and blocked with 1% BSA/10% goat serum/0.3M glycine in PBS 
containing 0.2% tween for 1 hour at room temperature. The cells were incubated with rabbit anti-
calnexin antibody (Abcam ab22595) at 1:1000 and mouse anti-V5 (ThermoFisher??) at 1:1000, 
overnight at 4°C in a humidified chamber. After 3 consecutive 10min washes with PBS containing 
0.2% tween, the cells were incubated with secondary antibody (goat anti rabbit 350 Alexa Fluor 
and donkey anti mouse 687 Alexa Fluor, diluted 1:250 in block buffer) for 1 hour at room 
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temperature. Cells were washed 3x for 10 minutes with PBS containing 0.2% tween before 
mounting with Prolong Gold. For non-ER staining, following WGA staining, cells were fixed with 
4% paraformaldehyde for 20 minutes, permeabilized with 0.2% triton in PBS for 10 minutes, and 
blocked with 5% BSA in 0.1% tween in TBS for 1 hour at room temperature. Cells were then 
incubated with mouse anti-V5 antibody diluted 1:1000 in block buffer, overnight at 4°C in a 
humidified chamber. After 3 10 min washes with PBS containing 0.2% tween, cells were incubated 
with secondary antibody (donkey anti mouse 687 Alexa Fluor, diluted 1:250 in block buffer) for 
1 hour at room temperature. Cells were washed 3x for 10 minutes with PBS containing 0.2% tween 
before mounting with Prolong Gold. Samples were imaged on a Zeiss LSM 880 with a 63x NA1.4 
Oil/DIC Plan-Apochromat objective in airyscan mode. Excitation was accomplished using 405, 
488, 561, and 633 nm lasers. All images were further processed in Adobe Photoshop CS6 software.  
Acyl Resin Assisted Capture (Acyl RAC) 
Stably transfected cells were grown until approximately 90% confluent in 100 mm tissue culture 
plates. Cells were lysed in buffer containing 100 mM HEPES, 1 mM EDTA, 2.5% SDS, and 2% 
methyl methanethiosulfonate (MMTS) (Sigma), adjusted to pH 7.5, sonicated, and left to rotate at 
40°C overnight. Acetone precipitation was performed to remove MMTS: 3x volume of cold 
acetone were used to precipitate the protein for 20 min at -20°C, before spinning down in standard 
bench-top ultracentrifuge at 5000 x g for 1 min. The supernatant was discarded and the pellet was 
washed 3x with 70% acetone, each time discarding the supernatant. Protein pellet was left to dry 
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in air and stored overnight at -20°C. Twelve hours later, protein was resuspended in 500 µL of 
“binding” buffer containing 100 mM HEPES, 1 mM EDTA, and 1% SDS, adjusted to pH 7.5, 
sonicated, and vigorously shook for 1 h, before splitting the protein sample into 3 1.5mL tubes, 1 
with 40 µL for “unmanipulated” starting material, and 2 with 220 µL for the palmitoylation assay 
(one for +HA and one for -HA condition). A 1:1 slurry of pre-activated thiopropyl sepharose beads 
(GE) was prepared using binding buffer (50 mg beads = 250 µL of binding buffer).  50 µL of the 
activated bead slurry was added to each 220 µL lysate. 50 µL of freshly prepared 2 M 
hydroxylamine (HA) (Sigma), adjusted to pH 7.5, were then added to the lysate designated “+HA”, 
while 50 µL of 2M NaCl were added to the sample designated “-HA”. Hydroxylamine/bead/lysate 
mixtures were left to incubate at RT for 2.5 h, rotating. To wash out the hydroxylamine and NaCl, 
the beads were spun at 5000 x g for 1 min, and the supernatant was removed and discarded. Bead 
resin was washed 5x with 1 mL of binding buffer, each time spinning at 5000 x g for 1 min and 
discarding the supernatant to recover the beads. Palmitoylated proteins were eluted using 50 µL of 
5x sample buffer supplemented with 100 mM DTT. Samples were heated at 65°C for 10 min, 
loaded on a 10% SDS-PAGE gel, and probed with anti-V5, using flotillin-1 as a positive control. 
Acyl PolyEthylene Glycol (Acyl PEG) 
Stably transfected cells were grown until approximately 90% confluent in 100 mm tissue culture 
plates. Cells were lysed with blocking buffer consisting of 100 mM HEPES, 150 mM NaCl, 5 mM 
EDTA, 2.5% SDS, and 200 mM tris(2-carboxyethyl)phosphine (TCEP) (Sigma), adjusted to pH 
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7.5, sonicated, and rotated at RT for 1 h. After 1 h, 12.5 µL of freshly prepared 1 M N-ethyl 
maleimide (NEM) (dissolved in ethanol) (Sigma) for 25 mM final NEM concentration were added 
to each lysate, with rotation overnight at room temperature. To scavenge the NEM, 12.5 µL of 2,3-
dimethyl 1,3-butadiene (Sigma) were added to each sample and rotated vigorously for one hour at 
RT. 100 µL of chloroform were added to each sample, vortexed vigorously for 1 min, and 
centrifuged at max speed for 3 min to achieve phase separation. The supernatant on top of the 
resulting ‘protein pancake’ was split into 3 1.5 mL tubes: 1 containing 40 µL for “unmanipulated” 
starting material, 1 containing 100 µL designed for “+HA” condition, and 1 containing 100 µL 
designated for “-HA” condition. 20 µL of 2 M freshly prepared hydroxylamine (HA) (Sigma), 
adjusted to pH 7.5, were added to the lysate designated “+HA”, while 20 µL of 2 M NaCl were 
added to the lysate designated “-HA”. The HA/lysate mixture was incubated for 2 h at 40°C, 
rotating. The HA and NaCl were desalted using a pre-equilibrated 40K MWCO Zebaspin desalting 
column (Thermofisher). 10 µL of a freshly prepared 20 mM stock of 5 kDa mPEG-maleimide 
(Sigma) (dissolved in water) were added to each desalted lysate and incubated for 2 h at 40°C, 
rotating. 100 µL of 5x sample buffer supplemented with 100 mM DTT were added to stop the 
mPEG-maleimide alkylation reaction and heated for 10 min at 65°C. The samples were loaded on 
a 10% SDS-PAGE gel and probed with anti-V5. 
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Fyn kinase assay 
Fyn kinase assay was performed according to manufacturer’s recommendations (Fyn kinase assay 
kit, Promega). Reactions were performed in triplicate and each reaction contained 200 ng of active 
GST-tagged Fyn kinase, 50 uM Ultrapure ATP, 0.2 mg/mL peptide substrate, 50 µM DTT diluted 
in a standard kinase reaction buffer (contents of 5X buffer: 40 mM Tris pH 7.5, 20 mM MgCl2, 
0.1 mg/mL BSA). β1 peptides corresponded to intracellular domain of β1 surrounding Y181 
(amino acids 175 to 185; β1 peptide, QENASEYLAITC; pYβ1 peptide, QENASE[pY]LAITC). 
The Poly E 4 Y 1 peptide is a well-characterized substrate of fyn kinase. Kinase reactions lacking 
substrate were used to normalize the kinase activity in substrate containing reactions. Three 
independent experiments were performed. Statistical significance was determined with Student’s 
t-test. 
Statistics  
Statistical analysis for cleavage assay experiments were completed with n=3-4 for each 
experiment. Data are represented as the mean ± SEM. β1 mutant cleavage experiments were 
completed as one-way ANOVA with multiple comparisons to WTb1 treated with DAPT. For the 
fyn kinase assay, three independent experiments were performed. Statistical significance was 
determined with Student’s t-test. Data are represented as the mean ± SEM. Electrophysiology 
experiments had an n of 10-15 cells per condition for each experiment. The voltage-dependence 
of activation and inactivation were compared using nonlinear fit, maximum current was analyzed 
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using one-way ANOVA with multiple comparisons, and current density was compared to the 
control, eGFP, with an unpaired t-test at each voltage-step.   
 148 
Chapter 4 Discussion and Future Directions 
 
 
Alexandra A. Bouza, Siena Snyder, Gemma L. Carvill, PhD, and Lori L. Isom, PhD 
Summary and Significance  
Variants in SCN1B, which encodes b1, are linked to diseases with high risk of sudden death, 
including  Early Infantile Epileptic Encephalopathy 52 (EIEE52, also called early infantile 
developmental and epileptic encepaholpathy) and Brugada Syndrome (Calhoun and Isom 2014, 
Bouza and Isom 2018). Scn1b-null mice are a model of EIEE52 and phenotypically present with 
spontaneous seizures and cardiac abnormalities as well as ataxia and failure-to-thrive (Chen, 
Westenbroek et al. 2004). Our research group is focused on understanding the roles of VGSC a 
and b subunits under normal physiological conditions and in pathology. My body of work has 
focused on VGSC β1 subunits, and how variants in SCN1B contribute to b1 dysfunction and 
ultimately, SCN1B-linked pathophysiology. My doctoral dissertation describes how I investigated 
the biochemical regulation and downstream signaling of VGSC b1 subunit processing by BACE1 
and g-secretase (Wong, Sakurai et al. 2005). 
Using a cell culture method, we demonstrated that b1 is a substrate for sequential cleavage by 
BACE1 and g-secretase. These sequential cleavage events generate a soluble peptide, the b1-ICD, 
which translocates to the nucleus where it can modulate transcription. Utilizing RNA-seq, we 
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identified gene ontology (GO) groups that were, in general, downregulated in response to b1-ICD 
overexpression in heterologous cells and, in general, upregulated in Scn1b null mouse cardiac 
ventricle, in which the b1-ICD was deleted. These results suggest that the b1-ICD may normally 
function as a molecular brake, both in vitro and in vivo. For example, in our experiments 
complementary changes in gene expression were observed for a group of voltage-gated potassium 
channel (VGKC) genes. Overexpression of the b1-ICD in cell culture resulted in decreases in 
VGKC mRNA, while Scn1b deletion in mouse cardiac ventricle led to increases in VKGC mRNA. 
Consistent with changes in gene expression, we observed increased potassium current in 
ventricular myocytes acutely isolated from Scn1b-null animals compared to wild-type. In addition 
to changes in VGKC gene expression, we found that heterologous overexpression of the b1-ICD 
resulted in increased VGSC a subunit mRNAs, although we were not able to detect changes in 
sodium current density. These data show b1 subunit processing by BACE1 and g-secretase 
generates a novel, transcriptional modulator, b1-ICD, which ultimately contributes to regulating 
cellular excitability by altering transcription of VGKC genes. Finally, we showed that b1 
palmitoylation, but not tyrosine phosphorylation, regulates b1 cell surface expression and thus β1 
cleavage. Using a b1 palmitoylation-null mutant, b1-p.C162A, we found that cleavage is 
significantly reduced, suggesting that BACE1-mediated b1 cleavage occurs at the plasma 
membrane. 
 150 
This body of work identified a novel, non-conducting role for VGSC b1 subunits as transcriptional 
modulators -  which ultimately contributes to the regulation of cellular excitability. Understanding 
the basic biochemistry and signaling mechanisms of b1 is critical in learning how patient variants 
in SCN1B result in neurological and cardiac diseases. Further work elucidating this newly 
identified b1-mediated signaling pathway may reveal novel therapeutic targets.  
Future Directions  
Although this work identified a novel, non-canonical function for b1 as a transcriptional 
modulator, it also raised important new questions, e.g. What is the mechanism of β1-ICD 
translocation to the nucleus? How does the β1-ICD alter of gene expression? What are the effects 
of SCN1B disease-linked variants on β1 subunit processing by BACE1 and γ-secretase? In the 
following sections, we will discuss these future directions, provide a hypothesis, and suggest 
potential approaches for addressing these important questions. 
 
Investigation of regulatory elements for b1 ectodomain shedding 
Ectodomain shedding occurs primarily for type-I transmembrane proteins. Release of the substrate 
protein’s ectodomain from the membrane results in altered protein function (Lichtenthaler, 
Lemberg et al. 2018). Ectodomain shedding occurs in all cellular organelles of the endocytic and 
secretory pathways as well as the plasma membrane, thus protein trafficking is one of the most 
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important regulatory mechanisms for ectodomain shedding (Lichtenthaler, Lemberg et al. 2018). 
Membrane-bound sheddases, such as BACE1, and their transmembrane substrates, must be 
trafficked to the same organelle in order for cleavage to occur (Lichtenthaler, Lemberg et al. 2018). 
The importance of trafficking as a regulatory mechanism for ectodomain shedding was originally 
shown for the substrate, SREBP, When cholesterol decreases, SREBP moves from the ER to the 
Golgi. In Golgi, SREBP is shed by S1P and then further processed by a site-2-protease (Rawson, 
Zelenski et al. 1997, Sakai, Rawson et al. 1998). Trafficking as a regulatory mechanism has also 
been demonstrated for APP (Haass, Hung et al. 1993, Koo and Squazzo 1994, Chyung and Selkoe 
2003, Carey, Balcz et al. 2005, Bhattacharyya, Barren et al. 2013, Sannerud, Esselens et al. 2016). 
Palmitoylation of APP is critical for its exit from the ER. A palmitoylation-deficient APP mutant 
is retained in the ER is unable to be cleaved (Bhattacharyya, Barren et al. 2013). In chapter 3, we 
demonstrate a similar mechanism for regulating b1 cleavage. b1 is also post-translationally 
palmitoylated. Expression of a palmitoylation-deficient b1 mutant leads to decreased plasma 
membrane localization compared to wild-type and subsequently, less b1 is cleaved by BACE1.  
Although protein trafficking is a highly important contributor to the regulation of ectodomain 
shedding, other factors such as, but not limited to, abundance of enzyme and substrate, lipid 
modulation, post-translational modification of the substrate, and ligand-dependent induction 
provide regulatory elements (Lichtenthaler, Lemberg et al. 2018). For example, substrate O-
glycosylation of amino acid residues near the cleavage site controls ectodomain shedding by 
ADAM proteases. Substrate ubiquitination has been shown to induce intramembrane proteolysis 
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following initial shedding (Fleig, Bergbold et al. 2012, Goth, Halim et al. 2015). Most famously, 
ligands, Delta and Jagged, bind to the notch receptor and only upon ligand binding is notch 
processed by RIP (Kopan 2012). Interestingly, glycosylated notch receptors have a higher affinity 
for Delta than Jagged-type ligands (Hicks, Johnston et al. 2000). Future work fully elucidating the 
complex regulatory mechanisms for b1 RIP will be critical in developing interventions to 
selectively block b1 RIP, while leaving b1’s other functions intact.  
b1 is highly N-linked glycosylated, accounting for approximately one-third of its molecular weight 
(Brackenbury and Isom 2011). While the majority of glycosylation sites are located within the β1 
Ig domain, a single site is located N-terminally adjacent to the predicted BACE1 cleavage site 
(Brackenbury and Isom 2011). We hypothesize that loss of glycosylation at this site may, like 
Notch and other ADAM protease substrates, contribute to regulating ectodomain shedding of b1. 
To test this hypothesis, each glycosylation site will need to be mutated and  cleavage assessed. It 
is also possible that b1 ectodomain shedding by BACE1 occurs constitutively. Should 
manipulation of other known regulatory elements of ectodomain shedding, such as mutating the 
Ig domain to prevent ligand interaction or manipulating lipid composition and substrate 
glycosylation, have no effect, it may be that trafficking is the only regulatory component for b1 
ectodomain shedding.   
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Determine the b1-ICD mechanism of nuclear entry and exit 
Chapter 2 of this work has shown the b1-ICD localizes to the nucleus. To enter and exit the 
nucleus, proteins interact with nuclear transport receptors that enable passage through nuclear pore 
complexes (NPC)(Di Ventura and Kuhlman 2016). The NPC restricts entry of proteins through 
the pore, although proteins smaller than approximately 40 kDa can diffuse through the barrier. 
Proteins larger than 40 kDa necessitate nuclear transport receptors, which can act as importins, 
assisting proteins in entering the nucleus, or exportins, assisting proteins in exiting the nucleus (Di 
Ventura and Kuhlman 2016). The interaction between proteins and nuclear transport receptors is 
typically facilitated by short amino acid motifs called nuclear localization signals (NLS) or nuclear 
export signals (NES) (Gorlich, Henklein et al. 1996, Chook and Suel 2011, Gorlich and Kriwacki 
2016). Nuclear entry and export are critical factors in regulating gene expression. In order to enable 
temporal regulation of gene expression, transcription factors and transcriptional coregulators are 
often retained in the cytoplasm until the proper stimuli initiate their translocation to the nucleus 
(Komeili and O'Shea 2000, Di Ventura and Kuhlman 2016). Cytoplasmic retention of transcription 
factors and transcriptional coregulators prevents their access to their binding partners, e.g. DNA, 
DNA binding proteins, and/or cofactors, and thus prevent their ability to modulate gene 
transcription (Komeili and O'Shea 2000). Proper nuclear export can be important in terminating a 
protein’s nuclear action (Shank and Paschal 2005). Thus, it is critical to determine the mechanism 
of nuclear entry and export of the b1-ICD. 
 154 
 
Interestingly, the b1-ICD contains neither a NLS nor a NES. Although the b1-ICD has a molecular 
weight less than 40 kDa and could enter the nucleus by diffusion through the NPC, we hypothesize 
that it enters and exits through a more regulated mechanism. Other known substrates of sequential 
cleavage that are small in size enter the nucleus by binding to a partner that does contain a NLS. 
For example, the ICD generated by sequential cleavage of APP, AICD, localizes to the nucleus 
only when it can bind to the adaptor protein, Fe65 (Cao and Sudhof 2001). Expression of a mutant 
version of APP that cannot bind Fe65 results in the loss of APP nuclear localization (Cao and 
Sudhof 2001). To address the question of how the b1-ICD enters and exits the nucleus, we 
performed an initial nomination of binding partners. Potential experimental approaches to address 
this question included yeast two hybrid screens, proteomics approaches, and bioinformatic 
approaches. Our lab decided to take this initial step using a proteomics approach. Using P18 mouse 
brain, we immunoprecipitated b1 and then performed liquid chromatography tandem mass 
spectrometry (LC-MS/MS) to identify the b1 interactome. We were surprised to find that b1 
interacts specifically with the nuclear pore complex protein, Nup160. Furthermore, our data 
showed that b1 interacts with a singular importin, importin-9, and with a singular exportin, 
exportin-5. As full-length b1 does not localize to the nucleus, these data support the hypothesis 
that the b1-ICD enters and exits the nucleus via the NPC with assistance from the nuclear transport 
receptors, importin-9 and exportin-5, rather than by passive diffusion. Additional work to validate 
these interactions will be critical to test this working hypothesis. Not only do these interactions 
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need to be confirmed by co-immunoprecipitation, but also functional studies must be completed. 
If importin-9 is necessary for b1-ICD entry into the nucleus, knockdown or knockout of importin-
9 should lead to the cytoplasmic accumulation of b1-ICD. Conversley, if exportin-5 is necessary 
for b1-ICD exit from the nucleus, knockdown or knockout of exportin-5 should lead to the nuclear 
accumulation of b1-ICD.  
 
Determine the mechanism by which the b1-ICD modulates gene transcription 
 
Chapter 2 demonstrates that expression of the b1-ICD leads to changes in gene expression, but the 
precise mechanism of how the b1-ICD drives differential gene expression remains unexplored. 
Many substrate-LPDs generated by RIP do not contain a DNA-binding domain (Lal and Caplan 
2011). The b1-ICD falls in the majority in that it too lacks a DNA-binding domain. Other similar 
substrates of RIP with transcriptional modulatory function do so as coregulators (Cao and Sudhof 
2001, Sardi, Murtie et al. 2006, Zhang, Wang et al. 2007, Haapasalo and Kovacs 2011, Bray and 
Gomez-Lamarca 2018). One example, APP, modulates transcription by binding with the adaptor 
protein, Fe65, and histone acetyltransferase, tip60. Tip60 functions in chromatin remodeling, DNA 
repair, and transcription (Cao and Sudhof 2001). Notch-1 is also processed by RIP, generating a 
Notch-ICD (NICD), which translocates to the nucleus to regulate transcription (Kopan, Nye et al. 
1994, van Tetering and Vooijs 2011, Bray and Gomez-Lamarca 2018). The NICD associates with 
the DNA binding protein, CSL, and the transcriptional coactivator, Mastermind (MAM), to 
modulate gene transcription (Kopan 2012, Bray and Gomez-Lamarca 2018). Thus, we hypothesize 
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that the b1-ICD modulates transcription by acting as a coregulator, rather than as a canonical 
transcription factor directly binding to DNA.  
To identify potential interacting partners that may function with the b1-ICD to regulate 
transcription, a bioinformatic or experimental approach could be used. Using gene expression data 
determining genes affected by expression of the b1-ICD, bioinformatic analysis could identify 
common promoters or DNA elements amongst those genes to nominate protein complexes that 
could alter expression of b1-ICD affected genes. Alternatively, experimental approaches such as 
yeast two hybrid or proteomics could be utilized to identify other members of a complex in which 
the b1-ICD modulates transcription. Based off our laboratory’s proteomics data set on the b1-
interactome, we hypothesize that the b1-ICD modulates gene expression through chromatin 
remodeling. b1 interacts with a core subunit of the PBAF complex (SWI/SNF-B), Smarcc2. The 
PBAF complex functions in chromatin remodeling (Yan, Cui et al. 2005). Interestingly, our data 
also show that b1 interacts with a variety of histones and histone modifying enzymes. Again, as 
full-length b1 does not localize to the nucleus, these data further support our hypothesis the b1-
ICD localizes to the nucleus and modulates transcription.  
 
Although we have exciting preliminary data, many additional experiments must be completed in 
order to test the hypothesis that the b1-ICD modulates transcription via chromatin remodeling. 
Initially, co-immunoprecipitations followed by western blot between the b1-ICD and those 
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proteins listed in Table 4.1 must be completed to validate the proteomics experiment. Should these 
binding partners be confirmed, interacting sites must be identified and mutants generated that 
specifically block interactions with each binding partner. Subsequent functional studies examining 
how preventing these interactions affect b1-ICD-mediated changes in gene transcription must be 
completed. Determining the exact mechanism by which the b1-ICD modulates transcription is 
critical to understanding how dysfunction of this signaling pathway in disease could be 






Histone H2AX Replaces convention H2A in a subset of 
nucleosomes.  
Histone H3.3C Core component of nucleosome. 
Histone H1.5 Binds to linker DNA between nucleosomes, 
forming the chromatin fiber.  
Heterochromatin protein 1-binding 
protein 3 
Component of heterochromatin that maintains 
heterochromatin integrity during G1/S progression.  
Histone H2A type 2-A Core component of nucleosome.  
Transcriptional regulator ATRX Involved in transcriptional regulation and 
chromatin remodeling.  
DNA (cytosine-5)-methyltransferase 
3A 
Required for genome-wide de novo methylation. 
Essential for establishment of DNA methylation 
patterns during development.  
Histone deacetylase complex subunit 
SAP18 
Component of SIN3-repressing complex. Enhances 
ability of SIN3-HDAC1-mediated transcriptional 
repression. 
SWI/SNF complex subunit 
SMARCC2 
Involved in transcriptional activation and 




Histone methyltransferase that plays essential role 
in early development and hematopoiesis.  
Histone-lysine N-methyltransferase 
EZH1 
Polycomb group protein. Catalytic subunit of 
PRC2/EED-EZH1 complex which methylates Lys-
27 of histone H3, leading to transcriptional 
repression of affected target gene.  
Methylosome protein 50 Non-catalytic component of methylosome complex, 
which modifies specific arginines to 
dimethylarginines in several spliceosomal Sm 
proteins and histones.  
 
Table 4.1: b1 binding partners which may implicate the b1-ICD in chromatin remodeling as a 




Enrichment analysis using the Gene Ontology (GO) knowledgebase and KEGG pathways were 
also completed for the b1 IP-mass spectrometry experiment. Surprisingly, gene set enrichment 
analysis (GSEA) revealed that spliceosome proteins were over-represented in the dataset (Figure 
4.1). Because we performed the immunoprecipitation experiment using a C-terminal anti-b1 
antibody, all three species of b1, full-length b1, b1-CTF, and b1-ICD, were detectable. Because 
our results show that full-length b1 and the b1-CTF do not localize to the nucleus, we hypothesize 
that b1-ICD is the b1 species interacting with the spliceosome. Additional experiments must be 
completed in order to test this hypothesis. First, b1 interaction with the spliceosome need to be 
validated by co-IP followed by western blot from mouse brain. Subsequently, using a cell line 
which only expresses the b1-ICD, co-immunoprecipitation followed by western blot would allow 
us to determine if the b1-ICD, but not other b1 species, is able to bind to spliceosome components. 
Additional work is underway to determine if expression of the b1-ICD has an effect on isoform 
switching, further solidifying that the b1-ICD interacts with the spliceosome and has a functional 
effect on splicing. This may provide an additional mechanism by which the b1-ICD contributes to 






Figure 4.1: Enrichment analysis of b1 interactome in mouse whole brain identifies spliceosome 
as major interacting partner. Enrichment groups shown in blue are related to splicing. A. Cellular 
component gene ontology groups enriched in data set. B. Biological function gene ontology groups 
enriched. C. Molecular function gene ontology group enriched in data set. D. KEGG pathways 
enriched. E. Cartoon diagram of splicing machinery and mechanism from iPathway guide.   
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Investigate cell-type specific alterations in gene transcription by the b1-ICD 
In this work, we have examined the role of the b1-ICD in regulating gene expression in 
heterologous cells and in mouse cardiac ventricle, but b1 plays important roles in many tissue 
types (Calhoun and Isom 2014, Bouza and Isom 2017). Work from other well-studied substrates 
of RIP, which result in modulating gene expression, have shown cell-type specific effects. Cell-
type specific effects of the NICD is arguably the most well characterized (Andersson, Sandberg et 
al. 2011). Although some conserved genes are modulated by NICD, genome-wide transcriptome 
studies in various cell-types have shown unique sets of NICD target genes in each individual cell 
type (Palomero, Lim et al. 2006, Weerkamp, Luis et al. 2006, Dohda, Maljukova et al. 2007, Buas, 
Kabak et al. 2009, Chadwick, Zeef et al. 2009, Mikhailik, Mazella et al. 2009, Main, Lee et al. 
2010, Meier-Stiegen, Schwanbeck et al. 2010, Aoyagi-Ikeda, Maeno et al. 2011). The NICD 
driven changes in gene expression can also change under specific cellular contexts, such as the 
cell cycle, cell lineage progression, and differentiation (Kageyama, Ohtsuka et al. 2009, Das, 
Lanner et al. 2010, Radtke, Fasnacht et al. 2010). Due to the high expression of b1, BACE1, and 
g-secretase in brain, examining b1-ICD driven changes in gene expression using genome-wide 
transcriptomics in neuronal tissue, taking into account specific brain regions, is critical (Vassar, 
Kovacs et al. 2009, Haapasalo and Kovacs 2011). Although these proteins are highly expressed 
and most well characterized in brain, they are found in many other tissue types. Work determining 
b1-ICD mediated gene expression in other tissues should also be pursued. More elaborate analysis 
of b1-ICD driven gene expression throughout development and differentiation, as well as cell 
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cycle in proliferating tissues, should be examined. This may have particular importance in SCN1B-
linked disease states, which show onset during critical periods of development.  
Determine the effect of disease-linked SCN1B variants on b1 cleavage and b1-ICD signaling 
Patient variants in SCN1B are linked to disease states with high risk of sudden death (Calhoun and 
Isom 2014, Bouza and Isom 2017). SCN1B patient variants to date are LOF and unable to properly 
modulate the ion channel pore and/or function in cell adhesion (Patino, Claes et al. 2009, Kruger, 
O'Malley et al. 2016, Aeby, Sculier et al. 2019). The effect of these variants on b1 RIP is yet to be 
determined. Disease-linked variants in other RIP substrates lead to dysregulation of the RIP 
pathway, which is thought to mechanistically contribute to disease onset and/or progression. For 
example, variants in Notch receptor genes are linked to adult T cell acute lymphoblastic leukemia 
and lymphoma (T-LL) (Aster, Blacklow et al. 2011). The most common of these variants are found 
in the Notch1 gene and result in ligand-independent ectodomain shedding. Other variants, which 
activate the Notch receptor, can lead to NICD buildup in the nucleus in T-LL (Aster, Blacklow et 
al. 2011). Variants in APP also affect its processing by RIP and are linked to early onset familial 
Alzheimer’s disease (FAD)(Weggen and Beher 2012). Nearly all FAD-linked APP variants are 
clustered around the BACE1 and g-secretase cleavage sites and lead to increased Ab production 
(Weggen and Beher 2012). Ab is the primary constituent in two out of three of the hallmarks of 
AD, senile plaques and vascular amyloid (Weggen and Beher 2012). We hypothesize that patient 
variants in SCN1B may lead to aberrant processing of β1 by BACE1 and/or g-secretase. In addition 
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to variants in other substrates that affect RIP, a Brugada Syndrome 5 patient variant in SCN1B, 
p.C162Y, it predicted to prevent b1 palmitoylation (ClinVar). In chapter 3, we showed that b1 
palmitoylation regulates b1 localization at the plasma membrane, and consequently its cleavage. 
The majority of SCN1B patient variants are located in the protein’s Ig domain (Bouza and Isom 
2018). Although this is distal to the predicted b1 cleavage sites, variants in the Ig domain may 
affect BACE1 recognition of the substrate (Table 4.2) (Wong, Sakurai et al. 2005). Additional 
disease-linked variants are located near the predicted BACE1 and g-secretase cleavage sites (Table 
4.2). Future work should assess the effect of SCN1B disease-linked variants on cleavage and 
subsequent signaling. Dysregulation of b1 RIP may be an important contributor to SCN1B-linked 




Variant Protein coding mutation Structural location of mutation 
c.133C>T p.R45C  Ig domain 
c.C253>T p.R85C Ig domain 
c.C319>A p.I106F Ig domain 
c.C363>G p.C121W  Ig domain 
c.C373>T p.R125C  Ig domain 
c.G412>A p.V138I Near BACE1 predicted cleavage site 
c.G415>A p.V139I Near BACE1 predicted cleavage site 
c.G542>A p.C162Y b1 palmitoylation site 
 




In all, this thesis describes a novel, non-canonical role of the VGSC b1 subunit, when processed 
by BACE1 and g-secretase, as a transcriptional modulator. Changes in gene expression driven by 
the b1-ICD lead to changes in cellular excitability. Thus this work provides a new mechanism to 
regulate excitability. β1 cleavage, like other substrates of RIP, is regulated in part by intracellular 
localization. When β1 cannot be palmitoylated, more protein is intracellularly retained. 
Consequently, less β1 is proteolytically processed. Furthermore, the identified b1-mediated 
signaling cascade may shed light on the mechanism by which differential gene expression occurs 
in the Scn1b-null mouse. Based on this work, we hypothesize that disease-linked variants in 
SCN1B may disrupt this signaling pathway, ultimately contributing to disease onset and/or 
progression. Future work will examine detailed mechanisms by which the b1-ICD modulates 
transcription, the effect of SCN1B variants on the identified pathway, and determine if targeting 
this pathway has therapeutic benefits for SCN1B-linked disease states. 
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Materials and Methods 
Immunoprecipitation 
P18 whole brain isolated from mice with an in-frame, C-terminal, V5-epitope tag knocked in  to 
the Scn1b locus (b1V5 mice) were utilized. Brains were flash frozen in liquid nitrogen immediately 
upon removal , crushed with a mortar and pestle, and suspended in 400 µL of dilution buffer (60 
mM Tris/HCl, 180mM NaCl, 6mM EDTA,  1% Triton X-100,  pH 7.5). Samples were incubated 
on ice for 30 minutes and sonicated three times for ten pulses   every 10 minutes during the 30 
minute incubation for a total of three times. 50 µL  of Protein G Sepharose  per sample was washed 
three times in DPBS. Protein G Sepharose was resuspended in 400 µL of  dilution buffer  and 
incubated with antibody for 1 hour at 4°C. Control antibody, mouse IgG (Jackson Immuno 
Research Laboratories) was diluted 1:10 in molecular biology grade water and 1 µL was added to 
Protein G Sepharose. 1 µL of experimental antibody, mouse V5 (Invitrogen) was added to Protein 
G Sepharose. After 1 hour incubation,  Protein G Sepharose was spun down at 2,500g for 1 minute 
and the supernatant was removed. 200  µL of brain lysate was added to each tube (mouse IgG, V5) 
and incubated at 4°C for 4 hours with shaking. Protein G Sepharose was spun down at 2,500g for 
1 minute and supernatant was removed. Resin was subsequently was three times with 400 µL of 
washing solution (50mM Tris/HCl, 150mM NaCl, 0.02% SDS, 5mM EDTA, pH7.5) and a final 
time with washing solution with 0.1% Triton X-100.  30 µL of sample buffer was added to each 
sample and heated at 85 C for 5 minutes. Samples were stored at -80°C until use. 
 
 167 
Mass Spectrometry and Proteomics Analysis  
 
 
The sample was reduced with dithiothreitol, alkylated with lodoacetamide, and digested using 
trypsin overnight at 37°C. Subsequently, the digested sample was analyzed by nano Liquid 
Chromatography tandem Mass Spectrometry (LC-MS/MS) on a ThermoScientific Orbitrap Velos. 
The digest was loaded and a gradient elution was over a 10 cm 75 µm ID C18 column at 400nL/min 
for 30 minutes.  Product ion data were searched against the NCBI protein database using Mascot 
and X-Tandem! search engines. Mascot files were assessed in Scaffold for filtering to assess false 
discovery rates, common contaminants, and non-specific interactions (also identified in IgG 
sample), to show only correct protein identifications.  
Gene Set Enrichment Analysis 
We performed gene ontology (GO), Kegg pathway and protein domain enrichment analysis of all 
immunoprecipitated proteins using the functional annotation tool, DAVID V6.8. To correct for 
multiple testing we considered functional enrichment only for categories with a Benjamini-




Adachi, K., M. Toyota, Y. Sasaki, T. Yamashita, S. Ishida, M. Ohe-Toyota, R. Maruyama, Y. 
Hinoda, T. Saito, K. Imai, R. Kudo and T. Tokino (2004). "Identification of SCN3B as a novel 
p53-inducible proapoptotic gene." Oncogene 23(47): 7791-7798. 
Aeby, A., C. Sculier, A. A. Bouza, B. Askar, D. Lederer, A.-S. Schoonjans, M. Vander Ghinst, B. 
Ceulemans, J. Offord, L. F. Lopez-Santiago and L. L. Isom (2019). "SCN1B-linked early infantile 
developmental and epileptic encephalopathy." Annals of Clinical and Translational Neurology 
6(12): 2354-2367. 
Agsten, M., S. Hessler, S. Lehnert, T. Volk, A. Rittger, S. Hartmann, C. Raab, D. Y. Kim, T. W. 
Groemer, M. Schwake, C. Alzheimer and T. Huth (2015). "BACE1 modulates gating of KCNQ1 
(Kv7.1) and cardiac delayed rectifier KCNQ1/KCNE1 (IKs)." J Mol Cell Cardiol 89(Pt B): 335-
348. 
Al-Chalabi, A., L. H. van den Berg and J. Veldink (2017). "Gene discovery in amyotrophic lateral 
sclerosis: implications for clinical management." Nat Rev Neurol 13(2): 96-104. 
Alders, M. and I. Christiaans (1993). Long QT Syndrome. GeneReviews(R). R. A. Pagon, M. P. 
Adam, H. H. Ardinger et al. Seattle (WA), University of Washington, Seattle 
University of Washington, Seattle. GeneReviews is a registered trademark of the University of 
Washington, Seattle. All rights reserved. 
Aman, T. K., T. M. Grieco-Calub, C. Chen, R. Rusconi, E. A. Slat, L. L. Isom and I. M. Raman 
(2009). "Regulation of persistent Na current by interactions between beta subunits of voltage-gated 
Na channels." J Neurosci 29(7): 2027-2042. 
Andersson, E. R., R. Sandberg and U. Lendahl (2011). "Notch signaling: simplicity in design, 
versatility in function." Development 138(17): 3593-3612. 
Andrikopoulos, P., S. P. Fraser, L. Patterson, Z. Ahmad, H. Burcu, D. Ottaviani, J. K. Diss, C. 
Box, S. A. Eccles and M. B. Djamgoz (2011). "Angiogenic functions of voltage-gated Na+ 
Channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) 
signaling." J Biol Chem 286(19): 16846-16860. 
Aoyagi-Ikeda, K., T. Maeno, H. Matsui, M. Ueno, K. Hara, Y. Aoki, F. Aoki, T. Shimizu, H. Doi, 
K. Kawai-Kowase, T. Iso, T. Suga, M. Arai and M. Kurabayashi (2011). "Notch Induces 
Myofibroblast Differentiation of Alveolar Epithelial Cells via Transforming Growth Factor–β–
Smad3 Pathway." American Journal of Respiratory Cell and Molecular Biology 45(1): 136-144. 
Aster, J. C., S. C. Blacklow and W. S. Pear (2011). "Notch signalling in T-cell lymphoblastic 
leukaemia/lymphoma and other haematological malignancies." J Pathol 223(2): 262-273. 
Audenaert, D., L. Claes, B. Ceulemans, A. Lofgren, C. Van Broeckhoven and P. De Jonghe (2003). 
"A deletion in SCN1B is associated with febrile seizures and early-onset absence epilepsy." 
Neurology 61(6): 854-856. 
Auerbach, D. S., J. Jones, B. C. Clawson, J. Offord, G. M. Lenk, I. Ogiwara, K. Yamakawa, M. 
H. Meisler, J. M. Parent and L. L. Isom (2013). "Altered cardiac electrophysiology and SUDEP in 
a model of Dravet syndrome." PLoS One 8(10): e77843. 
 169 
Bant, J. S. and I. M. Raman (2010). "Control of transient, resurgent, and persistent current by open-
channel block by Na channel beta4 in cultured cerebellar granule neurons." Proc Natl Acad Sci U 
S A 107(27): 12357-12362. 
Bao, Y., B. C. Willis, C. R. Frasier, L. F. Lopez-Santiago, X. Lin, R. Ramos-Mondragon, D. S. 
Auerbach, C. Chen, Z. Wang, J. Anumonwo, H. H. Valdivia, M. Delmar, J. Jalife and L. L. Isom 
(2016). "Scn2b Deletion in Mice Results in Ventricular and Atrial Arrhythmias." Circ Arrhythm 
Electrophysiol 9(12). 
Barao, S., A. Gartner, E. Leyva-Diaz, G. Demyanenko, S. Munck, T. Vanhoutvin, L. Zhou, M. 
Schachner, G. Lopez-Bendito, P. F. Maness and B. De Strooper (2015). "Antagonistic Effects of 
BACE1 and APH1B-gamma-Secretase Control Axonal Guidance by Regulating Growth Cone 
Collapse." Cell Rep 12(9): 1367-1376. 
Baum, L., B. S. Haerian, H. K. Ng, V. C. Wong, P. W. Ng, C. H. Lui, N. C. Sin, C. Zhang, B. 
Tomlinson, G. W. Wong, H. J. Tan, A. A. Raymond, Z. Mohamed and P. Kwan (2014). "Case-
control association study of polymorphisms in the voltage-gated sodium channel genes SCN1A, 
SCN2A, SCN3A, SCN1B, and SCN2B and epilepsy." Hum Genet 133(5): 651-659. 
Bharadwaj, M. and O. A. Bizzozero (1995). "Myelin P0 glycoprotein and a synthetic peptide 
containing the palmitoylation site are both autoacylated." J Neurochem 65(4): 1805-1815. 
Bhattacharyya, R., C. Barren and D. M. Kovacs (2013). "Palmitoylation of amyloid precursor 
protein regulates amyloidogenic processing in lipid rafts." J Neurosci 33(27): 11169-11183. 
Blackburn-Munro, G. and S. M. Fleetwood-Walker (1999). "The sodium channel auxiliary 
subunits beta1 and beta2 are differentially expressed in the spinal cord of neuropathic rats." 
Neuroscience 90(1): 153-164. 
Blanc, M., F. David, L. Abrami, D. Migliozzi, F. Armand, J. Burgi and F. G. van der Goot (2015). 
"SwissPalm: Protein Palmitoylation database." F1000Res 4: 261. 
Borghetti, G., C. A. Eisenberg, S. Signore, A. Sorrentino, K. Kaur, A. Andrade-Vicenty, J. G. 
Edwards, M. Nerkar, K. Qanud, D. Sun, P. Goichberg, A. Leri, P. Anversa, L. M. Eisenberg, J. T. 
Jacobson, T. H. Hintze and M. Rota (2018). "Notch signaling modulates the electrical behavior of 
cardiomyocytes." Am J Physiol Heart Circ Physiol 314(1): H68-h81. 
Bouza, A. A. and L. L. Isom (2017). "Voltage-Gated Sodium Channel beta Subunits and Their 
Related Diseases." Handb Exp Pharmacol. 
Bouza, A. A. and L. L. Isom (2018). "Voltage-Gated Sodium Channel beta Subunits and Their 
Related Diseases." Handb Exp Pharmacol 246: 423-450. 
Bouza, A. A., Nnamdi Edokobi, Alexa M. Pinsky, James Offord, PhD, Lin Piao, MD, PhD, Anatoli 
N. Lopatin, PhD, Luis F. Lopez-Santiago, PhD, and Lori L. Isom, PhD (2020). "Voltage-gated 
sodium channel β1 subunits mediate excitation-transcription coupling through regulated 
intramembrane proteolysis." In Review. 
Brackenbury, W. J. (2012). "Voltage-gated sodium channels and metastatic disease." Channels 
(Austin) 6(5): 352-361. 
Brackenbury, W. J., J. D. Calhoun, C. Chen, H. Miyazaki, N. Nukina, F. Oyama, B. Ranscht and 
L. L. Isom (2010). "Functional reciprocity between Na+ channel Nav1.6 and beta1 subunits in the 
coordinated regulation of excitability and neurite outgrowth." Proc Natl Acad Sci U S A 107(5): 
2283-2288. 
Brackenbury, W. J., T. H. Davis, C. Chen, E. A. Slat, M. J. Detrow, T. L. Dickendesher, B. Ranscht 
and L. L. Isom (2008). "Voltage-gated Na+ channel beta1 subunit-mediated neurite outgrowth 
requires Fyn kinase and contributes to postnatal CNS development in vivo." J Neurosci 28(12): 
3246-3256. 
 170 
Brackenbury, W. J. and L. L. Isom (2011). "Na Channel beta Subunits: Overachievers of the Ion 
Channel Family." Front Pharmacol 2: 53. 
Brackenbury, W. J., Y. Yuan, H. A. O'Malley, J. M. Parent and L. L. Isom (2013). "Abnormal 
neuronal patterning occurs during early postnatal brain development of Scn1b-null mice and 
precedes hyperexcitability." Proc Natl Acad Sci U S A 110(3): 1089-1094. 
Bray, S. J. and M. Gomez-Lamarca (2018). "Notch after cleavage." Curr Opin Cell Biol 51: 103-
109. 
Breunig, J. J., J. Silbereis, F. M. Vaccarino, N. Sestan and P. Rakic (2007). "Notch regulates cell 
fate and dendrite morphology of newborn neurons in the postnatal dentate gyrus." Proc Natl Acad 
Sci U S A 104(51): 20558-20563. 
Brigidi, G. S., B. Santyr, J. Shimell, B. Jovellar and S. X. Bamji (2015). "Activity-regulated 
trafficking of the palmitoyl-acyl transferase DHHC5." Nat Commun 6: 8200. 
Brigidi, G. S., Y. Sun, D. Beccano-Kelly, K. Pitman, M. Mobasser, S. L. Borgland, A. J. 
Milnerwood and S. X. Bamji (2014). "Palmitoylation of delta-catenin by DHHC5 mediates 
activity-induced synapse plasticity." Nat Neurosci 17(4): 522-532. 
Buas, M. F., S. Kabak and T. Kadesch (2009). "Inhibition of myogenesis by Notch: Evidence for 
multiple pathways." Journal of Cellular Physiology 218(1): 84-93. 
Buffington, S. A. and M. N. Rasband (2013). "Na+ channel-dependent recruitment of Navbeta4 to 
axon initial segments and nodes of Ranvier." J Neurosci 33(14): 6191-6202. 
Cai, J., X. Qi, N. Kociok, S. Skosyrski, A. Emilio, Q. Ruan, S. Han, L. Liu, Z. Chen, C. Bowes 
Rickman, T. Golde, M. B. Grant, P. Saftig, L. Serneels, B. de Strooper, A. M. Joussen and M. E. 
Boulton (2012). "beta-Secretase (BACE1) inhibition causes retinal pathology by vascular 
dysregulation and accumulation of age pigment." EMBO Mol Med 4(9): 980-991. 
Calhoun, J. D. and L. L. Isom (2014). "The role of non-pore-forming beta subunits in physiology 
and pathophysiology of voltage-gated sodium channels." Handb Exp Pharmacol 221: 51-89. 
Cao, L., G. T. Rickenbacher, S. Rodriguez, T. W. Moulia and M. W. Albers (2012). "The precision 
of axon targeting of mouse olfactory sensory neurons requires the BACE1 protease." Sci Rep 2: 
231. 
Cao, X. and T. C. Sudhof (2001). "A transcriptionally [correction of transcriptively] active 
complex of APP with Fe65 and histone acetyltransferase Tip60." Science 293(5527): 115-120. 
Cao, X. and T. C. Sudhof (2004). "Dissection of amyloid-beta precursor protein-dependent 
transcriptional transactivation." J Biol Chem 279(23): 24601-24611. 
Carey, R. M., B. A. Balcz, I. Lopez-Coviella and B. E. Slack (2005). "Inhibition of dynamin-
dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and 
reduces generation of amyloid beta protein." BMC Cell Biol 6: 30. 
Catterall, W. A. "From Ionic Currents to Molecular Mechanisms." Neuron 26(1): 13-25. 
Chadwick, N., L. Zeef, V. Portillo, C. Fennessy, F. Warrander, S. Hoyle and A. M. Buckle (2009). 
"Identification of novel Notch target genes in T cell leukaemia." Mol Cancer 8: 35. 
Chavez-Gutierrez, L., L. Bammens, I. Benilova, A. Vandersteen, M. Benurwar, M. Borgers, S. 
Lismont, L. Zhou, S. Van Cleynenbreugel, H. Esselmann, J. Wiltfang, L. Serneels, E. Karran, H. 
Gijsen, J. Schymkowitz, F. Rousseau, K. Broersen and B. De Strooper (2012). "The mechanism 
of gamma-Secretase dysfunction in familial Alzheimer disease." Embo j 31(10): 2261-2274. 
Chen, C., V. Bharucha, Y. Chen, R. E. Westenbroek, A. Brown, J. D. Malhotra, D. Jones, C. 
Avery, P. J. Gillespie, 3rd, K. A. Kazen-Gillespie, K. Kazarinova-Noyes, P. Shrager, T. L. 
Saunders, R. L. Macdonald, B. R. Ransom, T. Scheuer, W. A. Catterall and L. L. Isom (2002). 
"Reduced sodium channel density, altered voltage dependence of inactivation, and increased 
 171 
susceptibility to seizures in mice lacking sodium channel beta 2-subunits." Proc Natl Acad Sci U 
S A 99(26): 17072-17077. 
Chen, C., J. D. Calhoun, Y. Zhang, L. Lopez-Santiago, N. Zhou, T. H. Davis, J. L. Salzer and L. 
L. Isom (2012). "Identification of the cysteine residue responsible for disulfide linkage of Na+ 
channel alpha and beta2 subunits." J Biol Chem 287(46): 39061-39069. 
Chen, C., R. E. Westenbroek, X. Xu, C. A. Edwards, D. R. Sorenson, Y. Chen, D. P. McEwen, H. 
A. O'Malley, V. Bharucha, L. S. Meadows, G. A. Knudsen, A. Vilaythong, J. L. Noebels, T. L. 
Saunders, T. Scheuer, P. Shrager, W. A. Catterall and L. L. Isom (2004). "Mice lacking sodium 
channel beta1 subunits display defects in neuronal excitability, sodium channel expression, and 
nodal architecture." J Neurosci 24(16): 4030-4042. 
Chen, Q., X. Liu, L. Xu, Y. Wang, S. Wang, Q. Li, Y. Huang and T. Liu (2016). "Long non-coding 
RNA BACE1-AS is a novel target for anisomycin-mediated suppression of ovarian cancer stem 
cell proliferation and invasion." Oncol Rep 35(4): 1916-1924. 
Cheret, C., M. Willem, F. R. Fricker, H. Wende, A. Wulf-Goldenberg, S. Tahirovic, K. A. Nave, 
P. Saftig, C. Haass, A. N. Garratt, D. L. Bennett and C. Birchmeier (2013). "Bace1 and Neuregulin-
1 cooperate to control formation and maintenance of muscle spindles." Embo j 32(14): 2015-2028. 
Chioni, A. M., W. J. Brackenbury, J. D. Calhoun, L. L. Isom and M. B. Djamgoz (2009). "A novel 
adhesion molecule in human breast cancer cells: voltage-gated Na+ channel beta1 subunit." Int J 
Biochem Cell Biol 41(5): 1216-1227. 
Chook, Y. M. and K. E. Suel (2011). "Nuclear import by karyopherin-betas: recognition and 
inhibition." Biochim Biophys Acta 1813(9): 1593-1606. 
Chyung, J. H. and D. J. Selkoe (2003). "Inhibition of receptor-mediated endocytosis demonstrates 
generation of amyloid beta-protein at the cell surface." J Biol Chem 278(51): 51035-51043. 
Cole, S. L. and R. Vassar (2007). "The Alzheimer's disease beta-secretase enzyme, BACE1." Mol 
Neurodegener 2: 22. 
Contreras-Cornejo, H., G. Saucedo-Correa, J. Oviedo-Boyso, J. J. Valdez-Alarcón, V. M. 
Baizabal-Aguirre, M. Cajero-Juárez and A. Bravo-Patiño (2016). "The CSL proteins, versatile 
transcription factors and context dependent corepressors of the notch signaling pathway." Cell Div 
11: 12. 
Coward, K., A. Jowett, C. Plumpton, A. Powell, R. Birch, S. Tate, C. Bountra and P. Anand (2001). 
"Sodium channel beta1 and beta2 subunits parallel SNS/PN3 alpha-subunit changes in injured 
human sensory neurons." Neuroreport 12(3): 483-488. 
Das, D., F. Lanner, H. Main, E. R. Andersson, O. Bergmann, C. Sahlgren, N. Heldring, O. 
Hermanson, E. M. Hansson and U. Lendahl (2010). "Notch induces cyclin-D1-dependent 
proliferation during a specific temporal window of neural differentiation in ES cells." Dev Biol 
348(2): 153-166. 
Davis, T. H., C. Chen and L. L. Isom (2004). "Sodium channel beta1 subunits promote neurite 
outgrowth in cerebellar granule neurons." J Biol Chem 279(49): 51424-51432. 
Davis, T. H., C. Chen and L. L. Isom (2004). "Sodium Channel β1 Subunits Promote Neurite 
Outgrowth In Cerebellar Granule Neurons." J. Biol. Chem. 279: 51424-51432. 
Deschenes, I., A. A. Armoundas, S. P. Jones and G. F. Tomaselli (2008). "Post-transcriptional 
gene silencing of KChIP2 and Navbeta1 in neonatal rat cardiac myocytes reveals a functional 
association between Na and Ito currents." J Mol Cell Cardiol 45(3): 336-346. 
Deschenes, I. and G. F. Tomaselli (2002). "Modulation of Kv4.3 current by accessory subunits." 
FEBS Lett 528(1-3): 183-188. 
 172 
Dhar Malhotra, J., C. Chen, I. Rivolta, H. Abriel, R. Malhotra, L. N. Mattei, F. C. Brosius, R. S. 
Kass and L. L. Isom (2001). "Characterization of sodium channel alpha- and beta-subunits in rat 
and mouse cardiac myocytes." Circulation 103(9): 1303-1310. 
Di Ventura, B. and B. Kuhlman (2016). "Go in! Go out! Inducible control of nuclear localization." 
Curr Opin Chem Biol 34: 62-71. 
Diss, J. K., S. P. Fraser, M. M. Walker, A. Patel, D. S. Latchman and M. B. Djamgoz (2008). 
"Beta-subunits of voltage-gated sodium channels in human prostate cancer: quantitative in vitro 
and in vivo analyses of mRNA expression." Prostate Cancer Prostatic Dis 11(4): 325-333. 
Dohda, T., A. Maljukova, L. Liu, M. Heyman, D. Grander, D. Brodin, O. Sangfelt and U. Lendahl 
(2007). "Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell 
acute lymphoblastic leukemia cell lines." Exp Cell Res 313(14): 3141-3152. 
Dunckley, T., T. G. Beach, K. E. Ramsey, A. Grover, D. Mastroeni, D. G. Walker, B. J. LaFleur, 
K. D. Coon, K. M. Brown, R. Caselli, W. Kukull, R. Higdon, D. McKeel, J. C. Morris, C. Hulette, 
D. Schmechel, E. M. Reiman, J. Rogers and D. A. Stephan (2006). "Gene expression correlates of 
neurofibrillary tangles in Alzheimer's disease." Neurobiol Aging 27(10): 1359-1371. 
Edbauer, D., E. Winkler, J. T. Regula, B. Pesold, H. Steiner and C. Haass (2003). "Reconstitution 
of gamma-secretase activity." Nat Cell Biol 5(5): 486-488. 
El-Husseini Ael, D., E. Schnell, S. Dakoji, N. Sweeney, Q. Zhou, O. Prange, C. Gauthier-
Campbell, A. Aguilera-Moreno, R. A. Nicoll and D. S. Bredt (2002). "Synaptic strength regulated 
by palmitate cycling on PSD-95." Cell 108(6): 849-863. 
Evin, G., A. Barakat and C. L. Masters (2010). "BACE: Therapeutic target and potential biomarker 
for Alzheimer's disease." Int J Biochem Cell Biol 42(12): 1923-1926. 
Fendri-Kriaa, N., F. Kammoun, I. H. Salem, C. Kifagi, E. Mkaouar-Rebai, I. Hsairi, A. Rebai, C. 
Triki and F. Fakhfakh (2011). "New mutation c.374C>T and a putative disease-associated 
haplotype within SCN1B gene in Tunisian families with febrile seizures." Eur J Neurol 18(5): 695-
702. 
Ficker, D. M., E. L. So, W. K. Shen, J. F. Annegers, P. C. O'Brien, G. D. Cascino and P. G. Belau 
(1998). "Population-based study of the incidence of sudden unexplained death in epilepsy." 
Neurology 51(5): 1270-1274. 
Fielden, M. R., J. Werner, J. A. Jamison, A. Coppi, D. Hickman, R. T. Dunn, 2nd, E. Trueblood, 
L. Zhou, C. A. Afshari and R. Lightfoot-Dunn (2015). "Retinal Toxicity Induced by a Novel beta-
secretase Inhibitor in the Sprague-Dawley Rat." Toxicol Pathol 43(4): 581-592. 
Fleig, L., N. Bergbold, P. Sahasrabudhe, B. Geiger, L. Kaltak and M. K. Lemberg (2012). 
"Ubiquitin-dependent intramembrane rhomboid protease promotes ERAD of membrane proteins." 
Mol Cell 47(4): 558-569. 
Forrester, M. T., D. T. Hess, J. W. Thompson, R. Hultman, M. A. Moseley, J. S. Stamler and P. J. 
Casey (2011). "Site-specific analysis of protein S-acylation by resin-assisted capture." J Lipid Res 
52(2): 393-398. 
Gaborit, N., S. Le Bouter, V. Szuts, A. Varro, D. Escande, S. Nattel and S. Demolombe (2007). 
"Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human 
heart." J Physiol 582(Pt 2): 675-693. 
Gataullina, S. and O. Dulac (2017). "From genotype to phenotype in Dravet disease." Seizure 44: 
58-64. 
Gilchrist, J., S. Das, F. Van Petegem and F. Bosmans (2013). "Crystallographic insights into 
sodium-channel modulation by the beta4 subunit." Proc Natl Acad Sci U S A 110(51): E5016-
5024. 
 173 
Giri, B., V. D. Dixit, M. C. Ghosh, G. D. Collins, I. U. Khan, K. Madara, A. T. Weeraratna and D. 
D. Taub (2007). "CXCL12-induced partitioning of flotillin-1 with lipid rafts plays a role in CXCR4 
function." Eur J Immunol 37(8): 2104-2116. 
Glasscock, E., J. W. Yoo, T. T. Chen, T. L. Klassen and J. L. Noebels (2010). "Kv1.1 potassium 
channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden 
unexplained death in epilepsy." J Neurosci 30(15): 5167-5175. 
Gomez-Ospina, N., G. Panagiotakos, T. Portmann, S. P. Pasca, D. Rabah, A. Budzillo, J. P. Kinet 
and R. E. Dolmetsch (2013). "A promoter in the coding region of the calcium channel gene 
CACNA1C generates the transcription factor CCAT." PLoS One 8(4): e60526. 
Gomez-Ospina, N., F. Tsuruta, O. Barreto-Chang, L. Hu and R. Dolmetsch (2006). "The C 
terminus of the L-type voltage-gated calcium channel Ca(V)1.2 encodes a transcription factor." 
Cell 127(3): 591-606. 
Gorlich, D., P. Henklein, R. A. Laskey and E. Hartmann (1996). "A 41 amino acid motif in 
importin-alpha confers binding to importin-beta and hence transit into the nucleus." Embo j 15(8): 
1810-1817. 
Gorlich, D. and R. W. Kriwacki (2016). "Editorial Overview: Functional and Mechanistic 
Landscape of the Nuclear Pore Complex." J Mol Biol 428(10 Pt A): 1947-1948. 
Goth, C. K., A. Halim, S. A. Khetarpal, D. J. Rader, H. Clausen and K. T. Schjoldager (2015). "A 
systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-
glycosylation." Proc Natl Acad Sci U S A 112(47): 14623-14628. 
Gray, B., C. Hasdemir, J. Ingles, T. Aiba, N. Makita, V. Probst, A. A. M. Wilde, R. Newbury-
Ecob, M. N. Sheppard, C. Semsarian, R. W. Sy and E. R. Behr (2018). "Lack of genotype-
phenotype correlation in Brugada Syndrome and Sudden Arrhythmic Death Syndrome families 
with reported pathogenic SCN1B variants." Heart Rhythm 15(7): 1051-1057. 
Grieco, T. M., J. D. Malhotra, C. Chen, L. L. Isom and I. M. Raman (2005). "Open-channel block 
by the cytoplasmic tail of sodium channel beta4 as a mechanism for resurgent sodium current." 
Neuron 45(2): 233-244. 
Haapasalo, A. and D. M. Kovacs (2011). "The many substrates of presenilin/gamma-secretase." J 
Alzheimers Dis 25(1): 3-28. 
Haass, C., A. Y. Hung, M. G. Schlossmacher, D. B. Teplow and D. J. Selkoe (1993). "beta-
Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms." J Biol Chem 
268(5): 3021-3024. 
Hakim, P., N. Brice, R. Thresher, J. Lawrence, Y. Zhang, A. P. Jackson, A. A. Grace and C. L. 
Huang (2010). "Scn3b knockout mice exhibit abnormal sino-atrial and cardiac conduction 
properties." Acta Physiol (Oxf) 198(1): 47-59. 
Hakim, P., I. S. Gurung, T. H. Pedersen, R. Thresher, N. Brice, J. Lawrence, A. A. Grace and C. 
L. Huang (2008). "Scn3b knockout mice exhibit abnormal ventricular electrophysiological 
properties." Prog Biophys Mol Biol 98(2-3): 251-266. 
Hemming, M. L., J. E. Elias, S. P. Gygi and D. J. Selkoe (2009). "Identification of beta-secretase 
(BACE1) substrates using quantitative proteomics." PLoS One 4(12): e8477. 
Hernandez-Plata, E., C. S. Ortiz, B. Marquina-Castillo, I. Medina-Martinez, A. Alfaro, J. 
Berumen, M. Rivera and J. C. Gomora (2012). "Overexpression of NaV 1.6 channels is associated 
with the invasion capacity of human cervical cancer." Int J Cancer 130(9): 2013-2023. 
Hesdorffer, D. C., T. Tomson, E. Benn, J. W. Sander, L. Nilsson, Y. Langan, T. S. Walczak, E. 
Beghi, M. J. Brodie and W. A. Hauser (2012). "Do antiepileptic drugs or generalized tonic-clonic 
seizure frequency increase SUDEP risk? A combined analysis." Epilepsia 53(2): 249-252. 
 174 
Hicks, C., S. H. Johnston, G. diSibio, A. Collazo, T. F. Vogt and G. Weinmaster (2000). "Fringe 
differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2." Nat Cell Biol 
2(8): 515-520. 
Hitt, B., S. M. Riordan, L. Kukreja, W. A. Eimer, T. W. Rajapaksha and R. Vassar (2012). "beta-
Site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)-deficient mice exhibit a close 
homolog of L1 (CHL1) loss-of-function phenotype involving axon guidance defects." J Biol Chem 
287(46): 38408-38425. 
Hitt, B. D., T. C. Jaramillo, D. M. Chetkovich and R. Vassar (2010). "BACE1-/- mice exhibit 
seizure activity that does not correlate with sodium channel level or axonal localization." Mol 
Neurodegener 5: 31. 
Holst, A. G., S. Saber, M. Houshmand, E. V. Zaklyazminskaya, Y. Wang, H. K. Jensen, L. 
Refsgaard, S. Haunso, J. H. Svendsen, M. S. Olesen and J. Tfelt-Hansen (2012). "Sodium current 
and potassium transient outward current genes in Brugada syndrome: screening and 
bioinformatics." Can J Cardiol 28(2): 196-200. 
Hu, D., H. Barajas-Martinez, A. Medeiros-Domingo, L. Crotti, C. Veltmann, R. Schimpf, J. 
Urrutia, A. Alday, O. Casis, R. Pfeiffer, E. Burashnikov, G. Caceres, D. J. Tester, C. Wolpert, M. 
Borggrefe, P. Schwartz, M. J. Ackerman and C. Antzelevitch (2012). "A novel rare variant in 
SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 
channel currents." Heart Rhythm 9(5): 760-769. 
Hu, X., Q. Fan, H. Hou and R. Yan (2016). "Neurological dysfunctions associated with altered 
BACE1-dependent Neuregulin-1 signaling." J Neurochem 136(2): 234-249. 
Hu, X., W. He, X. Luo, K. E. Tsubota and R. Yan (2013). "BACE1 regulates hippocampal 
astrogenesis via the Jagged1-Notch pathway." Cell Rep 4(1): 40-49. 
Hu, X., C. W. Hicks, W. He, P. Wong, W. B. Macklin, B. D. Trapp and R. Yan (2006). "Bace1 
modulates myelination in the central and peripheral nervous system." Nat Neurosci 9(12): 1520-
1525. 
Hu, X., X. Zhou, W. He, J. Yang, W. Xiong, P. Wong, C. G. Wilson and R. Yan (2010). "BACE1 
deficiency causes altered neuronal activity and neurodegeneration." J Neurosci 30(26): 8819-8829. 
Hull, J. M. and L. L. Isom (2018). "Voltage-gated sodium channel beta subunits: The power 
outside the pore in brain development and disease." Neuropharmacology 132: 43-57. 
Isom, L. L. (2002). "The role of sodium channels in cell adhesion." Front Biosci 7: 12-23. 
Isom, L. L. and W. A. Catterall (1996). "Na+ channel subunits and Ig domains." Nature 383(6598): 
307-308. 
Isom, L. L., K. S. De Jongh and W. A. Catterall (1994). "Auxiliary subunits of voltage-gated ion 
channels." Neuron 12(6): 1183-1194. 
Isom, L. L., K. S. De Jongh, D. E. Patton, B. F. Reber, J. Offord, H. Charbonneau, K. Walsh, A. 
L. Goldin and W. A. Catterall (1992). "Primary structure and functional expression of the beta 1 
subunit of the rat brain sodium channel." Science 256(5058): 839-842. 
Isom, L. L., D. S. Ragsdale, K. S. De Jongh, R. E. Westenbroek, B. F. Reber, T. Scheuer and W. 
A. Catterall (1995). "Structure and function of the beta 2 subunit of brain sodium channels, a 
transmembrane glycoprotein with a CAM motif." Cell 83(3): 433-442. 
Isom, L. L., T. Scheuer, A. B. Brownstein, D. S. Ragsdale, B. J. Murphy and W. A. Catterall 
(1995). "Functional Co-expression of the 1 and Type IIA Subunits of Sodium Channels in a 
Mammalian Cell Line." Journal of Biological Chemistry 270(7): 3306-3312. 
 175 
Isom, L. L., T. Scheuer, A. B. Brownstein, D. S. Ragsdale, B. J. Murphy and W. A. Catterall 
(1995). "Functional co-expression of the b1 and type IIA a subunits of sodium channels in a 
mammalian cell line." J. Biol. Chem. 270: 3306-3312. 
Jansen, K. and L. Lagae (2010). "Cardiac changes in epilepsy." Seizure 19(8): 455-460. 
Jansson, K. H., J. E. Lynch, N. Lepori-Bui, K. J. Czymmek, R. L. Duncan and R. A. Sikes (2012). 
"Overexpression of the VSSC-associated CAM, beta-2, enhances LNCaP cell metastasis 
associated behavior." Prostate 72(10): 1080-1092. 
Johnson, D., M. L. Montpetit, P. J. Stocker and E. S. Bennett (2004). "The sialic acid component 
of the beta1 subunit modulates voltage-gated sodium channel function." J Biol Chem 279(43): 
44303-44310. 
Kageyama, R., T. Ohtsuka, H. Shimojo and I. Imayoshi (2009). "Dynamic regulation of Notch 
signaling in neural progenitor cells." Curr Opin Cell Biol 21(6): 733-740. 
Kalume, F., R. E. Westenbroek, C. S. Cheah, F. H. Yu, J. C. Oakley, T. Scheuer and W. A. Catterall 
(2013). "Sudden unexpected death in a mouse model of Dravet syndrome." J Clin Invest 123(4): 
1798-1808. 
Kaplan, D. I., L. L. Isom and S. Petrou (2016). "Role of Sodium Channels in Epilepsy." Cold 
Spring Harb Perspect Med 6(6). 
Kazarinova-Noyes, K., J. D. Malhotra, D. P. McEwen, L. N. Mattei, E. O. Berglund, B. Ranscht, 
S. R. Levinson, M. Schachner, P. Shrager, L. L. Isom and Z. C. Xiao (2001). "Contactin associates 
with Na+ channels and increases their functional expression." J Neurosci 21(19): 7517-7525. 
Kazen-Gillespie, K. A., D. S. Ragsdale, M. R. D'Andrea, L. N. Mattei, K. E. Rogers and L. L. 
Isom (2000). "Cloning, localization, and functional expression of sodium channel beta1A 
subunits." J Biol Chem 275(2): 1079-1088. 
Kelleher, R. J., 3rd and J. Shen (2017). "Presenilin-1 mutations and Alzheimer's disease." Proc 
Natl Acad Sci U S A 114(4): 629-631. 
Kim, D. Y., B. W. Carey, H. Wang, L. A. Ingano, A. M. Binshtok, M. H. Wertz, W. H. Pettingell, 
P. He, V. M. Lee, C. J. Woolf and D. M. Kovacs (2007). "BACE1 regulates voltage-gated sodium 
channels and neuronal activity." Nat Cell Biol 9(7): 755-764. 
Kim, D. Y., M. T. Gersbacher, P. Inquimbert and D. M. Kovacs (2011). "Reduced sodium channel 
Na(v)1.1 levels in BACE1-null mice." J Biol Chem 286(10): 8106-8116. 
Kim, D. Y., L. A. Ingano, B. W. Carey, W. H. Pettingell and D. M. Kovacs (2005). 
"Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-
subunit regulates cell adhesion and migration." J Biol Chem 280(24): 23251-23261. 
Kim, D. Y., L. A. Mackenzie Ingano, B. W. Carey, W. P. Pettingell and D. M. Kovacs (2005). 
"Presenilin/gamma -secretase-mediated cleavage of the voltage-gated sodium channel beta 2 
subunit regulates cell adhesion and migration." J Biol Chem. 
Kim, H. S., E. M. Kim, J. P. Lee, C. H. Park, S. Kim, J. H. Seo, K. A. Chang, E. Yu, S. J. Jeong, 
Y. H. Chong and Y. H. Suh (2003). "C-terminal fragments of amyloid precursor protein exert 
neurotoxicity by inducing glycogen synthase kinase-3beta expression." Faseb j 17(13): 1951-1953. 
Ko, S. H., P. W. Lenkowski, H. C. Lee, J. P. Mounsey and M. K. Patel (2005). "Modulation of 
Na(v)1.5 by beta1-- and beta3-subunit co-expression in mammalian cells." Pflugers Arch 449(4): 
403-412. 
Kobayashi, D., M. Zeller, T. Cole, M. Buttini, L. McConlogue, S. Sinha, S. Freedman, R. G. 
Morris and K. S. Chen (2008). "BACE1 gene deletion: impact on behavioral function in a model 
of Alzheimer's disease." Neurobiol Aging 29(6): 861-873. 
 176 
Komeili, A. and E. K. O'Shea (2000). "Nuclear transport and transcription." Curr Opin Cell Biol 
12(3): 355-360. 
Koo, E. H. and S. L. Squazzo (1994). "Evidence that production and release of amyloid beta-
protein involves the endocytic pathway." J Biol Chem 269(26): 17386-17389. 
Kopan, R. (2012). "Notch signaling." Cold Spring Harb Perspect Biol 4(10). 
Kopan, R. and M. X. G. Ilagan (2004). "γ-Secretase: proteasome of the membrane?" Nature 
Reviews Molecular Cell Biology 5(6): 499-504. 
Kopan, R., J. S. Nye and H. Weintraub (1994). "The intracellular domain of mouse Notch: a 
constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of 
MyoD." Development 120(9): 2385-2396. 
Krous, H. F., J. B. Beckwith, R. W. Byard, T. O. Rognum, T. Bajanowski, T. Corey, E. Cutz, R. 
Hanzlick, T. G. Keens and E. A. Mitchell (2004). "Sudden infant death syndrome and unclassified 
sudden infant deaths: a definitional and diagnostic approach." Pediatrics 114(1): 234-238. 
Kruger, L. C. and L. L. Isom (2016). "Voltage-Gated Na+ Channels: Not Just for Conduction." 
Cold Spring Harb Perspect Biol 8(6). 
Kruger, L. C., H. A. O'Malley, J. M. Hull, A. Kleeman, G. A. Patino and L. L. Isom (2016). "beta1-
C121W Is Down But Not Out: Epilepsy-Associated Scn1b-C121W Results in a Deleterious Gain-
of-Function." J Neurosci 36(23): 6213-6224. 
Laedermann Cé, J., N. Syam, M. Pertin, I. Decosterd and H. Abriel (2013). "β1- and β3- voltage-
gated sodium channel subunits modulate cell surface expression and glycosylation of Na(v)1.7 in 
HEK293 cells." Front Cell Neurosci 7. 
Lal, M. and M. Caplan (2011). "Regulated Intramembrane Proteolysis: Signaling Pathways and 
Biological Functions." Physiology 26(1): 34-44. 
Lal, M. and M. Caplan (2011). "Regulated intramembrane proteolysis: signaling pathways and 
biological functions." Physiology (Bethesda) 26(1): 34-44. 
Lee, Y. J. and T. H. Ch'ng (2020). "RIP at the Synapse and the Role of Intracellular Domains in 
Neurons." Neuromolecular Med 22(1): 1-24. 
Lemberg, M. K. and M. Freeman (2007). "Cutting Proteins within Lipid Bilayers: Rhomboid 
Structure and Mechanism." Molecular Cell 28(6): 930-940. 
Levental, I., D. Lingwood, M. Grzybek, U. Coskun and K. Simons (2010). "Palmitoylation 
regulates raft affinity for the majority of integral raft proteins." Proc Natl Acad Sci U S A 107(51): 
22050-22054. 
Li, H., Y. Chen, B. Zhou, Y. Peng, Y. Sheng and L. Rao (2011). "Polymorphisms of presenilin-1 
gene associate with dilated cardiomyopathy susceptibility." Mol Cell Biochem 358(1-2): 31-36. 
Li, R. G., Q. Wang, Y. J. Xu, M. Zhang, X. K. Qu, X. Liu, W. Y. Fang and Y. Q. Yang (2013). 
"Mutations of the SCN4B-encoded sodium channel beta4 subunit in familial atrial fibrillation." Int 
J Mol Med 32(1): 144-150. 
Lichtenthaler, S. F., C. Haass and H. Steiner (2011). "Regulated intramembrane proteolysis – 
lessons from amyloid precursor protein processing." Journal of Neurochemistry 117(5): 779-796. 
Lichtenthaler, S. F., M. K. Lemberg and R. Fluhrer (2018). "Proteolytic ectodomain shedding of 
membrane proteins in mammals-hardware, concepts, and recent developments." Embo j 37(15). 
Lin, X., H. O'Malley, C. Chen, D. Auerbach, M. Foster, A. Shekhar, M. Zhang, W. Coetzee, J. 
Jalife, G. I. Fishman, L. Isom and M. Delmar (2014). "Scn1b deletion leads to increased 
tetrodotoxin-sensitive sodium current, altered intracellular calcium homeostasis and arrhythmias 
in murine hearts." J Physiol. 
 177 
Lin, X., H. O'Malley, C. Chen, D. Auerbach, M. Foster, A. Shekhar, M. Zhang, W. Coetzee, J. 
Jalife, G. I. Fishman, L. Isom and M. Delmar (2015). "Scn1b deletion leads to increased 
tetrodotoxin-sensitive sodium current, altered intracellular calcium homeostasis and arrhythmias 
in murine hearts." J Physiol 593(6): 1389-1407. 
Lo, W. L., D. L. Donermeyer and P. M. Allen (2012). "A voltage-gated sodium channel is essential 
for the positive selection of CD4(+) T cells." Nat Immunol 13(9): 880-887. 
Lopez-Santiago, L. F., W. J. Brackenbury, C. Chen and L. L. Isom (2011). "Na+ channel Scn1b 
gene regulates dorsal root ganglion nociceptor excitability in vivo." J Biol Chem 286(26): 22913-
22923. 
Lopez-Santiago, L. F., W. J. Brackenbury, C. Chen and L. L. Isom (2011). "Na+ channel SCN1B 
regulates dorsal root ganglion nociceptor excitability in vivo." J Biol Chem. 
Lopez-Santiago, L. F., L. S. Meadows, S. J. Ernst, C. Chen, J. D. Malhotra, D. P. McEwen, A. 
Speelman, J. L. Noebels, S. K. Maier, A. N. Lopatin and L. L. Isom (2007). "Sodium channel 
Scn1b null mice exhibit prolonged QT and RR intervals." J Mol Cell Cardiol 43(5): 636-647. 
Lopez-Santiago, L. F., M. Pertin, X. Morisod, C. Chen, S. Hong, J. Wiley, I. Decosterd and L. L. 
Isom (2006). "Sodium channel beta2 subunits regulate tetrodotoxin-sensitive sodium channels in 
small dorsal root ganglion neurons and modulate the response to pain." J Neurosci 26(30): 7984-
7994. 
Lu, L., P. Sirish, Z. Zhang, R. L. Woltz, N. Li, V. Timofeyev, A. A. Knowlton, X. D. Zhang, E. 
N. Yamoah and N. Chiamvimonvat (2015). "Regulation of gene transcription by voltage-gated L-
type calcium channel, Cav1.3." J Biol Chem 290(8): 4663-4676. 
Maier, S. K., R. E. Westenbroek, K. A. McCormick, R. Curtis, T. Scheuer and W. A. Catterall 
(2004). "Distinct subcellular localization of different sodium channel alpha and beta subunits in 
single ventricular myocytes from mouse heart." Circulation 109(11): 1421-1427. 
Main, H., K. L. Lee, H. Yang, S. Haapa-Paananen, H. Edgren, S. Jin, C. Sahlgren, O. Kallioniemi, 
L. Poellinger, B. Lim and U. Lendahl (2010). "Interactions between Notch- and hypoxia-induced 
transcriptomes in embryonic stem cells." Exp Cell Res 316(9): 1610-1624. 
Malhotra, J. D., K. Kazen-Gillespie, M. Hortsch and L. L. Isom (2000). "Sodium channel beta 
subunits mediate homophilic cell adhesion and recruit ankyrin to points of cell-cell contact." J Biol 
Chem 275(15): 11383-11388. 
Malhotra, J. D., M. C. Koopmann, K. A. Kazen-Gillespie, N. Fettman, M. Hortsch and L. L. Isom 
(2002). "Structural requirements for interaction of sodium channel b1 subunits with ankyrin." J 
Biol Chem 277(29): 26681-26688. 
Malhotra, J. D., M. C. Koopmann, K. A. Kazen-Gillespie, N. Fettman, M. Hortsch and L. L. Isom 
(2002). "Structural requirements for interaction of sodium channel beta 1 subunits with ankyrin." 
J Biol Chem 277(29): 26681-26688. 
Malhotra, J. D., V. Thyagarajan, C. Chen and L. L. Isom (2004). "Tyrosine-phosphorylated and 
nonphosphorylated sodium channel beta1 subunits are differentially localized in cardiac 
myocytes." J Biol Chem 279(39): 40748-40754. 
Marionneau, C., Y. Carrasquillo, A. J. Norris, R. R. Townsend, L. L. Isom, A. J. Link and J. M. 
Nerbonne (2012). "The Sodium Channel Accessory Subunit Navβ1 Regulates Neuronal 
Excitability through Modulation of Repolarizing Voltage-Gated K(+) Channels." J Neurosci 
32(17): 5716-5727. 
Massey, C. A., L. P. Sowers, B. J. Dlouhy and G. B. Richerson (2014). "SUDEP Mechanisms: 
The pathway to prevention." Nat Rev Neurol 10(5): 271-282. 
 178 
Mattsson, N., M. Axelsson, S. Haghighi, C. Malmestrom, G. Wu, R. Anckarsater, S. 
Sankaranarayanan, U. Andreasson, S. Fredrikson, A. Gundersen, L. Johnsen, T. Fladby, A. 
Tarkowski, E. Trysberg, A. Wallin, H. Anckarsater, J. Lycke, O. Andersen, A. J. Simon, K. 
Blennow and H. Zetterberg (2009). "Reduced cerebrospinal fluid BACE1 activity in multiple 
sclerosis." Mult Scler 15(4): 448-454. 
McCarthy, A. J., C. Coleman-Vaughan and J. V. McCarthy (2017). "Regulated intramembrane 
proteolysis: emergent role in cell signalling pathways." Biochem Soc Trans 45(6): 1185-1202. 
McCormick, K. A., L. L. Isom, D. Ragsdale, D. Smith, T. Scheuer and W. A. Catterall (1998). 
"Molecular determinants of Na+ channel function in the extracellular domain of the beta1 subunit." 
J Biol Chem 273(7): 3954-3962. 
McEwen, D. P., C. Chen, L. S. Meadows, L. Lopez-Santiago and L. L. Isom (2009). "The voltage-
gated Na+ channel beta3 subunit does not mediate trans homophilic cell adhesion or associate with 
the cell adhesion molecule contactin." Neurosci Lett 462(3): 272-275. 
McEwen, D. P. and L. L. Isom (2004). "Heterophilic interactions of sodium channel beta1 subunits 
with axonal and glial cell adhesion molecules." J Biol Chem 279(50): 52744-52752. 
McEwen, D. P., L. S. Meadows, C. Chen, V. Thyagarajan and L. L. Isom (2004). "Sodium channel 
beta1 subunit-mediated modulation of Nav1.2 currents and cell surface density is dependent on 
interactions with contactin and ankyrin." J Biol Chem 279(16): 16044-16049. 
Meadows, L., J. D. Malhotra, A. Stetzer, L. L. Isom and D. S. Ragsdale (2001). "The intracellular 
segment of the sodium channel beta 1 subunit is required for its efficient association with the 
channel alpha subunit." J Neurochem 76(6): 1871-1878. 
Meadows, L. S., J. Malhotra, A. Loukas, V. Thyagarajan, K. A. Kazen-Gillespie, M. C. Koopman, 
S. Kriegler, L. L. Isom and D. S. Ragsdale (2002). "Functional and biochemical analysis of a 
sodium channel beta1 subunit mutation responsible for generalized epilepsy with febrile seizures 
plus type 1." J Neurosci 22(24): 10699-10709. 
Medeiros-Domingo, A., T. Kaku, D. J. Tester, P. Iturralde-Torres, A. Itty, B. Ye, C. Valdivia, K. 
Ueda, S. Canizales-Quinteros, M. T. Tusie-Luna, J. C. Makielski and M. J. Ackerman (2007). 
"SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome." Circulation 
116(2): 134-142. 
Mei, L. and K. A. Nave (2014). "Neuregulin-ERBB signaling in the nervous system and 
neuropsychiatric diseases." Neuron 83(1): 27-49. 
Meier-Stiegen, F., R. Schwanbeck, K. Bernoth, S. Martini, T. Hieronymus, D. Ruau, M. Zenke 
and U. Just (2010). "Activated Notch1 target genes during embryonic cell differentiation depend 
on the cellular context and include lineage determinants and inhibitors." PLoS One 5(7): e11481. 
Mikhailik, A., J. Mazella, S. Liang and L. Tseng (2009). "Notch ligand-dependent gene expression 
in human endometrial stromal cells." Biochem Biophys Res Commun 388(3): 479-482. 
Miyazaki, H., F. Oyama, R. Inoue, T. Aosaki, T. Abe, H. Kiyonari, Y. Kino, M. Kurosawa, J. 
Shimizu, I. Ogiwara, K. Yamakawa, Y. Koshimizu, F. Fujiyama, T. Kaneko, H. Shimizu, K. 
Nagatomo, K. Yamada, T. Shimogori, N. Hattori, M. Miura and N. Nukina (2014). "Singular 
localization of sodium channel beta4 subunit in unmyelinated fibres and its role in the striatum." 
Nat Commun 5: 5525. 
Miyazaki, H., F. Oyama, H. K. Wong, K. Kaneko, T. Sakurai, A. Tamaoka and N. Nukina (2007). 
"BACE1 modulates filopodia-like protrusions induced by sodium channel beta4 subunit." 
Biochem Biophys Res Commun 361(1): 43-48. 
Morgan, K., E. B. Stevens, B. Shah, P. J. Cox, A. K. Dixon, K. Lee, R. D. Pinnock, J. Hughes, P. 
J. Richardson, K. Mizuguchi and A. P. Jackson (2000). "beta 3: an additional auxiliary subunit of 
 179 
the voltage-sensitive sodium channel that modulates channel gating with distinct kinetics." Proc 
Natl Acad Sci U S A 97(5): 2308-2313. 
Morrison, S. J., S. E. Perez, Z. Qiao, J. M. Verdi, C. Hicks, G. Weinmaster and D. J. Anderson 
(2000). "Transient Notch activation initiates an irreversible switch from neurogenesis to 
gliogenesis by neural crest stem cells." Cell 101(5): 499-510. 
Nakano, Y. and W. Shimizu (2016). "Genetics of long-QT syndrome." J Hum Genet 61(1): 51-55. 
Namadurai, S., D. Balasuriya, R. Rajappa, M. Wiemhofer, K. Stott, J. Klingauf, J. M. Edwardson, 
D. Y. Chirgadze and A. P. Jackson (2014). "Crystal structure and molecular imaging of the Nav 
channel beta3 subunit indicates a trimeric assembly." J Biol Chem 289(15): 10797-10811. 
Nashef, L., E. L. So, P. Ryvlin and T. Tomson (2012). "Unifying the definitions of sudden 
unexpected death in epilepsy." Epilepsia 53(2): 227-233. 
Nejatbakhsh, N. and Z. P. Feng (2011). "Calcium binding protein-mediated regulation of voltage-
gated calcium channels linked to human diseases." Acta Pharmacol Sin 32(6): 741-748. 
Nelson, M., R. Millican-Slater, L. C. Forrest and W. J. Brackenbury (2014). "The sodium channel 
beta1 subunit mediates outgrowth of neurite-like processes on breast cancer cells and promotes 
tumour growth and metastasis." Int J Cancer 135(10): 2338-2351. 
Nguyen, H. M., H. Miyazaki, N. Hoshi, B. J. Smith, N. Nukina, A. L. Goldin and K. G. Chandy 
(2012). "Modulation of voltage-gated K+ channels by the sodium channel beta1 subunit." Proc 
Natl Acad Sci U S A 109(45): 18577-18582. 
Noritake, J., Y. Fukata, T. Iwanaga, N. Hosomi, R. Tsutsumi, N. Matsuda, H. Tani, H. Iwanari, Y. 
Mochizuki, T. Kodama, Y. Matsuura, D. S. Bredt, T. Hamakubo and M. Fukata (2009). "Mobile 
DHHC palmitoylating enzyme mediates activity-sensitive synaptic targeting of PSD-95." J Cell 
Biol 186(1): 147-160. 
Nutini, M., A. Spalloni, F. Florenzano, R. E. Westenbroek, C. Marini, W. A. Catterall, G. Bernardi 
and P. Longone (2011). "Increased expression of the beta3 subunit of voltage-gated Na+ channels 
in the spinal cord of the SOD1G93A mouse." Mol Cell Neurosci 47(2): 108-118. 
O'Malley, H. A. and L. L. Isom (2015). "Sodium channel beta subunits: emerging targets in 
channelopathies." Annu Rev Physiol 77: 481-504. 
O'Malley, H. A., A. B. Shreiner, G. H. Chen, G. B. Huffnagle and L. L. Isom (2009). "Loss of Na+ 
channel beta2 subunits is neuroprotective in a mouse model of multiple sclerosis." Mol Cell 
Neurosci 40(2): 143-155. 
Oakley, J. C., F. Kalume and W. A. Catterall (2011). "Insights into pathophysiology and therapy 
from a mouse model of Dravet syndrome." Epilepsia 52 Suppl 2: 59-61. 
Ogiwara, I., T. Nakayama, T. Yamagata, H. Ohtani, E. Mazaki, S. Tsuchiya, Y. Inoue and K. 
Yamakawa (2012). "A homozygous mutation of voltage-gated sodium channel beta(I) gene 
SCN1B in a patient with Dravet syndrome." Epilepsia 53(12): e200-203. 
Olesen, M. S., A. G. Holst, J. H. Svendsen, S. Haunso and J. Tfelt-Hansen (2012). "SCN1Bb 
R214Q found in 3 patients: 1 with Brugada syndrome and 2 with lone atrial fibrillation." Heart 
Rhythm 9(5): 770-773. 
Olesen, M. S., T. Jespersen, J. B. Nielsen, B. Liang, D. V. Moller, P. Hedley, M. Christiansen, A. 
Varro, S. P. Olesen, S. Haunso, N. Schmitt and J. H. Svendsen (2011). "Mutations in sodium 
channel beta-subunit SCN3B are associated with early-onset lone atrial fibrillation." Cardiovasc 
Res 89(4): 786-793. 
Oyama, F., H. Miyazaki, N. Sakamoto, C. Becquet, Y. Machida, K. Kaneko, C. Uchikawa, T. 
Suzuki, M. Kurosawa, T. Ikeda, A. Tamaoka, T. Sakurai and N. Nukina (2006). "Sodium channel 
 180 
beta4 subunit: down-regulation and possible involvement in neuritic degeneration in Huntington's 
disease transgenic mice." J Neurochem 98(2): 518-529. 
Ozaki, T., Y. Li, H. Kikuchi, T. Tomita, T. Iwatsubo and A. Nakagawara (2006). "The intracellular 
domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis." Biochem 
Biophys Res Commun 351(1): 57-63. 
Palomero, T., W. K. Lim, D. T. Odom, M. L. Sulis, P. J. Real, A. Margolin, K. C. Barnes, J. O'Neil, 
D. Neuberg, A. P. Weng, J. C. Aster, F. Sigaux, J. Soulier, A. T. Look, R. A. Young, A. Califano 
and A. A. Ferrando (2006). "NOTCH1 directly regulates <em>c-MYC</em> and activates a feed-
forward-loop transcriptional network promoting leukemic cell growth." Proceedings of the 
National Academy of Sciences 103(48): 18261-18266. 
Pandis, D. and N. Scarmeas (2012). "Seizures in Alzheimer Disease: Clinical and Epidemiological 
Data." Epilepsy Currents 12(5): 184-187. 
Pardossi-Piquard, R. and F. Checler (2012). "The physiology of the beta-amyloid precursor protein 
intracellular domain AICD." J Neurochem 120 Suppl 1: 109-124. 
Paris, D., A. Quadros, N. Patel, A. DelleDonne, J. Humphrey and M. Mullan (2005). "Inhibition 
of angiogenesis and tumor growth by beta and gamma-secretase inhibitors." Eur J Pharmacol 
514(1): 1-15. 
Patino, G. A., W. J. Brackenbury, Y. Bao, L. F. Lopez-Santiago, H. A. O'Malley, C. Chen, J. D. 
Calhoun, R. G. Lafreniere, P. Cossette, G. A. Rouleau and L. L. Isom (2011). "Voltage-gated Na+ 
channel beta1B: a secreted cell adhesion molecule involved in human epilepsy." J Neurosci 31(41): 
14577-14591. 
Patino, G. A., L. R. Claes, L. F. Lopez-Santiago, E. A. Slat, R. S. Dondeti, C. Chen, H. A. 
O'Malley, C. B. Gray, H. Miyazaki, N. Nukina, F. Oyama, P. De Jonghe and L. L. Isom (2009). 
"A functional null mutation of SCN1B in a patient with Dravet syndrome." J Neurosci 29(34): 
10764-10778. 
Pedrozo, Z., N. Torrealba, C. Fernandez, D. Gatica, B. Toro, C. Quiroga, A. E. Rodriguez, G. 
Sanchez, T. G. Gillette, J. A. Hill, P. Donoso and S. Lavandero (2013). "Cardiomyocyte ryanodine 
receptor degradation by chaperone-mediated autophagy." Cardiovasc Res 98(2): 277-285. 
Percher, A., S. Ramakrishnan, E. Thinon, X. Yuan, J. S. Yount and H. C. Hang (2016). "Mass-tag 
labeling reveals site-specific and endogenous levels of protein S-fatty acylation." Proc Natl Acad 
Sci U S A 113(16): 4302-4307. 
Pertin, M., R. R. Ji, T. Berta, A. J. Powell, L. Karchewski, S. N. Tate, L. L. Isom, C. J. Woolf, N. 
Gilliard, D. R. Spahn and I. Decosterd (2005). "Upregulation of the voltage-gated sodium channel 
beta2 subunit in neuropathic pain models: characterization of expression in injured and non-injured 
primary sensory neurons." J Neurosci 25(47): 10970-10980. 
Pink, A. E., M. A. Simpson, N. Desai, R. C. Trembath and J. N. W. Barker (2013). "γ-Secretase 
Mutations in Hidradenitis Suppurativa: New Insights into Disease Pathogenesis." Journal of 
Investigative Dermatology 133(3): 601-607. 
Qin, N., M. R. D'Andrea, M. L. Lubin, N. Shafaee, E. E. Codd and A. M. Correa (2003). 
"Molecular cloning and functional expression of the human sodium channel beta1B subunit, a 
novel splicing variant of the beta1 subunit." Eur J Biochem 270(23): 4762-4770. 
Radtke, F., N. Fasnacht and H. R. Macdonald (2010). "Notch signaling in the immune system." 
Immunity 32(1): 14-27. 
Rajapaksha, T. W., W. A. Eimer, T. C. Bozza and R. Vassar (2011). "The Alzheimer's beta-
secretase enzyme BACE1 is required for accurate axon guidance of olfactory sensory neurons and 
normal glomerulus formation in the olfactory bulb." Mol Neurodegener 6: 88. 
 181 
Ransdell, J. L., E. Dranoff, B. Lau, W. L. Lo, D. L. Donermeyer, P. M. Allen and J. M. Nerbonne 
(2017). "Loss of Navbeta4-Mediated Regulation of Sodium Currents in Adult Purkinje Neurons 
Disrupts Firing and Impairs Motor Coordination and Balance." Cell Rep 19(3): 532-544. 
Ratcliffe, C. F., Y. Qu, K. A. McCormick, V. C. Tibbs, J. E. Dixon, T. Scheuer and W. A. Catterall 
(2000). "A sodium channel signaling complex: modulation by associated receptor protein tyrosine 
phosphatase beta." Nat Neurosci 3(5): 437-444. 
Ratcliffe, C. F., R. E. Westenbroek, R. Curtis and W. A. Catterall (2001). "Sodium channel beta1 
and beta3 subunits associate with neurofascin through their extracellular immunoglobulin-like 
domain." J Cell Biol 154(2): 427-434. 
Rawson, R. B., N. G. Zelenski, D. Nijhawan, J. Ye, J. Sakai, M. T. Hasan, T. Y. Chang, M. S. 
Brown and J. L. Goldstein (1997). "Complementation cloning of S2P, a gene encoding a putative 
metalloprotease required for intramembrane cleavage of SREBPs." Mol Cell 1(1): 47-57. 
Reid, C. A., B. Leaw, K. L. Richards, R. Richardson, V. Wimmer, C. Yu, E. L. Hill-Yardin, H. 
Lerche, I. E. Scheffer, S. F. Berkovic and S. Petrou (2014). "Reduced dendritic arborization and 
hyperexcitability of pyramidal neurons in a Scn1b-based model of Dravet syndrome." Brain 137(Pt 
6): 1701-1715. 
Remme, C. A. and C. R. Bezzina (2010). "Sodium channel (dys)function and cardiac arrhythmias." 
Cardiovasc Ther 28(5): 287-294. 
Reverter, M., C. Rentero, S. V. de Muga, A. Alvarez-Guaita, V. Mulay, R. Cairns, P. Wood, K. 
Monastyrskaya, A. Pol, F. Tebar, J. Blasi, T. Grewal and C. Enrich (2011). "Cholesterol transport 
from late endosomes to the Golgi regulates t-SNARE trafficking, assembly, and function." Mol 
Biol Cell 22(21): 4108-4123. 
Ricci, M. T., S. Menegon, S. Vatrano, G. Mandrile, N. Cerrato, P. Carvalho, M. De Marchi, F. 
Gaita, C. Giustetto and D. F. Giachino (2014). "SCN1B gene variants in Brugada Syndrome: a 
study of 145 SCN5A-negative patients." Sci Rep 4: 6470. 
Riuro, H., P. Beltran-Alvarez, A. Tarradas, E. Selga, O. Campuzano, M. Verges, S. Pagans, A. 
Iglesias, J. Brugada, P. Brugada, F. M. Vazquez, G. J. Perez, F. S. Scornik and R. Brugada (2013). 
"A missense mutation in the sodium channel beta2 subunit reveals SCN2B as a new candidate 
gene for Brugada syndrome." Hum Mutat 34(7): 961-966. 
Riuro, H., O. Campuzano, E. Arbelo, A. Iglesias, M. Batlle, F. Perez-Villa, J. Brugada, G. J. Perez, 
F. S. Scornik and R. Brugada (2014). "A missense mutation in the sodium channel beta1b subunit 
reveals SCN1B as a susceptibility gene underlying long QT syndrome." Heart Rhythm 11(7): 
1202-1209. 
Roger, S., J. Rollin, A. Barascu, P. Besson, P. I. Raynal, S. Iochmann, M. Lei, P. Bougnoux, Y. 
Gruel and J. Y. Le Guennec (2007). "Voltage-gated sodium channels potentiate the invasive 
capacities of human non-small-cell lung cancer cell lines." Int J Biochem Cell Biol 39(4): 774-
786. 
Sachse, C. C., Y. H. Kim, M. Agsten, T. Huth, C. Alzheimer, D. M. Kovacs and D. Y. Kim (2013). 
"BACE1 and presenilin/gamma-secretase regulate proteolytic processing of KCNE1 and 2, 
auxiliary subunits of voltage-gated potassium channels." Faseb j 27(6): 2458-2467. 
Sachse, C. C., Y. H. Kim, M. Agsten, T. Huth, C. Alzheimer, D. M. Kovacs and D. Y. Kim (2013). 
"BACE1 and presenilin/γ-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary 
subunits of voltage-gated potassium channels." Faseb j 27(6): 2458-2467. 
Sakai, J., R. B. Rawson, P. J. Espenshade, D. Cheng, A. C. Seegmiller, J. L. Goldstein and M. S. 
Brown (1998). "Molecular identification of the sterol-regulated luminal protease that cleaves 
SREBPs and controls lipid composition of animal cells." Mol Cell 2(4): 505-514. 
 182 
Sanchez-Sandoval, A. L. and J. C. Gomora (2019). "Contribution of voltage-gated sodium channel 
β-subunits to cervical cancer cells metastatic behavior." Cancer Cell Int 19: 35. 
Sannerud, R., C. Esselens, P. Ejsmont, R. Mattera, L. Rochin, A. K. Tharkeshwar, G. De Baets, 
V. De Wever, R. Habets, V. Baert, W. Vermeire, C. Michiels, A. J. Groot, R. Wouters, K. Dillen, 
K. Vints, P. Baatsen, S. Munck, R. Derua, E. Waelkens, G. S. Basi, M. Mercken, M. Vooijs, M. 
Bollen, J. Schymkowitz, F. Rousseau, J. S. Bonifacino, G. Van Niel, B. De Strooper and W. 
Annaert (2016). "Restricted Location of PSEN2/gamma-Secretase Determines Substrate 
Specificity and Generates an Intracellular Abeta Pool." Cell 166(1): 193-208. 
Sardi, S. P., J. Murtie, S. Koirala, B. A. Patten and G. Corfas (2006). "Presenilin-dependent ErbB4 
nuclear signaling regulates the timing of astrogenesis in the developing brain." Cell 127(1): 185-
197. 
Scheffer, I. E., L. A. Harkin, B. E. Grinton, L. M. Dibbens, S. J. Turner, M. A. Zielinski, R. Xu, 
G. Jackson, J. Adams, M. Connellan, S. Petrou, R. M. Wellard, R. S. Briellmann, R. H. Wallace, 
J. C. Mulley and S. F. Berkovic (2007). "Temporal lobe epilepsy and GEFS+ phenotypes 
associated with SCN1B mutations." Brain 130(Pt 1): 100-109. 
Schroder, E., M. Byse and J. Satin (2009). "L-type calcium channel C terminus autoregulates 
transcription." Circ Res 104(12): 1373-1381. 
Selkoe, D. J. and M. S. Wolfe (2007). "Presenilin: running with scissors in the membrane." Cell 
131(2): 215-221. 
Shah, B. S., E. B. Stevens, M. I. Gonzalez, S. Bramwell, R. D. Pinnock, K. Lee and A. K. Dixon 
(2000). "beta3, a novel auxiliary subunit for the voltage-gated sodium channel, is expressed 
preferentially in sensory neurons and is upregulated in the chronic constriction injury model of 
neuropathic pain." Eur J Neurosci 12(11): 3985-3990. 
Shah, B. S., E. B. Stevens, R. D. Pinnock, A. K. Dixon and K. Lee (2001). "Developmental 
expression of the novel voltage-gated sodium channel auxiliary subunit beta3, in rat CNS." J 
Physiol 534(Pt 3): 763-776. 
Shank, L. C. and B. M. Paschal (2005). "Nuclear transport of steroid hormone receptors." Crit Rev 
Eukaryot Gene Expr 15(1): 49-73. 
Shimizu, H., H. Miyazaki, N. Ohsawa, S. Shoji, Y. Ishizuka-Katsura, A. Tosaki, F. Oyama, T. 
Terada, K. Sakamoto, M. Shirouzu, S. Sekine, N. Nukina and S. Yokoyama (2016). "Structure-
based site-directed photo-crosslinking analyses of multimeric cell-adhesive interactions of 
voltage-gated sodium channel beta subunits." Sci Rep 6: 26618. 
Shimizu, H., A. Tosaki, N. Ohsawa, Y. Ishizuka-Katsura, S. Shoji, H. Miyazaki, F. Oyama, T. 
Terada, M. Shirouzu, S. I. Sekine, N. Nukina and S. Yokoyama (2017). "Parallel homodimer 
structures of the extracellular domains of the voltage-gated sodium channel beta4 subunit explain 
its role in cell-cell adhesion." J Biol Chem. 
Spampanato, J., J. A. Kearney, G. de Haan, D. P. McEwen, A. Escayg, I. Aradi, B. T. MacDonald, 
S. I. Levin, I. Soltesz, P. Benna, E. Montalenti, L. L. Isom, A. L. Goldin and M. H. Meisler (2004). 
"A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for 
beta subunit interaction." J Neurosci 24(44): 10022-10034. 
Spasic, D. and W. Annaert (2008). "Building gamma-secretase: the bits and pieces." J Cell Sci 
121(Pt 4): 413-420. 
Srinivasan, J., M. Schachner and W. A. Catterall (1998). "Interaction of voltage-gated sodium 
channels with the extracellular matrix molecules tenascin-C and tenascin-R." Proceedings of the 
National Academy of Sciences 95(26): 15753-15757. 
 183 
Surges, R. and J. W. Sander (2012). "Sudden unexpected death in epilepsy: mechanisms, 
prevalence, and prevention." Curr Opin Neurol 25(2): 201-207. 
Takahashi, N., S. Kikuchi, Y. Dai, K. Kobayashi, T. Fukuoka and K. Noguchi (2003). "Expression 
of auxiliary beta subunits of sodium channels in primary afferent neurons and the effect of nerve 
injury." Neuroscience 121(2): 441-450. 
Tan, B. H., K. N. Pundi, D. W. Van Norstrand, C. R. Valdivia, D. J. Tester, A. Medeiros-Domingo, 
J. C. Makielski and M. J. Ackerman (2010). "Sudden infant death syndrome-associated mutations 
in the sodium channel beta subunits." Heart Rhythm 7(6): 771-778. 
Tester, D. J. and M. J. Ackerman (2014). "GENETICS OF LONG QT SYNDROME." Methodist 
Debakey Cardiovasc J 10(1): 29-33. 
Theile, J. W., B. W. Jarecki, A. D. Piekarz and T. R. Cummins (2011). "Nav1.7 mutations 
associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 
peptide-mediated resurgent sodium currents." J Physiol 589(Pt 3): 597-608. 
Valdivia, C. R., A. Medeiros-Domingo, B. Ye, W. K. Shen, T. J. Algiers, M. J. Ackerman and J. 
C. Makielski (2010). "Loss-of-function mutation of the SCN3B-encoded sodium channel {beta}3 
subunit associated with a case of idiopathic ventricular fibrillation." Cardiovasc Res 86(3): 392-
400. 
Van Norstrand, D. W. and M. J. Ackerman (2009). "Sudden infant death syndrome: do ion 
channels play a role?" Heart Rhythm 6(2): 272-278. 
van Tetering, G. and M. Vooijs (2011). "Proteolytic cleavage of Notch: "HIT and RUN"." Curr 
Mol Med 11(4): 255-269. 
Vassar, R., B. D. Bennett, S. Babu-Khan, S. Kahn, E. A. Mendiaz, P. Denis, D. B. Teplow, S. 
Ross, P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M. A. Jarosinski, 
A. L. Biere, E. Curran, T. Burgess, J. C. Louis, F. Collins, J. Treanor, G. Rogers and M. Citron 
(1999). "Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane 
aspartic protease BACE." Science 286(5440): 735-741. 
Vassar, R., D. M. Kovacs, R. Yan and P. C. Wong (2009). "The beta-secretase enzyme BACE in 
health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential." J 
Neurosci 29(41): 12787-12794. 
Veeraraghavan, R., G. S. Hoeker, A. Alvarez-Laviada, D. Hoagland, X. Wan, D. R. King, J. 
Sanchez-Alonso, C. Chen, J. Jourdan, L. L. Isom, I. Deschenes, J. W. Smyth, J. Gorelik, S. 
Poelzing and R. G. Gourdie (2018). "The adhesion function of the sodium channel beta subunit 
(beta1) contributes to cardiac action potential propagation." Elife 7. 
von Rotz, R. C., B. M. Kohli, J. Bosset, M. Meier, T. Suzuki, R. M. Nitsch and U. Konietzko 
(2004). "The APP intracellular domain forms nuclear multiprotein complexes and regulates the 
transcription of its own precursor." J Cell Sci 117(Pt 19): 4435-4448. 
Wallace, R. H., I. E. Scheffer, G. Parasivam, S. Barnett, G. B. Wallace, G. R. Sutherland, S. F. 
Berkovic and J. C. Mulley (2002). "Generalized epilepsy with febrile seizures plus: mutation of 
the sodium channel subunit SCN1B." Neurology 58(9): 1426-1429. 
Wallace, R. H., D. W. Wang, R. Singh, I. E. Scheffer, A. L. George, H. A. Phillips, K. Saar, A. 
Reis, E. W. Johnson, G. R. Sutherland, S. F. Berkovic and J. C. Mulley (1998). "Febrile seizures 
and generalized epilepsy associated with a mutation in the Na+-channel sz1 subunit gene SCN1B." 
Nat Genet 19(4): 366-370. 
Wang, H., A. Megill, P. C. Wong, A. Kirkwood and H. K. Lee (2014). "Postsynaptic target specific 
synaptic dysfunctions in the CA3 area of BACE1 knockout mice." PLoS One 9(3): e92279. 
 184 
Wang, H., L. Song, F. Laird, P. C. Wong and H. K. Lee (2008). "BACE1 knock-outs display 
deficits in activity-dependent potentiation of synaptic transmission at mossy fiber to CA3 synapses 
in the hippocampus." J Neurosci 28(35): 8677-8681. 
Wang, P., Q. Yang, X. Wu, Y. Yang, L. Shi, C. Wang, G. Wu, Y. Xia, B. Yang, R. Zhang, C. Xu, 
X. Cheng, S. Li, Y. Zhao, F. Fu, Y. Liao, F. Fang, Q. Chen, X. Tu and Q. K. Wang (2010). 
"Functional dominant-negative mutation of sodium channel subunit gene SCN3B associated with 
atrial fibrillation in a Chinese GeneID population." Biochem Biophys Res Commun 398(1): 98-
104. 
Watanabe, H., D. Darbar, D. W. Kaiser, K. Jiramongkolchai, S. Chopra, B. S. Donahue, P. J. 
Kannankeril and D. M. Roden (2009). "Mutations in sodium channel beta1- and beta2-subunits 
associated with atrial fibrillation." Circ Arrhythm Electrophysiol 2(3): 268-275. 
Watanabe, H., T. T. Koopmann, S. Le Scouarnec, T. Yang, C. R. Ingram, J. J. Schott, S. 
Demolombe, V. Probst, F. Anselme, D. Escande, A. C. Wiesfeld, A. Pfeufer, S. Kaab, H. E. 
Wichmann, C. Hasdemir, Y. Aizawa, A. A. Wilde, D. M. Roden and C. R. Bezzina (2008). 
"Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac 
conduction disease in humans." J Clin Invest 118(6): 2260-2268. 
Weerkamp, F., T. C. Luis, B. A. E. Naber, E. E. L. Koster, L. Jeannotte, J. J. M. van Dongen and 
F. J. T. Staal (2006). "Identification of Notch target genes in uncommitted T-cell progenitors: no 
direct induction of a T-cell specific gene program." Leukemia 20(11): 1967-1977. 
Weggen, S. and D. Beher (2012). "Molecular consequences of amyloid precursor protein and 
presenilin mutations causing autosomal-dominant Alzheimer's disease." Alzheimers Res Ther 
4(2): 9. 
Willem, M., A. N. Garratt, B. Novak, M. Citron, S. Kaufmann, A. Rittger, B. DeStrooper, P. Saftig, 
C. Birchmeier and C. Haass (2006). "Control of peripheral nerve myelination by the beta-secretase 
BACE1." Science 314(5799): 664-666. 
Wimmer, V. C., C. A. Reid, S. Mitchell, K. L. Richards, B. B. Scaf, B. T. Leaw, E. L. Hill, M. 
Royeck, M. T. Horstmann, B. A. Cromer, P. J. Davies, R. Xu, H. Lerche, S. F. Berkovic, H. Beck 
and S. Petrou (2010). "Axon initial segment dysfunction in a mouse model of genetic epilepsy with 
febrile seizures plus." J Clin Invest 120(8): 2661-2671. 
Wolfe, M. S. (2019). "Dysfunctional gamma-Secretase in Familial Alzheimer's Disease." 
Neurochem Res 44(1): 5-11. 
Wolfe, M. S., J. De Los Angeles, D. D. Miller, W. Xia and D. J. Selkoe (1999). "Are Presenilins 
Intramembrane-Cleaving Proteases? Implications for the Molecular Mechanism of Alzheimer's 
Disease." Biochemistry 38(35): 11223-11230. 
Wong, H. K., T. Sakurai, F. Oyama, K. Kaneko, K. Wada, H. Miyazaki, M. Kurosawa, B. De 
Strooper, P. Saftig and N. Nukina (2005). "beta Subunits of voltage-gated sodium channels are 
novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-
secretase." J Biol Chem 280(24): 23009-23017. 
Xiao, Z. C., D. S. Ragsdale, J. D. Malhotra, L. N. Mattei, P. E. Braun, M. Schachner and L. L. 
Isom (1999). "Tenascin-R is a functional modulator of sodium channel beta subunits." J Biol Chem 
274(37): 26511-26517. 
Xu, H., W. Guo and J. M. Nerbonne (1999). "Four kinetically distinct depolarization-activated K+ 
currents in adult mouse ventricular myocytes." J Gen Physiol 113(5): 661-678. 
Xu, R., E. A. Thomas, E. V. Gazina, K. L. Richards, M. Quick, R. H. Wallace, L. A. Harkin, S. E. 
Heron, S. F. Berkovic, I. E. Scheffer, J. C. Mulley and S. Petrou (2007). "Generalized epilepsy 
 185 
with febrile seizures plus-associated sodium channel beta1 subunit mutations severely reduce beta 
subunit-mediated modulation of sodium channel function." Neuroscience 148(1): 164-174. 
Yan, R. (2017). "Physiological Functions of the beta-Site Amyloid Precursor Protein Cleaving 
Enzyme 1 and 2." Front Mol Neurosci 10: 97. 
Yan, R., Q. Fan, J. Zhou and R. Vassar (2016). "Inhibiting BACE1 to reverse synaptic dysfunctions 
in Alzheimer's disease." Neurosci Biobehav Rev 65: 326-340. 
Yan, Z., K. Cui, D. M. Murray, C. Ling, Y. Xue, A. Gerstein, R. Parsons, K. Zhao and W. Wang 
(2005). "PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to 
regulate expression of selective interferon-responsive genes." Genes Dev 19(14): 1662-1667. 
Yu, F. H., R. E. Westenbroek, I. Silos-Santiago, K. A. McCormick, D. Lawson, P. Ge, H. Ferriera, 
J. Lilly, P. S. DiStefano, W. A. Catterall, T. Scheuer and R. Curtis (2003). "Sodium channel beta4, 
a new disulfide-linked auxiliary subunit with similarity to beta2." J Neurosci 23(20): 7577-7585. 
Yuan, L., J. T. Koivumaki, B. Liang, L. G. Lorentzen, C. Tang, M. N. Andersen, J. H. Svendsen, 
J. Tfelt-Hansen, M. Maleckar, N. Schmitt, M. S. Olesen and T. Jespersen (2014). "Investigations 
of the Navbeta1b sodium channel subunit in human ventricle; functional characterization of the 
H162P Brugada syndrome mutant." Am J Physiol Heart Circ Physiol 306(8): H1204-1212. 
Yuan, Y., H. A. O'Malley, M. A. Smaldino, A. A. Bouza, J. M. Hull and L. L. Isom (2019). 
"Delayed maturation of GABAergic signaling in the Scn1a and Scn1b mouse models of Dravet 
Syndrome." Sci Rep 9(1): 6210. 
Zhang, Y. W., R. Wang, Q. Liu, H. Zhang, F. F. Liao and H. Xu (2007). "Presenilin/gamma-
secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor 
expression." Proc Natl Acad Sci U S A 104(25): 10613-10618. 
Zhao, Y. T., Y. B. Guo, L. Gu, X. X. Fan, H. Q. Yang, Z. Chen, P. Zhou, Q. Yuan, G. J. Ji and S. 
Q. Wang (2017). "Sensitized signalling between L-type Ca2+ channels and ryanodine receptors in 
the absence or inhibition of FKBP12.6 in cardiomyocytes." Cardiovasc Res 113(3): 332-342. 
Zhao, Y. T., C. R. Valdivia, G. B. Gurrola, P. P. Powers, B. C. Willis, R. L. Moss, J. Jalife and H. 
H. Valdivia (2015). "Arrhythmogenesis in a catecholaminergic polymorphic ventricular 
tachycardia mutation that depresses ryanodine receptor function." Proc Natl Acad Sci U S A 
112(13): E1669-1677. 
Zhou, J., A. Jeron, B. London, X. Han and G. Koren (1998). "Characterization of a slowly 
inactivating outward current in adult mouse ventricular myocytes." Circ Res 83(8): 806-814. 
Zhou, T. T., Z. W. Zhang, J. Liu, J. P. Zhang and B. H. Jiao (2012). "Glycosylation of the sodium 
channel beta4 subunit is developmentally regulated and involves in neuritic degeneration." Int J 
Biol Sci 8(5): 630-639. 
Zuhl, A. M., C. E. Nolan, M. A. Brodney, S. Niessen, K. Atchison, C. Houle, D. A. Karanian, C. 
Ambroise, J. W. Brulet, E. M. Beck, S. D. Doran, B. T. O'Neill, C. W. Am Ende, C. Chang, K. F. 
Geoghegan, G. M. West, J. C. Judkins, X. Hou, D. R. Riddell and D. S. Johnson (2016). 
"Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of 
beta-secretase inhibitors." Nat Commun 7: 13042.  
